Document:

2013 Distribution Agreement

 Exhibit 10.18 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks (********) denote omissions. 

2013 DISTRIBUTION AGREEMENT 

This 2013 Distribution Agreement is made and entered into as of October 12, 2013 (the “Effective Date”),
by and between Medtronic Sofamor Danek USA, Inc,, a Tennessee corporation (“MSD”), and RTI Surgical, Inc., a Delaware corporation (“RTI”). 

Recitals 
 WHEREAS,
RTI and MSD each acknowledge that the processing and use of human tissue for human transplantation purposes are in the public interest and in the interest of medicine generally, and that this Agreement will enhance these interests through
facilitating the availability of processed tissue for use in medical procedures and thereby advance the medical and scientific application thereof; 

WHEREAS, up to the Effective Date of this Agreement, RTI and MSD are parties to that certain agreement entitled “Fourth Amendment
to First Amended Exclusive Distribution and License Agreement”, having an effective date of September 12, 2006, as amended by the “First Amendment to Exhibit A to the Fourth Amendment to the First Amended Exclusive Distribution
Agreement”, having an effective date of May 1, 2009 (the “Prior Agreement”); 
 WHEREAS, the
Prior Agreement would have expired on June 1, 2014; 
 WHEREAS, the Parties desire to engage in a mutually beneficial
relationship beyond the natural term of the Prior Agreement, but on revised terms and conditions reflecting both historical and anticipated changes in market dynamics; 

WHEREAS, concurrent with the execution of this Agreement, RTI and MSD desire to terminate, and hereby do terminate, said Prior
Agreement, as amended, in accordance with Section 7.2(c) therein; and 
 WHEREAS, RTI desires to appoint MSD as a distributor of
Implants throughout the Territory for use in the Field (each capitalized term as defined below), and MSD desires to accept such appointment in accordance with the terms and conditions of this Agreement. 

Agreement 
 In
consideration of the mutual covenants contained in this Agreement, MSD and RTI agree as follows: 
 ARTICLE I  

DEFINITIONS AND RULES OF CONSTRUCTION 

1.1. Definitions. 

(a) Terms Defined in this Article. For purposes of this Agreement, including the Recitals above, the following terms shall have the
following meanings: 
 “Adverse Event” means any adverse health event to which an Implant has or may have contributed. The
term is generally limited to those events that would be reportable to a Regulatory Authority; e.g., applicable reporting through MedWatch to the FDA (U.S.) or Adverse Reaction/Vigilance Reporting to Competent Authorities (EU). 

  
 1 

 Confidential Treatment Requested 

“Affiliate” means, when used with reference to a Party, any individual or entity directly or indirectly controlling,
controlled by, or under common control with such Party. For purposes of this definition, “control” means (i) the direct or indirect ownership of at least fifty percent (50%) of the outstanding voting securities or other ownership
interest of an entity, (ii) the right to control the policy decisions of such entity, or (iii) has the power to elect or appoint at least fifty percent (50%) of the members of the governing body of the entity. Affiliates of MSD
include, without limitation, Medtronic Inc. and Warsaw Orthopedics Inc.. Affiliates of RTI include, without limitation, Tutogen Medical GmbH and Pioneer Surgical Technologies Inc. 

“Agreement” means this 2013 Distribution Agreement, including its Exhibits attached hereto, as such may be amended from time
to time. 
 “Applicable Industry Standards” means (as applied to MSD and its Affiliates and Marketing Partners as
Distributors of Implants, and as applied to RTI and its Affiliates as Manufacturers of Implants) all applicable standards, requirements, rules and codes of the American Association of Tissue Banks, Advanced Medical Technology Association and other
industry organizations mutually recognized by the Parties as authoritative bodies governing the conduct addressed in this Agreement, as any of the foregoing may be revised. 

“Applicable Laws” means (as applied to MSD and its Affiliates and Marketing Partners as Distributors of Implants, and as
applicable to RTI and its Affiliates as Manufacturers of Implants) common law, statutes, ordinances, rules, regulations or orders of any Governmental Authority, including Regulatory Laws, governing the Manufacture and Distribution of Implants, as
any of the foregoing may be revised. 
 “Base Amount” means the cumulative total of Fees received by RTI from MSD for the
respective Implants or Implant categories, whichever is applicable, as specified in Exhibit A, during the consecutive twelve (12) calendar month trailing period through May 31, 2012. The Base amount will be deemed automatically adjusted in
direct proportion to the annual Fee increases, as specified in Section 4.1. 
 “Business Day” means any day other than
a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is authorized or obligated by law or executive order to remain closed. 

“Change of Control” means a transaction or series of related transactions as a result of which a Person or group of Persons
acting in concert directly or indirectly acquires, after the Effective Date, control of a Party such that (i) said Party would meet the definition of an Affiliate of the acquiring Person(s) or (ii) the acquiring Person(s) acquires
ownership of all or substantially all of the Party’s assets. 

  
 2 

 Confidential Treatment Requested 

“CPI” means the consumer price index for all urban consumers, U.S. city average for all items, as published by the
United States Department of Labor, Bureau of Labor Statistics. 
 “End User” means the health care provider (including
hospitals and surgical facilities) who acquires the Implants from MSD (or its Marketing Partner) for implantation or administration to a patient. 

“Exclusive Territory” means the designated portion of the Territory in which MSD has exclusive rights to Distribute certain
specific Implants designated in Exhibit A as exclusive to MSD for such portion of the Territory. 
 “FDA” means the
United States Food and Drug Administration or any successor agency having the administrative authority to grant Marketing Authorization in the United States. 

“Fees” means the tissue transfer fees (transfer pricing) to be paid by MSD to RTI for the Implants. 

“Field” means marketing efforts targeted to End Users utilizing Implants for spine, general orthopaedic, and trauma surgical
applications. 
 “cGTPs” means current good tissue practices as specified in the Regulatory Laws of the applicable
Regulatory Authority, as such Regulatory Laws are in effect at the time of manufacturing and as applicable to RTI (as a tissue processor) and to MSD (as a tissue distributor), including without limitation, Section 361 of the Public Health
Services (PHS) Act (42 U.S.C. §264), as amended from time to time, and FDA tissue regulations, including 21 C.F.R. Part 1271, Subparts C and D, as revised from time to time. 

“Force Majeure” means any event beyond the affected Party’s reasonable control and without the fault or negligence of
the Party seeking to excuse performance, including without limitation acts of God, fire, terrorism, Third Party criminal acts, explosion, weather, delay or loss in transportation, flood, earthquake, storm, war, riot, revolt, act of a public enemy,
embargo, civil strife, strike labor dispute, loss or shortage of power, impossibility of performance, impracticability of performance, or shortage in supply of raw materials. 

“Governmental Authority” means any country and all states or other political subdivisions thereof and supranational bodies
applicable thereto, including the European Union, and all agencies, commissions, officials, courts or other instrumentalities thereof, in which the Implants are Manufactured or Distributed. 

“Implants” means the processed and finished human allografts for transplantation listed and described in Exhibit A to
this Agreement. 
 “Insolvency Event” means that the Party has (i) commenced a voluntary proceeding under any
insolvency law, (ii) had an involuntary proceeding commenced against it under any insolvency law which has continued undismissed or unstayed for 60 consecutive days, (iii) had a receiver, trustee or similar official appointed for it
or for any substantial part of its 

  
 3 

 Confidential Treatment Requested 

property, (iv) made an assignment for the benefit of creditors or (v) had an order for relief entered with respect to it by a court of competent
jurisdiction under any insolvency law. For purposes hereof, the term “insolvency law” means any applicable bankruptcy, insolvency or other similar law now or hereafter in effect. 

“Intellectual Property” means all works, including literary works, pictorial, graphic and sculptural works, architectural
works, works of visual art, and any other work that may be the subject matter of copyright protection; Trademarks; Confidential Information, including trade secrets; and any foreign and domestic pending patent applications and issued, valid and
enforceable patents, including divisions, continuations, continuations-in-part, and other progeny thereof. 
 “Label” means
the display of written, printed or graphic matter either upon the immediate container of any article (i.e., on the outside container or wrapper, if any, of the retail package of the article) or that is easily legible through the outside
container or wrapper. 
 “Laws” has the same meaning set forth for “Applicable Laws”. 

“Manufacture” means those functions performed by RTI and/or its Affiliates in their capacity as processors of allograft
tissue to produce an Implant, said functions consisting of tissue processing, packaging, storing, sterilizing, labeling, releasing and shipping an Implant in accordance with Applicable Industry Standards, Applicable Laws, and Specifications, as such
Applicable Industry Standards, Applicable Laws and Specifications pertain to the foregoing specific functions. 
 “Marketing
Authorization” means, with respect to any country or jurisdiction, the act of the applicable Regulatory Authority that is necessary under applicable Regulatory Laws for the Manufacture, marketing, transfer, and/or Distribution of Implants
in that country or jurisdiction, and satisfaction of all applicable regulatory and notification requirements. 
 “Marketing
Partner” means a Third Party that promotes, markets, and/or distributes for fee a Party’s allografts, which may include Implants, or products under a contractual arrangement with that Party (use of the term Marketing Partner is
for convenience only, and not intended to imply the existence of a relationship constituting a legal partnership). 
 “MSD
Rights” means all Intellectual Property that is subject as of the Effective Date, or becomes subject during the Term, to MSD’s and/or its Affiliates’ control and that is necessary or useful for the Manufacture and Distribution of
the Implants and Licensed Products. For this purpose, MSD shall be considered to control Intellectual Property if MSD owns or has a license to it and also has the right to sublicense such rights to RTI, such rights to sublicense including, without
limitation, Intellectual Property rights assigned to Warsaw Orthopedic, Inc. 
 “Net Revenue” means the aggregate amount of
all gross revenue received in the Exclusive Territory charged to Third Parties for Spinal Allografts by RTI or any Affiliate for less (i) amounts repaid or credited in the ordinary course of business, (ii) sales, excise, value added and/or
use taxes actually paid by RTI to the extent included in revenue received from Third Parties for Licensed Products, (iii) trade and quantity discounts actually allowed by RTI as customary in the trade, (iv) commissions paid,
(v) duties and similar governmental assessments 

  
 4 

 Confidential Treatment Requested 

paid by RTI to the extent included in revenue received from Third Parties for Licensed Products, and (vi) customary transportation, shipping, and
insurance costs to the extent included in the revenue received from Third Parties for Licensed Products. 
 “Package
Inserts/Instructions for Use (IFU)” means information supplied by the manufacturer of an implant or product that includes all the information and/or instructions for the safe use of the Implants. Specifications for Package Insert/IFU
content vary with regulatory jurisdiction, but typically include operating instructions, warnings and/or precautions, indications, contraindications, information relative to sterilization, Summary of Records instructions in the event of damage to
sterile packaging, cleaning, disinfection information, etc. The Package Insert/IFU must accompany the implant or product in most jurisdictions, except in the U.S. where electronic provision is an alternative. 

“Parties” means MSD and RTI. 

“Party” means MSD or RTI, as the context requires. 

“Person” means any individual, group or entity, including Governmental Authorities. 

“Point of Destination” means the location within the Territory for shipment of the Implants as designated by MSD in the
applicable Firm Order. 
 “Recall” means any recall, withdrawal, field correction or removal action with respect to any
Implants by RTI or MSD due to safety, efficacy, quality or regulatory compliance concerns, including actions to recover title to or possession of, or to halt distribution of, Implants that previously have been shipped to End Users. 

“Regulatory Authority” means, with respect to any country or jurisdiction, any Governmental Authority involved in granting
Marketing Authorization or in administering Regulatory Laws in that country or jurisdiction. 
 “Regulatory Laws” means all
Applicable Laws governing (i) the import, export, design, testing, Manufacture, or Distribution of an Implant, (ii) establishing recordkeeping or reporting obligations for Third Party Complaints or Adverse Events, (iii) Recalls or
(iv) similar regulatory matters. 
 “RTI Rights” means all Intellectual Property that is subject as of the Effective
Date, or becomes subject during the Term, to RTI’s and/or its Affiliates’ control and that is necessary or useful or is used for the Manufacture and Distribution of the Implants. For this purpose, RTI shall be considered to control
Intellectual Property if RTI owns or has a license to it and also has the right to sublicense such rights to MSD. 

“Specifications” means, with respect to each Implant, (i) RTI’s design, functionality, processing, storing,
packaging, shipping, sterilizing and Labeling used in the Manufacture of Implants, and (ii) any standards, instructions or protocols for processing, testing, storing, packaging, shipping, sterilizing or labeling the Implant set forth in any
approved application for Marketing Authorization and any supplements and amendments thereto. 

  
 5 

 Confidential Treatment Requested 

“Spinal Allograft” means any allograft reasonably anticipated to be used primarily for spinal procedures; provided that the
term “Spinal Allograft” shall not include (i) Non-Exclusive Specialty Allografts as indicated on Exhibit A; (ii) allografts listed in Exhibit B attached hereto, with the exception of Cortical Cervical Spacers; (iii) Bone
Paste; (iv) stem cell allografts and scaffolds, e.g. map3TM; (v) allografts introduced to market after the Effective Date that have been designed by RTI or its Affiliates; or (vi) any allograft whose rights to manufacture or
distribute are acquired by RTI from a third party engaged in the manufacture or distribution of spinal allografts pursuant to a bona fide arms-length acquisition or merger transaction closing after September 12, 2006 and involving up-front
consideration payable by RTI having a fair market value in excess of ten million dollars ($10,000,000). 
 “Supply
Shortfall” means a failure of RTI to timely supply at least ******** of the Tissue Transfer Orders submitted by MSD under this Agreement for a specific category of Implants (as designated in Exhibit A) for two (2) consecutive
months. 
 “Territory” means the entire world. 

“Third Party” means any Person other than the Parties and their Affiliates. 

“Third Party Complaint” means any expression by a Third Party of dissatisfaction relating to the identity, durability,
reliability, or safety including actual or suspected Implant tampering, contamination, mislabeling or misformulation. 

“Trademarks” means all trademarks, service marks, trade dress, logos and trade names, together with all translations,
adaptations, derivations and combinations thereof (including all goodwill associated therewith), and all applications, registrations and renewals in connection therewith. 

“United States” or “U.S.” means the United States of America, including its territories,
commonwealths and possessions. 
 (b) Terms Defined Elsewhere. Capitalized terms not defined in Section 1.1(a) shall have the
meanings specified elsewhere in the text of this Agreement. Those terms include the following: 
  

			
	 Term
	  	 Section

	Binding Forecast	  	Section 3.1
	Claim	  	Section 10.1
	Confidential Information	  	Section 7.1(a)
	Confirmed Order	  	Section 3.2
	Distribute/Distribution	  	Section 2.1
	Distributor	  	Section 2.1
	Effective Date	  	Opening paragraph
	Indemnitee	  	Section 10.3
	Indemnitor	  	Section 10.3
	Initial Term	  	Section 11.1
	Interim Order	  	Section 3.4

  
 6 

 Confidential Treatment Requested 

 

			
	 Term
	  	 Section

	Licensed Products	  	Section 2.5(a)
	MSD	  	Opening paragraph
	New Implant	  	Section 2.3(c)
	New Implant Notice	  	Section 2.3(c)
	Prior Agreement	  	Whereas clauses
	Renewal Term	  	Section 11.1
	Return Policy	  	Section 3.6
	Rolling Forecast	  	Section 3.1
	RTI	  	Opening paragraph
	RTI Products	  	Section 2.5
	Supply Shortfall Period	  	Section 2.3(b)
	Term	  	Section 11.1
	Tissue Transfer Orders	  	Section 3.2
	TUR	  	Section 6.4

 1.2. Rules of Construction. 

(a) Elements of this Agreement. When a reference is made in this Agreement to a Recital, an Article, a Section, or an Exhibit, such
reference is to a Recital, Article or Section of, or an Exhibit to, this Agreement, unless otherwise indicated. 
 (b) Meaning of
“Include” and Variations Thereof. Whenever the words “include,” “included,” “includes” or “including” are used in this Agreement, they shall be understood to be followed by the words
“without limitation.” 
 (c) Use of Pronouns. Pronouns, including “he,” “she” and “it,” when
used in reference to any Person, shall be deemed applicable to entities or individuals, male or female, as appropriate in any given case. 

(d) Headings. Articles, Sections and other headings contained in this Agreement are for reference purposes only and are not intended to
describe, interpret, define or limit the scope, extent or intent of any provision of this Agreement. 
 (e) Variation on Terms.
Standard variations on defined terms (such as the plural form of a term defined in the singular form, and the past tense of a term defined in the present tense) shall be deemed to have meanings that correlate to the meanings of the defined terms.

 (f) Currency. The symbol “$” means United States dollars. 

ARTICLE II  

DISTRIBUTION OF THE IMPLANTS 

2.1. Distribution Rights. RTI hereby grants to MSD, and MSD hereby accepts, the right to promote, market, transfer and distribute for
fee (collectively, “Distribute” or “Distribution”; MSD being a “Distributor”) the non-exclusive Implants throughout the 

  
 7 

 Confidential Treatment Requested 

Territory for all uses and applications for which such Implants were distributed in the Prior Agreement, and Implants specified as exclusive to MSD for all
uses and applications in the Field with respect to such specified Implants. Such Distribution rights are non-exclusive throughout the Territory to MSD and its Affiliates and Marketing Partners, unless expressly indicated otherwise in
Exhibit A. MSD’s Distribution rights include the right for MSD to authorize its Affiliates and Marketing Partners to Distribute Implants to the full extent of MSD’s rights to so Distribute; provided, however, that MSD’s
agreements with its Affiliates and Marketing Partners shall contain terms sufficient to require said Affiliates and Marketing Partners to be bound by Medtronic’s Code of Business Conduct which is available on Medtronic’s website:
http://www.medtronic.com/corporate-governance/principles-and-ethics/global-business-conduct-policy/index.htm. For reference purposes, the current version of the Medtronic’s U.S. Business Conduct Standards and Code of Conduct is attached hereto
as Exhibit C. 
 2.2. Distribution Activities. MSD will use commercially reasonable efforts to Distribute the Implants in the
Territory in the Field. MSD’s Distribution efforts may include development of collateral marketing materials, surgical training, attendance at professional tradeshows, and pre-clinical and clinical studies, at MSD’s cost. MSD shall provide
RTI with a reasonable opportunity to review and approve all marketing and collateral materials relating to the Implants, which approval shall not be unreasonably withheld or delayed. MSD shall have sole discretion to establish the transfer fee terms
and other terms and conditions in connection with the Distribution of the Implants to MSD’s customers, provided that such transfer fees and other terms and conditions comply with Applicable Laws. 

2.3. Right to Compete.  

(a) Nothing in this Agreement shall prohibit MSD from manufacturing, marketing or distributing allograft tissue or other products that
compete either directly or indirectly, with Implants; provided that the foregoing shall not be construed as conferring any license or other right, by implication, estoppel or otherwise, under any Intellectual Property Rights of RTI. 

(b) Supply Shortfall. In the event of a Supply Shortfall with respect to Implants Manufactured by RTI for MSD, MSD shall have
the right to utilize Third Party suppliers for the purpose of filling its shortfall with respect to the affected Implants until such time as RTI reasonably establishes its ability to meet and maintain capacity sufficient to meet MSD’s demand
for such affected Implants, but in no event will MSD’s right to utilize a Third Party supplier for such purpose be less than one year (the “Supply Shortfall Period”). During a Supply Shortfall Period, MSD will continue ordering
affected Implants from RTI to the extent RTI can supply such Implants. MSD shall have a reasonable period of time, not to exceed one (1) year, following the Supply Shortfall Period during which to wind-down its supply arrangement with any Third
Party supplier utilized during the Supply Shortfall Period. These temporary rights granted by RTI to MSD in the event of a Supply Shortfall (a “Supply Shortfall License” as further defined in Section 8.3) shall be MSD’s
exclusive remedy as to RTI and its Affiliates with respect to any damages allegedly arising from such Supply Shortfall. A Supply Shortfall shall not impact the Parties’ respective rights and obligations with respect to Implants unaffected by
the Supply Shortfall. Anything herein to the contrary notwithstanding, no rights granted during a Supply Shortfall Period will extend beyond the earlier of (i) the conclusion of the Supply Shortfall Period (including wind-down), or
(ii) the expiration or termination of this Agreement. 

  
 8 

 Confidential Treatment Requested 

(c) New Implant Notice and Proposal. If MSD seeks to develop and/or distribute any new human allograft-based tissue graft for
use within the Field (a “New Implant”) along with seeking development or supply of the New Implant internally or from any Third Party, MSD may request from RTI a development proposal for such New Implant by providing written notice
in the form of New Implant request (“New Implant Notice”). Within thirty (30) days after RTI receives the New Implant Notice, RTI shall notify MSD in writing whether it is interested in pursuing a development and/or supply
arrangement with MSD for the New Implant. The notification from RTI shall be accompanied by a proposed development timeline and fee (such fee to be estimated in contemplation of Section 8.5(b) if applicable). During the negotiations, MSD will
continue to provide RTI with any relevant information regarding the New Implant or that RTI reasonably requests. MSD may continue to negotiate with any Third Party or develop the New Implant internally until such time as terms are reached on the
development (see Section 8.5 re. Jointly-Developed New Implants) and/or supply arrangement or the negotiations between RTI and MSD are terminated. All information provided by RTI to MSD in connection with said proposal and negotiation shall be
deemed Confidential Information of RTI and will not be used by MSD for any purpose other than for negotiations with RTI. Nothing herein shall require MSD to provide RTI with a right of first offer or first refusal in the development and/or supply of
a New Implant. 
 2.4. Conversion of Exclusive Implants to Non-Exclusive. With respect to Implant categories designated in Exhibit
A as exclusive to MSD, such Implant categories shall be converted to non-exclusive in the event of (i) mutual written agreement of the Parties; or (ii) the cumulative Fees received by RTI from MSD for a respective Implant category
during any given trailing consecutive twelve (12) calendar months during the Term declines more than ********. 
 2.5. RTI’s
Distribution Rights. During the Term of this Agreement, RTI shall not market or distribute in the Exclusive Territory those Implants which are exclusive to MSD, provided such Implants remain exclusive in accordance with this Agreement. Nothing
contained herein shall otherwise limit, prevent or prohibit RTI, including its Affiliates and Marketing Partners, from, as may be applicable, manufacturing, marketing or distributing allografts, products and associated surgical and surgical
performance technologies (“RTI Products”), throughout the Territory in the Field. 
 2.6. Royalty. RTI shall pay MSD
a royalty equal to ******** of Net Revenues of Spinal Allografts only throughout the Initial Term of this Agreement. Notice of payments along with the report required under Section 2.7 shall be sent by RTI to MSD address for notices in
Section 12.7. All royalty payments by RTI hereunder shall be made in U.S. dollars without deduction or offset. 
 2.7. Royalty
Report. Within 30 days of the end of each calendar quarter, the chief financial officer of RTI shall certify for that quarter in a written report delivered to MSD as to the Net Revenue for Spinal Allografts during such calendar quarter.
Simultaneous with the delivery of such report, RTI shall pay the amount of royalties due for the applicable reporting period. 

  
 9 

 Confidential Treatment Requested 

Further, RTI shall maintain the information described below and copies of such information shall be made available to MSD upon reasonable request: 

(a) the identity (by commercial product name, RTI product catalog name or similar indicia) of all Spinal Allograft transferred to Third
Parties. 
 (b) for each identified Spinal Allograft, the number of such allografts transferred during the applicable reporting period and
the resulting Net Revenue thereof; and 
 (c) for each identified Spinal Allograft, RTI’s computation of the royalties due. 

2.8. Records. With respect to the royalty and reporting set forth in Section 2.6 and Section 2.7, RTI shall keep accurate
records with respect to all Spinal Allografts transferred or disposed of to Third Parties. These records shall be retained for a period of five (5) years from the date of reporting and payment notwithstanding the expiration or termination of
this agreement. MSD shall have the right at its expense (except as provided below), with at least four weeks’ advance written notice to RTI, to examine and audit, not more than once in any six month period, and during normal business hours, all
records and accounts as may contain information bearing upon the amount and the calculation of royalties payable to MSD under this Agreement. Prompt adjustment shall be made by RTI or by MSD to compensate for any errors and/or omissions disclosed by
such examination or audit. If RTI disputes the disclosed error and/or omissions, and provided the Parties are unable to reach a negotiated resolution within two (2) weeks of RTI providing MSD with notice of such dispute, the Parties will engage
the services of a mutually agreeable accounting firm to audit the findings, and the results of such audit shall be binding on the Parties. RTI shall bear the initial cost of such audit. If, however, such error and/or omission results in an error to
RTI’s benefit exceeding five (5%) of the alleged error and/or omission disclosed by MSD, MSD shall bear the cost of such audit. In the event of an underpayment by RTI to MSD exceeding five percent (5%) of the royalties due and owing
in any particular period, RTI shall pay MSD for its out-of-pocket costs and expenses and an additional fee equal to ten percent (10%) of such underpayment. Neither such right to examine and audit nor the right to receive such additional fee
shall be affected by any statement to the contrary appearing on checks or otherwise and shall not relieve RTI of it obligations to make the payments required hereunder. 

ARTICLE III
 TISSUE
TRANSFER ORDERS 
 3.1. Forecasts and Distribution Summaries. On or before the fifth (5th) Business Day of each month, MSD shall issue to RTI a good faith, twelve (12) month rolling forecast reflecting the anticipated quantities and requested delivery dates of the Implants, by
catalog number, that MSD expects to order (the “Rolling Forecast”). The first sixty (60) days of each Rolling Forecast (as determined by the requested delivery dates) will be binding on MSD (such portion of the Rolling Forecast
being the “Binding Forecast”). Each Binding Forecast will specify the Tissue Transfer Order number(s), if yet submitted, applicable to such Implants covered by the Binding Forecast. The remaining portion of the Rolling Forecast
shall be a good faith, non-binding projection used by RTI for purposes of anticipating and facilitating the lead times needed by RTI to supply Implants by the requested delivery date. In addition, MSD will

  
 10 

 Confidential Treatment Requested 

provide RTI with a quarterly summary of the number of Implants Distributed by MSD and its Affiliates and Marketing Partners in the prior quarter, as well as a
summary of Implants held in their respective inventories. 
 (a) To the extent the requested quantity of an Implant designated for a
given delivery date in the Binding Forecast exceeds by more than ******** the requested quantity for such Implant in the Rolling Forecast for the immediately preceding month (i.e. the month immediately before the requested quantity of the Implant
became binding on MSD), such excess above the ten percent increase will not be counted for the purpose of determining a Supply Shortfall. 

(b) From time to time, and upon the request of a Party at a mutually agreeable time and location, such agreement not to be unreasonably
withheld, the Parties will meet to discuss the status of MSD’s then present inventory of Implants and anticipated future needs. 

3.2. Tissue Transfer Orders. MSD will submit to RTI orders for Implants correlating to the Binding Forecast and further specifying the
Implant’s Point of Destination and the identity of the MSD Affiliate to be invoiced (“Tissue Transfer Orders”). Tissue Transfer Orders will be firm and binding on MSD. Due to the inherent nature of tissue donation which results
in variability in the amount of tissue available from tissue recovery organizations for subsequent transfer to tissue processors, such as RTI, for processing into Implants, each Tissue Transfer Order is subject to acceptance by RTI. Within five
(5) Business Days following RTI’s receipt of a Tissue Transfer Order, RTI will notify MSD of the number of Implants accepted for supply to MSD by the requested delivery date (“Confirmed Order”). 

3.3. Fulfillment of Orders. RTI will timely deliver to MSD those Implants accepted by RTI in the applicable Confirmed Orders. Timely
delivery for purposes of this Agreement will be deemed fulfilled when Implants are delivered to MSD within five (5) Business Days before or after MSD’s requested delivery date. Though recognized by the Parties as an important customer
relationship tool, MSD’s Supplier Scorecard shall not be deemed evidence of performance of the terms and conditions of this Agreement. To the extent the number of Implants subject to a Tissue Transfer Order exceeds the number of Implants
accepted by RTI in the Confirmed Order, RTI will use commercially reasonable efforts to deliver the excess Implants to MSD as soon as commercially practicable. 

3.4. Interim Orders. In addition to Tissue Transfer Orders correlating to the Binding Forecast, MSD may submit additional orders for
Implants in excess of the amount specified in the Binding Forecast (an “Interim Order”). RTI agrees to respond in writing to each Interim Order within ten (10) Business Days of receipt, specifying the volumes accepted for
production and the estimated date(s) by which said Implants could be delivered. Interim Orders will not be counted for the purpose of determining a Supply Shortfall. 

3.5. Shipping. RTI shall package, Label, store and ship the Implants in compliance with Applicable Laws (including cGTPs), all
applicable Specifications and in accordance with good commercial and industry practice. The Implants corresponding to Tissue Transfer Orders will be shipped FOB point of origin to the facility designated by MSD in such corresponding Tissue Transfer
Order via nationally recognized courier of MSD’s choice, e.g. FedEx or UPS. If 

  
 11 

 Confidential Treatment Requested 

MSD does not specify a courier, RTI may select among such nationally recognized couriers in its own discretion. Shipments will be made at least once per week
at RTI’s sole cost and expense, provided such shipments are to MSD’s facility located in Memphis, Tennessee. MSD shall reimburse RTI for actual and reasonable expenses incurred by RTI in expediting shipments or making additional shipments
pursuant to Interim Orders at MSD’s request. MSD shall reimburse RTI for the actual and reasonable difference in increased expenses incurred by RTI for (i) shipments to facilities designated by MSD other than its facility located in
Memphis, Tennessee, or (ii) to the extent the shipping charges of a courier selected by MSD are more than ******** greater than FedEx or UPS (whichever is lower) would have charged RTI for the same shipment. 

3.6. Nonconforming Implants. MSD shall have a reasonable right of inspection to verify that the Implants conform to the terms of this
Agreement. Within fifteen (15) days of MSD’s receipt of Implants at the Point of Destination, MSD shall inform RTI of any claim that a shipment fails to conform. If such notice is not provided to RTI within the prescribed time frame, and
except for latent defects, MSD shall be deemed to have accepted the shipment of the Implants as being in conformity with this Agreement. In the event a purported defect in an Implant is detected, regardless of whether such purported defect is
discovered during the aforementioned inspection period or is a latent defect, MSD will notify RTI, pursuant to Section 12.7, of any related warranty claim. RTI shall bear all costs of return (including freight and insurance) for defective
Implants and shall replace the defective Implant without charge to MSD (including payment of freight and insurance for delivery of the replacement Implant). Returns shall be made in accordance with the return policy set forth in Exhibit D (the
“Return Policy”). 
 (a) Latent Defects. With respect to latent defects, MSD shall promptly notify RTI after receiving
notification from an End User of such End User’s discovery thereof, and MSD and such End User shall have the right to reject such Implant. For the avoidance of doubt, and notwithstanding any provision of the Return Policy, MSD shall be
permitted to reject Implants due to latent defects at any time after discovery of such latent defects or at any time after receiving notification from a End User of such End User’s discovery of such latent defects. Any notification of rejection
to RTI shall state the basis for the rejection. 
 ARTICLE IV

PAYMENTS AND FEES 
 4.1.
Fees for Implants. 
 (a) The Fees for Implants ordered by MSD under this Agreement are specified in Exhibit A and
those Fees shall be firm through December 31, 2013. 
 (b) For the 2014 calendar year, the Fees for the Implants shall be
adjusted as reflected in the attached Fee schedule. The new Fee will be for grafts ordered after January 1, 2014. Grafts received pursuant to a purchase order issued prior to January 1, 2014, will be invoiced at the Fee in effect at the
time of order. 
 (i) In the event extraordinary cost increases greater than ******** are incurred by RTI in a calendar year due to changes
in Laws or ********, RTI and MSD agree to negotiate adjustments to Fees to offset such cost increases. With thirty (30) days’ advance 

  
 12 

 Confidential Treatment Requested 

written notice to RTI, MSD shall have the right, at its expense, to audit RTI’s records concerning such costs represented by RTI to MSD as having
increased more than ******** in a calendar year. 
 (c) If the Parties are unable to agree on a revised Fee schedule before the
commencement of any Renewal Term, then unless and until the Parties subsequently reach a written agreement to amend Exhibit A to reflect fees during the Renewal Term, the new Fees for each calendar year of such Renewal Term shall be equal to
the Fees for the immediately preceding calendar year increased by the percentage increase, if any, in the CPI during the 12-month period ending October 31 of such immediately preceding calendar year. 

4.2. ******** 
 4.3.
Taxes. MSD shall pay, in addition to the Fees, any tax imposed on the Distribution of the Implants from RTI to MSD. 
 4.4. Payment
Terms. Payment from MSD is due to be received by RTI within thirty (30) days of the date of the applicable RTI invoice submitted to MSD. 

ARTICLE V
 PROCESSING AND
SUPPLY 
 5.1. Inventory. RTI will use commercially reasonable efforts to maintain ******** of Implants in inventory, and an
adequate source of unprocessed tissue to meet MSD’s forecasted demand for the Implants. 
 5.2. ******** 

5.3. Processing. RTI will Manufacture all Implants in accordance with industry standards, cGTPs, Applicable Laws and the applicable
Specifications. RTI will maintain throughout the Term and for the specified shelf-life of the Implant (or for such longer period as may be required by Applicable Laws) accurate and complete records relating to the Manufacture of the Implants,
including all records required under Applicable Laws and Applicable Industry Standards.  
 5.4. Implant Modifications. RTI
will not, without written notice to MSD, modify or amend the Implant Specifications or quality procedures for the Manufacture of the Implants in such a manner as to affect the durability, reliability or safety of the Implants. MSD will be allowed
reasonable time to comment on the proposed change prior to its implementation. MSD will not be required to agree to any change that, in its reasonable discretion, would adversely impact the quality, safety or efficacy of the Implant.  

5.5. Implant Shelf-Life. Implants delivered to MSD under this Agreement shall have at least ******** of their shelf-life remaining as
measured from the date of delivery to MSD.  

  
 13 

 Confidential Treatment Requested 

5.6. Right to Cease Supply. RTI shall have the right to cease supplying MSD with a particular Implant category(ies) if RTI determines,
in its own discretion, that such supply of a particular Implant category(ies) to MSD is not economically advantageous for RTI. RTI may exercise its right to cease supply to MSD provided that RTI has provided MSD with at least six
(6) months’ advance written notice of its intent to cease supply. Such cessation of supply shall be deemed a Supply Shortfall with respect to the affected Implant category(ies) provided that MSD has place a Tissue Transfer Order for a
member of such Implant category(ies) during the one (1) year period immediately preceding RTI’s notification of the cessation of supply. 

ARTICLE VI
 REGULATORY
MATTERS 
 6.1. Packaging. 

(a) Materials. Packaging materials will utilize RTI designs suited to its production capabilities. RTI shall maintain records of
packaging Specifications. 
 (b) Branding. Package branding shall identify RTI as the manufacturer of the Implants and MSD as the
distributor. MSD will consult with RTI regarding branding the Implants and package design, aesthetics and Trademarks. Except for any MSD Trademarks included on the packaging to designate MSD as a distributor and any name for the Implants that is or
has been conceived or developed by MSD (which shall be the property of MSD), any and all Trademarks, copyrights, or service marks shall be the property of RTI and shall be deemed RTI Rights and works made for hire to the benefit of RTI. RTI shall
have sole responsibility for obtaining legal protection of RTI Rights in its own discretion and its own expense. MSD shall cooperate with RTI to obtain and enforce such RTI Rights as may be reasonably requested by RTI. 

6.2. Package Inserts. RTI shall develop package inserts in consultation with MSD, and RTI shall maintain records of package insert
Specifications. 
 6.3. Package Labels. RTI shall develop package Labels incorporating MSD requirements into RTI labeling materials
and shall maintain records of label Specifications. 
 6.4. Tissue Utilization Report. RTI shall include its customary Tissue
Utilization Report (“TUR”) in the Implant packaging. Returned TUR cards and the information contained therein shall be the property and Confidential Information of RTI. 

6.5. Storage Records. RTI and MSD will each retain storage records documenting equipment maintenance, calibration and monitoring for
storage of Implants. RTI shall provide handling and storage specifications to MSD. End User storage instructions will be listed in the package insert (Section 6.2, above) and on the package label (Section 6.3, above) that RTI will provide to MSD.

 6.6. Distribution Records. MSD will maintain Distribution records sufficient to facilitate tracing of final disposition of
Implants to End Users. RTI will have the responsibility for supplying, receiving and maintaining records of returned TUR cards. 

  
 14 

 Confidential Treatment Requested 

6.7. Registrations and Licenses. RTI and MSD shall maintain appropriate federal, state, local and foreign registrations, certifications
and licenses as required by Applicable Laws for their respective duties under this Agreement, including applicable registrations with the FDA. 

6.8. Compliance with Laws. The Parties shall at all times conduct themselves with respect to their activities performed under this
Agreement in full compliance with all Applicable Laws, including anti-bribery Laws (e.g. the United States Foreign Corrupt Practices Act), anti-kickback Laws, health care provider payment sunshine Laws, and those portions of 21 C.F.R. Party 1271
applicable to tissue processors (with respect to RTI) and tissue distributors (with respect to MSD). 
 6.9. AATB Compliance. The
Parties shall at all times conduct themselves and all activities performed under this Agreement in full compliance with standards of the AATB, as may be revised, applicable to tissue processors (with respect to RTI) and tissue distributors (with
respect to MSD). 
 6.10. Acceptance of AdvaMed Code. The Parties recognize and accept the AdvaMed Code of Ethics for Interaction
with Health Care Professionals, as may be revised. 
 6.11. Actions by Regulatory Authorities. RTI shall be responsible to Regulatory
Authorities throughout the Territory as the manufacturer of the Implants. If either Party receives notice of an actual or threatened inspection, investigation, inquiry, import or export ban, implant seizure, enforcement proceeding or similar action
by a Regulatory Authority with respect to any Implant or a Party’s activities in connection with any Implant, it will notify the other Party within forty-eight (48) hours after its receipt of notice of the action and will deliver to the
other Party, within a further twenty-four (24) hours, copies of all relevant documents received from the Regulatory Authority. The Parties shall cooperate with each other in formulating a response to the action, including providing information
and documentation as requested by the Regulatory Authority (with copies of any such information and documentation to be provided to the other Party). If the action primarily concerns MSD’s activities, then MSD shall have primary responsibility
to respond to the Regulatory Authority; otherwise, RTI shall have primary responsibility to respond. In either case, upon timely request of the responding Party, the other Party shall, at its own expense, provide up to a cumulative total of twelve
(12) hours of personnel time per action by Regulatory Authority assisting the responding Party in their response. The actual cost for Personnel time incurred by the assisting Party in excess of the twelve (12) hours will be reimbursed by
the responding Party; provide, however, that the assisting Party first provide the responding Party with a good-faith budget estimate of the cost and provided the responding Party with reasonable advance notice in the event it appears that the costs
will exceed the budget estimate. 
 (a) In addition to providing assistance to a Party as set forth in Section 6.11, a Party may
make reasonable requests to the other Party for quality and regulatory consulting services to be compensated at a rate agreed upon by the Parties. 

6.12. Costs. All costs associated with obtaining and/or maintaining any regulatory or governmental authorization, within the United
States, or accreditation with AATB as set forth in Section 6.7 shall be borne solely by RTI insofar as those costs relate to activities performed by 

  
 15 

 Confidential Treatment Requested 

RTI. All costs associated with regulatory requirements or AATB accreditation related to distribution activities performed by MSD, shall be borne by MSD. All
costs associated with obtaining international market approvals, Implant registrations and licensure for any markets outside of the United States where MSD proposes to begin distribution and where those products have not been previously registered,
licensed and approved shall be the responsibility of MSD. 
 6.13. Third Party Complaints and Reports. MSD will promptly advise RTI
of Third Party Complaints attributed to the Implants that are received by MSD. If any such complaint is an Adverse Event, MSD will report such Adverse Event to RTI immediately. Reportable events include adverse outcomes, reported transmission of
disease and other complications. RTI will maintain complaint and Adverse Event files, including the results of related investigations. 

6.14. Traceability. With respect to the Implants, RTI shall maintain manufacturing and traceability records, and MSD shall maintain
storage and Distribution records by tissue number, as required by Applicable Laws and Applicable Industry Standards. 
 6.15. Recalls /
Market Withdrawals / Field Corrections. RTI shall have the authority and responsibility to conduct Recalls of the Implants in accordance with Applicable Laws, at RTI’s cost and expense; provided, however, that to the extent any such Recall
is attributable to (i) statements made verbally or in writing by representatives or agents of MSD with respect to Implants that expand upon or are inconsistent Implant literature reviewed and approved by RTI, or other information furnished by
RTI with respect to the Implants, or (ii) the storage or handling of Implants by MSD or its representatives or agents is inconsistent with instructions provided by RTI, MSD shall bear all costs and expenses associated with such Recall. In the
event RTI fails to perform any required Recall, then MSD may perform such activities. In any event, the Parties shall cooperate and coordinate the activities necessary to effect a Recall. Records of Recalls will be maintained by RTI. 

ARTICLE VII

CONFIDENTIALITY 
 7.1.
Confidentiality. In the course of their activities pursuant to this Agreement, the Parties anticipate that they may disclose Confidential Information to one another and that either Party may, from time to time, be either the disclosing Party or
the recipient of Confidential Information. The Parties wish to protect such Confidential Information in accordance with this Section 7.1. The provisions of this Section shall apply to disclosures furnished to or received by a Party and its
agents and representatives (which may include agents and representatives of its Affiliates and Marketing Partners). Each Party shall advise its agents and representatives of the requirements of this Section and shall be responsible to ensure their
compliance with such provisions. 
 (a) Definition of Confidential Information. For purposes hereof, “Confidential
Information” with respect to a disclosing Party means all information, in any form or media, concerning the disclosing Party (including patient and donor records) that the disclosing Party furnishes to the recipient, whether furnished
before or after the Effective Date, and includes all notes, analyses, compilations, studies and other materials, whether prepared by the recipient or others, that contain or reflect such information; provided, however, that

  
 16 

 Confidential Treatment Requested 

Confidential Information does not include information that (i) is or hereafter becomes generally available to the public other than as a result of a
disclosure by the recipient, (ii) except as noted below with respect to information exchanged by the Parties under the Prior Agreement, was already known to the recipient prior to receipt from the disclosing Party as evidenced by prior written
documents in its possession not subject to an existing confidentiality obligation to the disclosing Party, (iii) is disclosed to the recipient on a non-confidential basis by a Person who is not in default
of any confidentiality obligation to the disclosing Party or (iv) is developed by or on behalf of the recipient without reliance on confidential information received under this Agreement. The contents of this Agreement shall be deemed to be
Confidential Information of each Party. The Parties further agree that information previously exchanged between the Parties which qualified as confidential information under the terms of the Prior Agreement shall be deemed Confidential Information
exchanged pursuant to this Agreement and shall be afforded the same protections contained herein to the extent not covered by any surviving provisions of the Prior Agreement. 

(b) Treatment of Confidential Information. The recipient of Confidential Information will (i) maintain its confidentiality using
efforts and precautions at least as great as those it uses and takes to protect its own Confidential Information and trade secrets, but no less than reasonable care, (ii) use such Confidential Information solely in connection with the discharge
of its obligations under this Agreement and (iii) not disclose such Confidential Information to any Person other than those of its agents and representatives who need to know such Confidential Information in order to accomplish the objectives
for which it was disclosed. Notwithstanding the foregoing, the recipient of Confidential Information may disclose it to the extent reasonably necessary to comply with Applicable Laws or with an order issued by a court or regulatory body with
competent jurisdiction; provided that, in connection with such disclosure, the recipient uses commercially reasonable efforts to obtain confidential treatment or an appropriate protective order, to the extent available, with respect to such
Confidential Information. To the extent permitted by Applicable Law, the recipient will provide notice to the disclosing Party immediately upon recipient’s receipt of notification that such disclosure of Confidential Information is being
requested pursuant to Applicable Laws, court or regulatory body order. 
 (c) Return and Destruction. Within ten (10) Business
Days of receipt of the disclosing Party’s written request, the recipient of Confidential Information, shall return, or with the disclosing Party’s permission destroy, all originals, copies, and summaries of documents, material, and other
tangible manifestations of the disclosing Party’s Confidential Information in its possession or control, together with written confirmation that it has returned or destroyed all such Confidential Information. The receiving Party will use its
best efforts upon such request to regain into its possession any materials containing the disclosing Party’s Confidential Information that may have been or may be transmitted to any of the receiving Party’s employees, directors or any
Third Party contractors. Notwithstanding the foregoing, (i) the receiving Party’s legal counsel shall be permitted to retain one copy of all Confidential Information, (ii) nothing contained in this Agreement shall require the
destruction, transfer, deletion, or modification of any backup tapes or other media made pursuant to automated backup or archival processes in the ordinary course of business, or (iii) nothing contained in this Agreement shall prevent any Party
to this Agreement from maintaining archival files in accordance with its document retention policies designed to achieve compliance with Applicable Laws. 

  
 17 

 Confidential Treatment Requested 

(d) Term of Obligation. The obligations under this Section shall remain in effect from the Effective Date through the
fifth anniversary of the expiration or termination of this Agreement, except that trade secrets of the disclosing Party shall remain confidential for so long as such trade secrets continue to qualify for trade secret status under the Uniform
Trade Secrets Act, as may be amended, published by the National Conference of Commissioners of Uniform State Laws or its successor organization. 

7.2. Publicity. Neither RTI nor MSD shall issue any press release or otherwise make any public statement related to the subject matter
of this Agreement without the prior written approval of the other Party, except to the extent that such press release or other public announcement is required by the rules governing a securities exchange on which the releasing Party’s stock is
listed, by law in the opinion of legal counsel to the releasing Party, or the substance thereof has been previously reviewed and released by the other Party or is in the public domain through no fault of the releasing Party. In the event of a
required press release or other public announcement, the releasing Party shall provide the other Party with a copy of the proposed text prior to such announcement. The Parties agree that if either Party is required to file this Agreement with any
Governmental Authority, the releasing Party shall endeavor to redact competitively sensitive terms of the Agreement to the extent permissible in accordance with the advice of its legal counsel and auditors. 

ARTICLE VIII

INTELLECTUAL PROPERTY AND DEVELOPMENT OF NEW IMPLANTS 

8.1. License of RTI Rights. During the Term of this Agreement, RTI hereby grants to MSD a non-exclusive, non-transferable,
sublicensable only to MSD’s Affiliates and Marketing Partners, license to the RTI Rights to the extent (i) such rights are applicable to the Implants, and (ii) such license is necessary for the sole and limited purpose of permitting
MSD and, as may be applicable, its Affiliates and Marketing Partners to Distribute the Implants in the Field throughout the Territory without infringing or otherwise breaching the RTI Rights. Nothing in this Section 8.2 shall be deemed to grant
(expressly, impliedly or by estoppel) to MSD, or its Affiliates or Marketing Partners, the right to use the RTI Rights for manufacturing or processing purposes. All right, title and interest in and to the RTI Rights shall remain exclusively in the
ownership of RTI, except that nothing in this Agreement should be construed as an admission by MSD as to RTI’s right, title, interest or inventorship in and to such RTI Rights. All licenses granted pursuant to this Section 8.1 shall
terminate upon the expiration or termination of this Agreement, except to the limited extent necessary for MSD and its Affiliates and Marketing Partners to Distribute their respective inventories of Implants remaining in their possession at the
expiration or termination of this Agreement, until such time as the remaining inventory has been depleted or one (1) year following the termination or expiration of this Agreement, whichever occurs first. 

(a) RTI Trademarks. To the extent Section 8.1 applies to Trademarks, MSD and its Affiliates and Marketing Partners shall have the
right to use RTI’s Trademarks associated with the Implants as required by applicable Regulatory Laws or as otherwise necessary to enable Distribution of the Implants. MSD and its Affiliates and Marketing Partners shall comply with the quality
control instructions of RTI as to the form and manner in which such Trademarks may be used. Any goodwill resulting from the use of the Trademarks pursuant to the license granted in this Section 8.1 shall be exclusively owned by and accrue to
the benefit of RTI. 

  
 18 

 Confidential Treatment Requested 

8.2. Supply Shortfall License. Upon the occurrence of a Supply Shortfall, and only during the Supply Shortfall Period (including
applicable wind-down), RTI will grant a non-exclusive, non-transferable, non-sublicensable license of RTI Rights to a Third Party (provided such Third Party is agreeable to both MSD and RTI, such consent not to be unreasonably withheld) to the
extent such license is necessary for said Third Party to machine, shape, package and ship for MSD and its Affiliates and Marketing Partners those Implants subject to the Supply Shortfall (“Supply Shortfall License”). Anything in
this Agreement to the contrary notwithstanding, RTI shall not be obligated under any circumstances (except as required by Applicable Law) to license or disclose RTI Rights respecting its proprietary sterilization processes, including the BioCleanse®, Cancelle®, and Tutoplast® sterilization processes, to any Person. In the event
MSD desires for RTI to sterilize the Implants subject to the Supply Shortfall and manufactured by a Third Party under a Supply Shortfall License, RTI and MSD will in good faith negotiate the fees, terms and conditions under which MSD may contract
RTI to sterilize the affected Implants using an applicable RTI proprietary sterilization process. 
 8.3. License of MSD
Rights. During the Term of this Agreement, MSD hereby grants to RTI a non-exclusive, non-transferable, sublicensable only to RTI’s Affiliates and Marketing Partners, license to the MSD Rights to the extent (i) such rights are
applicable to the Implants, and (ii) such license is necessary for the sole and limited purpose of permitting RTI and its Affiliates to Manufacture the Implants without infringing or otherwise breaching the MSD Rights. All right, title and
interest in and to the MSD Rights shall remain exclusively in the ownership of MSD, except that nothing in this Agreement should be construed as an admission by RTI as to MSD’s right, title, interest or inventorship in and to such MSD Rights.

 (a) MSD Trademarks. To the extent Section 8.3 applies to Trademarks, RTI and its Affiliates shall have the right to use
MSD’s Trademarks associated with the Implants as required by applicable Regulatory Laws or as otherwise necessary to enable Manufacture and Distribution of the Implants. RTI and its Affiliates shall comply with the quality control instructions
of MSD as to the form and manner in which such Trademarks may be used. Any goodwill resulting from the use of the Trademarks pursuant to the license granted in this Section 8.3 shall be exclusively owned by and accrue to the benefit of MSD.

 8.4. Reserved. 

8.5. Development of New Implants. 

(a) New Implants. The Parties acknowledge that while working under this Agreement, new Implants not listed in Exhibit A may
be developed by the Parties jointly (“Jointly-Developed New Implants”) The Parties acknowledge that the provisions of this Section 8.5 are not intended to cover bone paste of any type. 

(b) Development of Jointly-Developed New Implants. If the Parties agree to develop a Jointly-Developed New Implant, they will do the
following: 
 (i) At MSD’s request, and subject to Section 8.5(b)(iii) below, RTI shall produce prototypes of any
Jointly-Developed New Implant design for testing and clinical evaluation under the terms provided in this Section 8.5. 

  
 19 

 Confidential Treatment Requested 

(ii) Subject to Section 8.5(b)(iii), the Parties will dedicate sufficient engineering and other resources to the ongoing development of
any Jointly-Developed New Implants so that such development will be timely and properly accomplished. The Parties will work to agree on Specifications, development schedules and a budget with respect to the development of any Jointly-Developed New
Allograft. Such Specifications, schedule and budget shall be reviewed and adjusted at least once per year, or as reasonably requested and agreed to by the Parties, such agreement not to be unreasonably withheld. 

(iii) All costs associated with the development of a Jointly-Developed New Implant shall be shared in accordance with the budgets agreed to
by the Parties; provided, however, (i) MSD and RTI shall share equally all costs related to regulatory tests, studies and approvals with respect to a Jointly-Developed New Implant; (ii) RTI shall be solely responsible for all costs related
to regulatory tests, studies and approvals with respect to its Manufacturing; and (iii) MSD shall reimburse RTI for its costs incurred in connection with the production of prototypes requested by MSD, provided that such costs are mutually
agreed to at the time of MSD’s request for such Prototypes. 
 (iv) The Jointly-Developed New Implant shall be added to Exhibit
A as an Implant. 
 (c) Exclusivity and Fees Applicable to Jointly-Developed New Implants. With respect to each Jointly-Developed
New Implant, such Jointly-Developed New Implant shall be an exclusive Implant; and (ii) the Parties will determine prior to the commencement of development the Fees to be charged by RTI to MSD for such Jointly-Developed New Implant. 

(d) Initial Jointly-Developed New Implant Forecast. With respect to any Jointly-Developed New Implant added to Exhibit A as an
Implant in accordance with the terms of this Section 8.5, MSD shall provide RTI with a mutually agreeable binding stocking order and a good faith non-binding twelve (12) month forecast of MSD’s demand for such Jointly-Developed New
Implant. As the time for launch approaches, MSD will include the Jointly-Developed New Implant in its forecasts and orders pursuant to Sections 3.1 and 3.2 of this Agreement. 

ARTICLE IX

REPRESENTATIONS AND WARRANTIES 

9.1. Mutual Warranties. Each Party hereby represents and warrants to, and covenants with, the other Party that: 

(a) Due Organization, Good Standing and Power. It is a corporation or other entity duly organized, validly existing and, if relevant in
its jurisdiction of organization, in good standing under the laws of its jurisdiction of organization and has the power and authority 

  
 20 

 Confidential Treatment Requested 

to own, lease and operate its assets and to conduct the business now being conducted by it. It has all requisite power and authority to enter into this
Agreement and to perform its obligations hereunder. 
 (b) Authorization and Validity of Agreement. The execution, delivery and
performance by it of this Agreement and the consummation by it of the transactions contemplated hereby have been duly authorized and approved by all necessary corporate or equivalent action on its part. This Agreement has been duly executed and
delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as the same may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws relating
to or affecting creditors’ rights generally and by general equity principles. 
 (c) Absence of Conflicts. The execution,
delivery and performance by it of this Agreement and the consummation by it of the transactions contemplated hereby do not and will not: (i) violate any Applicable Laws; (ii) conflict with, or result in the breach of any provision of, its
certificate or articles of incorporation, bylaws or equivalent organizational documents; (iii) result in the creation of any lien or encumbrance of any nature upon any property being transferred or licensed by it pursuant to this Agreement or
(iv) violate, conflict with, result in the breach or termination of, or constitute a default under (or event which, with notice, lapse of time or both, would constitute a default under), any permit, contract or agreement to which it is a party
or by which any of its properties or businesses are bound. 
 9.2. Implant Warranty. RTI warrants to MSD that the Implants, when
delivered to MSD by RTI or its Affiliates, will (i) conform to the applicable Specifications, and (ii) have been Manufactured by RTI and/or its Affiliates in compliance with Applicable Laws and Applicable Industry Standards. The foregoing
warranties shall be in effect with respect to each Implant for the labeled shelf-life of the Implant. RTI further warrants to MSD that the Implants, when delivered, shall be free and clear of any liens, security interests or encumbrances. 

9.3. NO OTHER WARRANTY OR REPRESENTATION; LIMITATION OF LIABILITY. EXCEPT AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT, RTI MAKES NO
EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES OF ANY KIND, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. MSD SHALL NOT MAKE ANY WARRANTIES OR OTHER REPRESENTATIONS REGARDING IMPLANTS. TO THE
FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, IN NO EVENT WILL (A) RTI BE LIABLE HEREUNDER FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR (B) RTI’S CUMULATIVE
LIABILITY TO MSD UNDER THIS AGREEMENT EXCEED THE AMOUNTS ACTUALLY PAID TO RTI BY MSD HEREUNDER IN THE TWELVE (12) MONTHS PRIOR TO THE DATE ON WHICH THE CLAIM GIVING RISE TO THE LIABILITY AROSE. THIS PROVISION SHALL SURVIVE THE TERMINATION OR
EXPIRATION OF THIS AGREEMENT. 

  
 21 

 Confidential Treatment Requested 

ARTICLE X

INDEMNIFICATION 
 10.1.
Indemnification by MSD. Subject to RTI’s indemnification obligations pursuant to Section 10.2 herein, MSD shall indemnify and hold RTI, its officers, directors, employees, agents, and Affiliates, harmless from losses, damages,
liabilities, costs and expenses that may result from any demand, claim or litigation (collectively a “Claim”) brought by a Third Party and relating to or resulting from criminal conduct, intentional torts, gross negligence,
negligence, misstatements or misrepresentations of MSD’s employees, Affiliates or Marketing Partners, and all other such Third Party Claims resulting from or arising out of (i) Distribution of the Implants; (ii) statements made
verbally or in writing by representatives or agents of MSD, including Affiliates and Marketing Partners, that expand upon or are inconsistent with Implant literature reviewed by RTI or other information furnished by RTI with respect to the Implants;
(iii) the storage and handling of Implants by representatives or agents of MSD, including Affiliates and Marketing Partners, that is inconsistent with the instructions provided by RTI; (iv) breach by an Implant of a Third Party’s
Intellectual Property rights provided that an infringing element is attributed to an Implant design or specification provided by MSD to RTI; or (v) actual breach by MSD of this Agreement or any warranty, representation or covenant contained
herein occurring as a result of MSD’s conduct. 
 10.2. Indemnification by RTI. Subject to MSD’s indemnification
obligations pursuant to Section 10.1 herein, RTI shall indemnify and hold MSD, its officers, directors, employees, agents, and Affiliates, harmless from losses, damages, liabilities, costs and expenses that may result from any Claim brought by
a Third Party and relating to or resulting from criminal conduct, intentional torts, gross negligence, negligence, misstatements or misrepresentations of RTI’s employees or Affiliates, and all other such Third Party Claims resulting from or
arising out of (i) Manufacture of the Implants; (ii) breach by an Implant of a Third Party’s Intellectual Property rights, except as provided for in Section 10.1(iv) above; or (iii) actual breach by RTI of this Agreement or
any warranty, representation or covenant contained herein occurring as a result of RTI’s conduct. 
 10.3. Indemnification
Procedure. To receive the foregoing indemnities, the Party seeking indemnification (“Indemnitee”) must (i) provide formal written notice (as per Section 12.7 of this Agreement) to be received by the indemnifying Party
(“Indemnitor”) within ten (10) Business Days of Indemnitee’s first written notice of the Claim; (ii) tender to Indemnitor full control and authority over the defense of the Claim; (iii) cooperate as reasonably
requested by Indemnitor (at Indemnitor’s expense) in Indemnitor’s defense of the Claim; and (iv) not enter into any settlement or compromise of such Claim defended by Indemnitor without the express written authorization of Indemnitor.
Indemnitor shall not settle or compromise a Claim without Indemnitee’s prior written consent (which consent shall not be unreasonably withheld or delayed), unless (i) the sole relief provided in such settlement or compromise shall be borne
in full by Indemnitor, and (ii) such settlement or compromise does not include any finding or admission of a violation by Indemnitee of any Applicable Laws or Third Party’s rights; or require any changes in the Indemnitor’s or
Indemnitee’s business practices that would impair performance of either Party’s obligations under this Agreement. 

  
 22 

 Confidential Treatment Requested 

(a) In the event Indemnitor does not accept the tender noted above, Indemnitee may proceed with the defense, settlement and/or
compromise of a Claim with counsel of the Indemnitee’s own choosing, with the reasonable fees, including attorneys’ fees, costs and expenses of such defense, settlement and/or compromise to be borne by Indemnitor, provided indemnification
is validly owed to Indemnitee by Indemnitor pursuant to the terms of this Agreement. At least once per calendar quarter following Indemnitor’s decline of the tender, Indemnitee will provide Indemnitor with an itemized report of all losses,
damages, liabilities, costs, expenses and attorneys’ fees that Indemnitee claims to be owed by Indemnitor. 
 10.4. Survival;
Waiver. The provisions of this Article X shall survive any termination or expiration of this Agreement. Any waiver by an indemnified Party of its rights under this Article must be set forth expressly and in writing in order to be
effective. 
 ARTICLE XI

TERM AND TERMINATION 

11.1. Term. This Agreement will become effective on the Effective Date and shall continue in effect until December 31, 2017 (the
“Initial Term”). The Initial Term will be renewed automatically thereafter for successive five-year terms (each a “Renewal Term”), unless at least one (1) year in advance
of the expiration of the Initial Term or applicable Renewal Term one Party provides written notice to the other Party that it does not intend to renew. This Agreement may be terminated before the expiration of the Initial Term or any renewal term
only by mutual written agreement of the Parties or in accordance with Section 11.2. The period from the Effective Date through the date of expiration or termination of this Agreement shall be referred to as the “Term.”

 11.2. Termination. 

(a) Dissolution or Insolvency Event. If a Party is dissolved under applicable corporate law or becomes subject to an Insolvency Event,
this Agreement will be terminable at will by the other Party. 
 (b) Default. If either Party believes the other is in default of any
of its material obligations under this Agreement, it may give notice to the other Party describing the default with reasonable specificity. The defaulting Party shall have sixty (60) calendar days in which to remedy such default. Such cure
period shall be extended in the case of a default not reasonably capable of being remedied in such 60-day period so long as the defaulting Party uses diligent efforts to remedy such default and is pursuing a
course of action that, if successful, will effect such a remedy. If such alleged default is not remedied in the time period set forth above, then the Party alleging default shall refer the matter to senior executive officers of each Party, who shall
meet and confer within fifteen (15) Business Days after notice from the non-defaulting Party of its desire for such a meeting. If the Parties are unable to resolve any dispute in such meeting, the non-defaulting Party may terminate this Agreement upon delivery to the defaulting Party of a written notice of termination at any time within six (6) months after the meeting but before such default is
remedied. The non-defaulting Party’s right to terminate this Agreement shall not be construed as an exclusive remedy. 

(c) Force Majeure. Either Party may terminate this Agreement in accordance with the terms of Section 12.2. 

  
 23 

 Confidential Treatment Requested 

11.3. Consequences of Termination. 

(a) General. Termination or expiration of this Agreement shall not relieve any Party of any obligations that are expressly indicated to
survive termination or expiration and, accordingly, any provision of this Agreement required for the interpretation or enforcement of any such obligation will survive the expiration or termination of this Agreement. Termination or expiration of this
Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. 

(b) Inventory. Upon the expiration or termination of this Agreement, (i) RTI shall continue to process and deliver to MSD all
Implants that are the subject of a Confirmed Order with a requested delivery date up to the date of expiration or termination of this Agreement, and (ii) MSD shall be permitted to Distribute any remaining inventory of the Implants, including
any Implants delivered pursuant to clause (i) above (and for such purpose MSD Distribution’s rights under this Agreement shall continue in effect) until the remaining inventory has been depleted or until the one (1) year anniversary
of the termination or expiration of this Agreement, whichever occurs first. 
 ARTICLE XII 

MISCELLANEOUS 
 12.1.
Agency. The Parties are independent contractors. No employee or agent of one Party is, nor shall they be deemed to be whether impliedly or by estoppel, an employee, agent, partner or legal representative of the other Party for any purpose.
Neither Party shall have the right, power or authority to enter into any verbal or written contracts, agreements or representation in the name of, or on behalf of, the other Party. Neither shall a Party have the right, power or authority to pledge
the credit of the other Party in any way or hold itself out as having the authority to do so. 
 12.2. Force Majeure. If the
performance of any obligation under this Agreement is prevented, restricted or interfered with by a Force Majeure event, then the Party so affected shall, upon giving prior written notice to the other Party, be excused from such performance to the
extent of such prevention, restriction, or interference, provided that the Party so affected shall use commercially reasonable efforts to avoid or remove such causes of nonperformance, and shall continue performance hereunder with reasonable
dispatch whenever such causes are removed. If such conditions inhibiting complete performance shall continue in excess of ninety (90) calendar days, the Parties shall attempt to arrive at a mutually acceptable compromise within the spirit and
intent of this Agreement. If the Parties fail to reach a mutually acceptable compromise within ninety (90) calendar days following the initial attempt to negotiate the same, then the Party who is not affected by the Force Majeure event shall
have the option, by delivery of written notice of termination to the affected Party, to immediately terminate this Agreement. 
 12.3.
Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the Parties hereto concerning its subject matter and supersedes all previous 

  
 24 

 Confidential Treatment Requested 

negotiations, agreements and commitments with respect thereto. This Agreement specifically terminates, supersedes and replaces the Prior Agreement, as
amended, including any predecessor agreements incorporated therein; provided, however, that any irrevocable rights and/or accured rights or obligations subject to post-expiration or termination survival shall continue to survive. This Agreement
shall not be released, discharged, amended or modified in any manner except by a written instrument signed by duly authorized officers or representatives of each of the Parties hereto. 

12.4. Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of
Delaware. The Parties agree that any legal action relating to this Agreement shall be commenced and maintained before any appropriate state or federal court located in the State of Delaware, and the Parties hereby submit to the jurisdiction of such
courts and waive any right to challenge or otherwise raise questions of personal jurisdiction or venue in any action commenced or maintained in such courts. 

12.5. Partial Illegality. If any provision of this Agreement, or the application thereof to any Party or circumstances, shall be
declared void, illegal or unenforceable, the remainder of this Agreement shall be valid and enforceable to the extent permitted by Applicable Laws. In such event, the Parties shall use their best efforts to replace the invalid or unenforceable
provision by a provision that, to the extent permitted by Applicable Laws, achieves the purposes intended under the invalid or unenforceable provision. Any deviation by either Party from the terms and provisions of this Agreement in order to comply
with Applicable Laws shall not be considered a breach of this Agreement. 
 12.6. Waiver of Compliance. No provision of this
Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees, except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party, which waiver shall
be effective only with respect to the specific obligation and instance described therein. 
 12.7. Notices. With the exception of
forecasts, royalty reports and payments to be provided under this Agreement, any official notice, waiver or consent required or permitted by this Agreement to be given or delivered shall be in writing and shall be either delivered in person, sent by
a nationally recognized courier (e.g. FedEx, UPS), sent by registered or certified mail (with postage prepaid and return receipt requested), or sent by facsimile (if confirmed), as follows: 

 

			
	TO RTI:	  	RTI Surgical, Inc.
		  	 11621 Research Circle
 Alachua, FL 32615

Attn: Chief Executive Officer
 Fax No.:
(386) 418-3608

  
 25 

 Confidential Treatment Requested 

 

			
	With copy to:	  	 RTI Surgical, Inc.
 11621 Research Circle

Alachua, FL 32615
 Attn: General Counsel

Facsimile: (386) 418-5157
  

and
  

Jerome W. Hoffman, Esq.
 Holland & Knight LLP

315 S. Calhoun Street, Suite 600
 Tallahassee, FL 32302-0810

Facsimile: 850-224-8832
  

and
  

Warren J. Nimetz, Esq.
 Fulbright & Jaworski LLP

666 Fifth Avenue, 31st Floor

New York, NY 10103-3198
 Facsimile: 202-318-3400

		
	TO MSD:	  	 Medtronic Sofamor Danek USA, Inc.
 2600 Sofamor
Danek Drive
 Memphis, TN 38132
 Attn: President of
Spine

		
	With a copy to:	  	 Medtronic Sofamor Danek USA, Inc.
 2600 Sofamor
Danek Drive
 Memphis, TN 38132
 Attn: Michael Herringshaw,
Senior Strategic Sourcing Director
  
 and

 
 Medtronic Sofamor Danek USA, Inc.

2600 Sofamor Danek Drive
 Memphis, TN 38132

Attention: Vice President and Chief Legal Counsel
 FAX:
(901) 344-1576

 Anything in this Agreement to the contrary notwithstanding, any notice intended to act as a formal and
official notice, waiver or consent under any provision of this Agreement (except production forecasts and royalty reports) must be sent by Brian Hutchison or his successor (if coming from RTI) or Douglas King or his successor (if coming from MSD) to
the designated 

  
 26 

 Confidential Treatment Requested 

recipients noted herein above. Any official notice, waiver or consent shall be effective (i) upon delivery if delivered in person, (ii) the next
Business Day in the locality of the recipient if delivered by express courier service, (iii) three (3) Business Days after post mark if sent by registered or certified mail, or (iv) if sent by fax, at the time shown in the confirmed
electronic receipt, or on the first Business Day thereafter if the notice is not sent on a Business Day or was sent after 5:00 pm in the recipient’s time zone. Either Party may change its address. 

12.8. Counterparts and Facsimile/Electronic. This Agreement may be executed in counterparts, each of which shall be deemed to be an
original and all of which together shall be deemed to be one and the same instrument. A manual signature on this Agreement or any document executed in connection with this Agreement, the image of which is transmitted electronically (including
facsimile or e-mail), shall constitute an original signature for purposes of this Agreement. 
 12.9. Limitation on Liability. Except
with respect to the Parties’ indemnification obligations, neither Party shall be liable to the other for indirect, incidental, consequential, punitive or special damages, including but not limited to lost profits, arising from or relating to
any breach of this Agreement, regardless of any notice of the possibility of such damages. 
 12.10. Further Actions. Each Party
agrees, subsequent to the execution and delivery of this Agreement and without any additional consideration, to execute, acknowledge and deliver such further documents and instruments, and to do all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement. 
 12.11. Assignment. This Agreement may not be assigned
without the prior written consent of the other Party except that no prior written consent will be required where the assignment occurs in connection with a merger, acquisition, or other Change in Control; provided, however, that such assignment
shall not relieve the assigning Party of its obligations hereunder. If and to the extent that a Party assigns any of its rights and/or obligations hereunder in accordance with this Section, then this Agreement shall be binding upon the assignee to
the same extent as if it were a Party hereto and each reference herein to the name of the assigning Party shall be deemed to include the assignee. Any assignment not in accordance with this Section shall be void. 

12.12. Jointly Prepared. This Agreement has been prepared jointly and shall not be strictly construed against either Party. 

12.13. No Third Party Beneficiaries. This Agreement is not intended to confer any benefits upon, or create any rights in favor of, any
Third Party. 
 12.14. Expenses. Except as otherwise expressly provided in this Agreement, each Party shall be responsible for its
own expenses incurred in connection with this Agreement and the transactions contemplated hereby. 
 12.15. Survival. The
following Sections shall survive the expiration or termination of this Agreement: 1.1; 1.2; 2.5; 4.3; 6.4; 6.5; 6.6; 6.8; 6.9; 6.10; 6.11; 6.12; 6.13; 6.14; 6.15; 7.1; 7.2; 9.2; 9.3; Article X; 11.3; 12.1; 12.2; 12.3; 12.4; 12.5; 12.6; 12.7; 12.8;
12.9; 12.12; 12.13; 12.14; and 12.15 

  
 27 

 Confidential Treatment Requested 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; 

SIGNATURES APPEAR ON FOLLOWING PAGE] 

  
 28 

 Confidential Treatment Requested 

IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its respective duly authorized representative as of the Effective
Date. 
  

			
	RTI SURGICAL, INC.
		
	By:	 	/s/ Thomas F. Rose
		
	Name:	 	Thomas F. Rose
		
	Title:	 	EVP - Administration
	
	MEDTRONIC SOFAMOR DANEK USA, INC.
		
	By:	 	/s/ Michael Herringshaw
		
	Name:	 	Michael Herringshaw
		
	Title:	 	Sr. Director Strategic Procurement

  
 29 

 EXHIBIT A 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks (********) denote omissions. 

EXHIBIT A 
 LIST OF
PRODUCTS 
 Revised/Restructured October 4, 2013. New fees effective for all purchase orders issued after 

January 1, 2014. Grafts to be invoiced at the fee in effect at the time of the purchase order issuance. 

(New products since 10/1/2006 highlighted in red) 

EXCLUSIVE PRODUCTS 
 Cornerstone SR (SR
Cortical Block) 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	 200511
	  	200511	    	 SR Cortical Block 5 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200541
	  	200541	    	 SR Cortical Block 5 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200544
	  	200544	    	 SR Cortical Block 5 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	 200611
	  	200611	    	 SR Cortical Block 6 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200641
	  	200641	    	 SR Cortical Block 6 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200644
	  	200644	    	 SR Cortical Block 6 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	 200711
	  	200711	    	 SR Cortical Block 7 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200741
	  	200741	    	 SR Cortical Block 7 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200744
	  	200744	    	 SR Cortical Block 7 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	 200811
	  	200811	    	 SR Cortical Block 8 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200841
	  	200841	    	 SR Cortical Block 8 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200844
	  	200844	    	 SR Cortical Block 8 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	 200911
	  	200911	    	 SR Cortical Block 9 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200941
	  	200941	    	 SR Cortical Block 9 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	 200944
	  	200944	    	 SR Cortical Block 9 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  

 Cornerstone ASR (Composite Cortical-Cancellous Block) 

 

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	245041	  	245041	    	 ASR Cortical-Cancellous Block 10 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245141	  	245141	    	 ASR Cortical-Cancellous Block 11 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245241	  	245241	    	 ASR Cortical-Cancellous Block 12 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245341	  	245341	    	 ASR Cortical-Cancellous Block 13 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245541	  	245541	    	 ASR Cortical-Cancellous Block 5 x 14x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	245641	  	245641	    	 ASR Cortical-Cancellous Block 6 x 14x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	245741	  	245741	    	 ASR Cortical-Cancellous Block 7 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245841	  	245841	    	 ASR Cortical-Cancellous Block 8 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	245941	  	245941	    	 ASR Cortical-Cancellous Block 9 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Cornerstone LASR (Lordotic Composite Cortical-Cancellous Block) 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	345011	  	345011	    	 Cornerstone L-ASR 10 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345041	  	345041	    	 Lordotic ASR Cortical-Cancellous Block 10 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345044	  	345044	    	 Cornerstone L-ASR 10 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	345111	  	345111	    	 Cornerstone L-ASR 11 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345141	  	345141	    	 Lordotic ASR Cortical-Cancellous Block 11 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345144	  	345144	    	 Cornerstone L-ASR 11 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	345211	  	345211	    	 Cornerstone L-ASR 12 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345241	  	345241	    	 Lordotic ASR Cortical-Cancellous Block 12 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345244	  	345244	    	 Cornerstone L-ASR 12 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	345511	  	345511	    	 Lordotic ASR Cortical-Cancellous Block 5 x 11x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345341	  	345341	    	 Lordotic ASR Cortical-Cancellous Block 13 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345541	  	345541	    	 Lordotic ASR Cortlcal-Cancellous Block 5 x 14x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345544	  	345544	    	 Lordotic ASR Cortical-Cancellous Block 5 x 14x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345611	  	345611	    	 Lordotic ASR Cortical-Cancellous Block 6 x 11x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345641	  	345641	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345644	  	345644	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345711	  	345711	    	 Cornerstone L-ASR 7 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345741	  	345741	    	 Lordotic ASR Cortical-Cancellous Block 7 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345744	  	345744	    	 Cornerstone L-ASR 7 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	345811	  	345811	    	 Cornerstone L-ASR 8 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345841	  	345841	    	 Lordotic ASR Cortical-Cancellous Block 8 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345844	  	345844	    	 Cornerstone L-ASR 8 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	345911	  	345911	    	 Cornerstone L-ASR 9 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345941	  	345941	    	 Lordotic ASR Cortical-Cancellous Block 9 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	345944	  	345944	    	 Cornerstone L-ASR 9 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Cornerstone LASR (Lordotic Composite Cortical-Cancellous Block) 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	345011INT	  	8S0101	    	 Lordotic ASR Cortical-Cancellous Block 10 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345041INT	  	8S0102	    	 Lordotic ASR Cortical-Cancellous Block 10 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345044INT	  	8S0103	    	 Lordotic ASR Cortical-Cancellous Block 10 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345541INT	  	8S0152	    	 Lordotic ASR Cortical-Cancellous Block 5 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345544INT	  	8S0153	    	 Lordotic ASR Cortlcal-Cancellous Block 5 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345611INT	  	8S0161	    	 Lordotic ASR Cortical-Cancellous Block 6 x 11x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345641INT	  	8S0162	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345644INT	  	8S0163	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345711INT	  	8S0171	    	 Lordotic ASR Cortical-Cancellous Block 7 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345741INT	  	8S0172	    	 Lordotic ASR Cortical-Cancellous Block 7 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345744INT	  	8S0173	    	 Lordotic ASR Cortical-Cancellous Block 7 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345811INT	  	8S0181	    	 Lordotic ASR Cortical-Cancellous Block 8 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345841INT	  	8S0182	    	 Lordotic ASR Cortical-Cancellous Block 8 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345844INT	  	8S0183	    	 Lordotic ASR Cortical-Cancellous Block 8 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345911INT	  	8S0191	    	 Lordotic ASR Cortical-Cancellous Block 9 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345941INT	  	8S0192	    	 Lordotic ASR Cortical-Cancellous Block 9 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345944INT	  	8S0193	    	 Lordotic ASR Cortical-Cancellous Block 9 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345011CAN	  	CS0101	    	 Lordotic ASR Cortical-Cancellous Block 10 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345041CAN	  	CS0102	    	 Lordotic ASR Cortical-Cancellous Block 10 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345044CAN	  	CS0103	    	 Lordotic ASR Cortical-Cancellous Block 10 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345111CAN	  	CS0111	    	 Lordotic ASR Cortical-Cancellous Block 11 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345141CAN	  	CS0112	    	 Lordotic ASR Cortical-Cancellous Block 11 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345144CAN	  	CS0113	    	 Lordotic ASR Cortical-Cancellous Block 11 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345211CAN	  	CS0121	    	 Lordotic ASR Cortical-Cancellous Block 12 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345241CAN	  	CS0122	    	 Lordotic ASR Cortical-Cancellous Block 12 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345244CAN	  	CS0123	    	 Lordotic ASR Cortical-Cancellous Block 12 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345511CAN	  	CS0151	    	 Lordotic ASR Cortical-Cancellous Block 5 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345541CAN	  	CS0152	    	 Lordotic ASR Cortical-Cancellous Block 5 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345544CAN	  	CS0153	    	 Lordotic ASR Cortical-Cancellous Block 5 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345611CAN	  	CS0161	    	 Lordotic ASR Cortical-Cancellous Block 6 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345641CAN	  	CS0162	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345644CAN	  	CS0163	    	 Lordotic ASR Cortical-Cancellous Block 6 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345711CAN	  	CS0171	    	 Lordotic ASR Cortical-Cancellous Block 7 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345741CAN	  	CS0172	    	 Lordotic ASR Cortical-Cancellous Block 7 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345744CAN	  	CS0173	    	 Lordotic ASR Cortical-Cancellous Block 7 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345811CAN	  	CS0181	    	 Lordotic ASR Cortical-Cancellous Block 8 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345841CAN	  	CS0182	    	 Lordotic ASR Cortical-Cancellous Block 8 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345844CAN	  	CS0183	    	 Lordotic ASR Cortical-Cancellous Block 8 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345911CAN	  	CS0191	    	 Lordotic ASR Cortical-Cancellous Block 9 x 11 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345941CAN	  	CS0192	    	 Lordotic ASR Cortical-Cancellous Block 9 x 14 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345944CAN	  	CS0193	    	 Lordotic ASR Cortical-Cancellous Block 9 x 14 x 14 mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Frozen Cornerstone LASR (Lordotic Composite Cortical-Cancellous Block) 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	345041FZ	  	347041	    	 FROZEN LASR 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345044FZ	  	347044	    	 FROZEN LASR 10 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345141FZ	  	347141	    	 FROZEN LASR 11 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345144FZ	  	347144	    	 FROZEN LASR 11 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345241FZ	  	347241	    	 FROZEN LASR 12 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345244FZ	  	347244	    	 FROZEN LASR 12 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345541FZ	  	347541	    	 FROZEN LASR 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345544FZ	  	347544	    	 FROZEN LASR 5 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345641FZ	  	347641	    	 FROZEN LASR 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345644FZ	  	347644	    	 FROZEN LASR 6 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345741FZ	  	347741	    	 FROZEN LASR 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345744FZ	  	347744	    	 FROZEN LASR 7 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345841FZ	  	347841	    	 FROZEN LASR 8 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345844FZ	  	347844	    	 FROZEN LASR 8 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345941FZ	  	347941	    	 FROZEN LASR 9 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	345944FZ	  	347944	    	 FROZEN LASR 9 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Cornerstone Lordotic MASR Pinnacle 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	645511	  	645511	    	 Lordotic MASR Cortical-Cancellous Block 5 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	645541	  	645541	    	 Lordotic MASR Cortical-Cancellous Block 5 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	645544	  	645544	    	 Lordotic MASR Cortical-Cancellous Block 5 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	645611	  	645611	    	 Lordotic MASR Cortical-Cancellous Block 6 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	645641	  	645641	    	 Lordotic MASR Cortical-Cancellous Block 6 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	645644	  	645644	    	 Lordotic MASR Cortical-Cancellous Block 6 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Cornerstone SR Assembled Cortical 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	330511	  	330511	    	 ACSR Cortical Block 5 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330541	  	330541	    	 ACSR Cortical Block 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330544	  	330544	    	 ACSR Cortical Block 5 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330611	  	330611	    	 ACSR Cortical Block 6 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330641	  	330641	    	 ACSR Cortical Block 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330644	  	330644	    	 ACSR Cortical Black 6 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330711	  	330711	    	 ACSR Cortical Block 7 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330741	  	330741	    	 ACSR Cortical Block 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330744	  	330744	    	 ACSR Cortical Block 7 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330811	  	330811	    	 ACSR Cortical Block 8 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330841	  	330841	    	 ACSR Cortical Block 8 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330844	  	330844	    	 ACSR Cortical Block 8 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330911	  	330911	    	 ACSR Cortical Block 9 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330941	  	330941	    	 ACSR Cortical Block 9 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	330944	  	330944	    	 ACSR Cortical Block 9 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331011	  	331011	    	 ACSR Cortical Block 10 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331041	  	331041	    	 ACSR Cortical Block 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331044	  	331044	    	 ACSR Cortical Block 10 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331111	  	331111	    	 ACSR Cortical Block 11 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331141	  	331141	    	 ACSR Cortical Block 11 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331144	  	331144	    	 ACSR Cortical Block 11 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331211	  	331211	    	 ACSR Cortical Block 12 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331241	  	331241	    	 ACSR Cortical Block 12 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331244	  	331244	    	 ACSR Cortical Block 12 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331311	  	331311	    	 ACSR Cortical Block 13 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331341	  	331341	    	 ACSR Cortical Block 13 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	331344	  	331344	    	 ACSR Cortical Block 13 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Lordotic SR Assembled Cortical 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	340511	  	340511	    	 L-ACSR Cortical Block 5 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340541	  	340541	    	 L-ACSR Cortical Block 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340544	  	340544	    	 L-ACSR Cortical Block 5 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340611	  	340611	    	 L-ACSR Cortical Block 6 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340641	  	340641	    	 L-ACSR Cortical Block 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340644	  	340644	    	 L-ACSR Cortical Block 6 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340711	  	340711	    	 L-ACSR Cortical Block 7 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340741	  	340741	    	 L-ACSR Cortical Block 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340744	  	340744	    	 L-ACSR Cortical Block 7 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340811	  	340811	    	 L-ACSR Cortical Block 8 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340841	  	340841	    	 L-ACSR Cortical Block 8 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340844	  	340844	    	 L-ACSR Cortical Block 8 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340911	  	340911	    	 L-ACSR Cortical Block 9 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340941	  	340941	    	 L-ACSR Cortical Block 9 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340944	  	340944	    	 L-ACSR Cortical Block 9 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341011	  	341011	    	 L-ACSR Cortical Block 10 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341041	  	341041	    	 L-ACSR Cortical Block 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341044	  	341044	    	 L-ACSR Cortical Block 10 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341111	  	341111	    	 L-ACSR Cortical Block 11 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341141	  	341141	    	 L-ACSR Cortical Block 11 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341144	  	341144	    	 L-ACSR Cortical Block 11 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341211	  	341211	    	 L-ACSR Cortical Block 12 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341241	  	341241	    	 L-ACSR Cortical Block 12 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341244	  	341244	    	 L-ACSR Cortical Block 12 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341011INT	  	8S0201	    	 L-ACSR Cortical Block 10 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341041INT	  	8S0204	    	 L-ACSR Cortical Block 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340541INT	  	8S0254	    	 L-ACSR Cortical Block 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340641INT	  	8S0264	    	 L-ACSR Cortical Block 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340741INT	  	8S0274	    	 L-ACSR Cortical Block 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341011CAN	  	CS0201	    	 L-ACSR Cortical Block 10 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341041CAN	  	CS0204	    	 L-ACSR Cortical Block 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341044CAN	  	CS0205	    	 L-ACSR Cortical Block 10 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341111CAN	  	CS0211	    	 L-ACSR Cortical Block 11 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341141CAN	  	CS0214	    	 L-ACSR Cortical Block 11 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341144CAN	  	CS0215	    	 L-ACSR Cortical Block 11 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341211CAN	  	CS0221	    	 L-ACSR Cortical Block 12 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341241CAN	  	CS0224	    	 L-ACSR Cortical Block 12 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	341244CAN	  	CS0225	    	 L-ACSR Cortical Block 12 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340511CAN	  	CS0251	    	 L-ACSR Cortical Block 5 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340541CAN	  	CS0254	    	 L-ACSR Cortical Block 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340544CAN	  	CS0255	    	 L-ACSR Cortical Block 5 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340611CAN	  	CS0261	    	 L-ACSR Cortical Block 6 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340641CAN	  	CS0264	    	 L-ACSR Cortical Block 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340644CAN	  	CS0265	    	 L-ACSR Cortical Block 6 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340711CAN	  	CS0271	    	 L-ACSR Cortical Block 7 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340741CAN	  	CS0274	    	 L-ACSR Cortical Block 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340744CAN	  	CS0275	    	 L-ACSR Cortical Block 7 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340811CAN	  	CS0281	    	 L-ACSR Cortical Block 8 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340841CAN	  	CS0284	    	 L-ACSR Cortical Block 8 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340844CAN	  	CS0285	    	 L-ACSR Cortical Block 8 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340911CAN	  	CS0291	    	 L-ACSR Cortical Block 9 x 11 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340941CAN	  	CS0294	    	 L-ACSR Cortical Block 9 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	340944CAN	  	CS0295	    	 L-ACSR Cortical Block 9 x 14 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Cornerstone Reserve (Cortical-Cancellous Ring) 

 

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	270050	  	270050	    	 RESERVE Cortical-Cancellous Ring 5mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270060	  	270060	    	 RESERVE Cortical-Cancellous Ring 6mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270070	  	270070	    	 RESERVE Cortical-Cancellous Ring 7mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270080	  	270080	    	 RESERVE Cortical-Cancellous Ring 8mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270090	  	270090	    	 RESERVE Cortical-Cancellous Ring 9mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270100	  	270100	    	 RESERVE Cortical-Cancellous Ring 10mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270110	  	270110	    	 RESERVE Cortical-Cancellous Ring 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270120	  	270120	    	 RESERVE Cortical-Cancellous Ring 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	270130	  	270130	    	 RESERVE Cortical-Cancellous Ring 13mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Corner Select (Fibula Wedge) 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	210500	  	210500	    	 SELECT Fibula Wedge 5mm
	  	 	********	  	  	 	********	  	  	 	********	  
	210500	  	210500	    	 SELECT Fibula Wedge 6mm
	  	 	********	  	  	 	********	  	  	 	********	  
	210700	  	210700	    	 SELECT Fibula Wedge 7mm
	  	 	********	  	  	 	********	  	  	 	********	  
	210800	  	210800	    	 SELECT Fibula Wedge 8mm
	  	 	********	  	  	 	********	  	  	 	********	  
	210900	  	210900	    	 SELECT Fibula Wedge 9mm
	  	 	********	  	  	 	********	  	  	 	********	  
	211000	  	211000	    	 SELECT Fibula Wedge 10mm
	  	 	********	  	  	 	********	  	  	 	********	  
	211100	  	211100	    	 SELECT Fibula Wedge 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	211200	  	211200	    	 SELECT Fibula Wedge 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	211300	  	211300	    	 SELECT Fibula Wedge 13mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Lordotic Cornerstone SR Cortical Block 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	300511	  	300511	    	 Lordotic SR Cortical Block 5 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300541	  	300541	    	 Lordotic SR Cortical Block 5 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300544	  	300544	    	 Lordotic SR Cortical Block 5 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	300611	  	300611	    	 Lordotic SR Cortical Block 6 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300641	  	300641	    	 Lordotic SR Cortical Block 6 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300644	  	300644	    	 Lordotic SR Cortical Block 6 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	300711	  	300711	    	 Lordotic SR Cortical Block 7 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300741	  	300741	    	 Lordotic SR Cortical Block 7 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300744	  	300744	    	 Lordotic SR Cortical Block 7 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	300811	  	300811	    	 Lordotic SR Cortical Block 8 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300841	  	300841	    	 Lordotic SR Cortical Block 8 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300844	  	300844	    	 Lordotic SR Cortical Block 8 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  
	300911	  	300911	    	 Lordotic SR Cortical Block 9 x 11 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300941	  	300941	    	 Lordotic SR Cortical Block 9 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	300944	  	300944	    	 Lordotic SR Cortical Block 9 x 14 x 14
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Tangent 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	160820	  	160820	    	 FROZEN Impacted Cortical Wedge 8 x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	160826	  	160826	    	 FROZEN Impacted Cortical Wedge 8 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	161020	  	161020	    	 FROZEN Impacted Cortical Wedge 10 x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	161026	  	161026	    	 FROZEN Impacted Cortical Wedge 10 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	161220	  	161220	    	 FROZEN Impacted Cortical Wedge 12 x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	161226	  	161226	    	 FROZEN Impacted Cortical Wedge 12 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	161426	  	161426	    	 FROZEN Impacted Cortical Wedge 14 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	170820	  	170820	    	 Tangent - Impacted Cortical Wedge 08 X 20
	  	 	********	  	  	 	********	  	  	 	********	  
	170826	  	170826	    	 Tangent - Impacted Cortical Wedge 08 X 26
	  	 	********	  	  	 	********	  	  	 	********	  
	171020	  	171020	    	 Tangent - Impacted Cortical Wedge 10 X 20
	  	 	********	  	  	 	********	  	  	 	********	  
	171026	  	171026	    	 Tangent - Impacted Cortical Wedge 10 X 26
	  	 	********	  	  	 	********	  	  	 	********	  
	171220	  	171220	    	 Tangent - Impacted Cortical Wedge 12 X 20
	  	 	********	  	  	 	********	  	  	 	********	  
	171226	  	171226	    	 Tangent - Impacted Cortical Wedge 12 X 26
	  	 	********	  	  	 	********	  	  	 	********	  
	171426	  	171426	    	 Tangent - Impacted Cortical Wedge 14 X 26
	  	 	********	  	  	 	********	  	  	 	********	  
	171626	  	171626	    	 Tangent - Impacted Cortical Wedge 16 x 26
	  	 	********	  	  	 	********	  	  	 	********	  

 Precision Graft 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	421266	  	421266	    	 Machined Cortical Ring 12” 12 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	421466	  	421466	    	 Machined Cortical Ring 12” 14 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	421666	  	421666	    	 Machined Cortical Ring 12” 16 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	421866	  	421866	    	 Machined Cortical Ring 12” 18 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	422066	  	422066	    	 Machined Cortical Ring 12” 20 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439010	  	439010	    	 Precision Graft 10 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439012	  	439012	    	 Precision Graft FD 12mm x 26mm x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439014	  	439014	    	 Precision Graft FD 14mm x 26mm x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439016	  	439016	    	 Precision Graft FD 16mm x 26mm x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439018	  	439018	    	 Precision Graft FD 18mm x 26mm x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	439020	  	439020	    	 Precision Graft FD 20mm x 26mm x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	451066	  	451066	    	 Precision Graft 10 x 26 x 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	451266	  	451266	    	 Precision Graft 12mm X 26mm X 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	451466	  	451466	    	 Precision Graft 14mm X 26mm X 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	451666	  	451666	    	 Precision Graft 16mm X 26mm X 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	451866	  	451866	    	 Precision Graft 18mm X 26mm X 26mm
	  	 	********	  	  	 	********	  	  	 	********	  
	452066	  	452066	    	 Precision Graft 20mm X 26mm X 26mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

MDII Threaded Cortical Bone Dowel Frozen 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	401114	  	401114	    	 MD-II Dowel (Threaded) 14MM X 20MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401116	  	401116	    	 MD-II Dowel (Threaded) 16MM X 20MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401118	  	401118	    	 MD-II Dowel (Threaded) 18MM X 20MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401120	  	401120	    	 MD-II Dowel (Threaded) 20MM X 20MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401214	  	401214	    	 MD-II Dowel (Threaded) 14MM X 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401216	  	401216	    	 MD-II Dowel (Threaded) 16MM X 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401218	  	401218	    	 MD-II Dowel (Threaded) 18MM X 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401220	  	401220	    	 MD-II Dowel (Threaded) 20MM X 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401222	  	401222	    	 MD-II Dowel (Threaded) 22MM X 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401224	  	401224	    	 MD-II Dowel (Threaded) 24MM x 23MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401316	  	401316	    	 MD-II Dowel (Threaded) 16MM X 26MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401318	  	401318	    	 MD-II Dowel (Threaded) 16MM X 26MM
	  	 	********	  	  	 	********	  	  	 	********	  
	401320	  	401320	    	 MD-II Dowel (Threaded) 20MM X 26MM
	  	 	********	  	  	 	********	  	  	 	********	  

 Crescent TLIF Assembled 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	293007	  	293007	    	 Lordotic Unilateral Spacer 7 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293008	  	293008	    	 Lordotic Unilateral Spacer 8 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293009	  	293009	    	 Lordotic Unilateral Spacer 9 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293010	  	293010	    	 Lordotic Unilateral Spacer 10 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293011	  	293011	    	 Lordotic Unilateral Spacer 11 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293012	  	293012	    	 Lordotic Unilateral Spacer 12 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293013	  	293013	    	 Lordotic Unilateral Spacer 13 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293014	  	293014	    	 Lordotic Unilateral Spacer 14 x 30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293015	  	293015	    	 Lordotic Unilateral Spacer 15x30mm
	  	 	********	  	  	 	********	  	  	 	********	  
	293016	  	293016	    	 Lordotic Unilateral Spacer 16x30mm
	  	 	********	  	  	 	********	  	  	 	********	  

 ISP Grafts 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	4578108	  	SB0608	    	 ISP Cortical Wedge, 8mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578110	  	SB0610	    	 ISP Cortical Wedge, 10mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578112	  	SB0612	    	 ISP Cortical Wedge, 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578114	  	SB0614	    	 ISP Cortical Wedge, 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578116	  	SB0616	    	 ISP Cortical Wedge, 16mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578118	  	SB0618	    	 ISP Cortical Wedge, 18mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578120	  	SB0620	    	 ISP Cortical Wedge, 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578710	  	SB0570	    	 ISP Cortical Spacer, 10mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578712	  	SB0572	    	 ISP Cortical Spacer, 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	4578714	  	SB0574	    	 ISP Cortical Spacer, 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781709	  	SB0079	    	 ISP Cancellous Spacer, 7 x 9 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781711	  	SB0071	    	 ISP Cancellous Spacer, 7 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781713	  	SB0073	    	 ISP Cancellous Spacer, 7 x 13 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781909	  	SB0099	    	 ISP Cancellous Spacer, 9 x 9 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781911	  	SB0091	    	 ISP Cancellous Spacer, 9 x 11 mm
	  	 	********	  	  	 	********	  	  	 	********	  
	45781913	  	SB0093	    	 ISP Cancellous Spacer, 9 x 13 mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Cancellous Plug 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	221019	  	221019	    	 Cornerstone Cancellous Plug, 10mm Large
	  	 	********	  	  	 	********	  	  	 	********	  
	221096	  	221096	    	 Cornerstone Cancellous Plug, 10mm Small
	  	 	********	  	  	 	********	  	  	 	********	  
	221219	  	221219	    	 Cornerstone Cancellous Plug, 12mm Large
	  	 	********	  	  	 	********	  	  	 	********	  
	221296	  	221296	    	 Cornerstone Cancellous Plug, 12mm Small
	  	 	********	  	  	 	********	  	  	 	********	  

 Facet Fix 
  

																	
	MDT CFN	  	RTI P/N	  	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	223510	  	223510	  	 FacetFix, 5mm x 10mm Facet Dowel
	  	 	********	  	  	 	********	  	  	 	********	  

 Anatomic Cervical Allograft Spacer 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	6940541	  	SA0541	    	 Anatomic Cervical Allograft Spacer 5 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940564	  	SA0564	    	 Anatomic Cervical Allograft Spacer 5 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940641	  	SA0641	    	 Anatomic Cervical Allograft Spacer 6 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940664	  	SA0664	    	 Anatomic Cervical Allograft Spacer 6 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940741	  	SA0741	    	 Anatomic Cervical Allograft Spacer 7 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940764	  	SA0764	    	 Anatomic Cervical Allograft Spacer 7 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940841	  	SA0841	    	 Anatomic Cervical Allograft Spacer 8 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940864	  	SA0864	    	 Anatomic Cervical Allograft Spacer 8 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940941	  	SA0941	    	 Anatomic Cervical Allograft Spacer 9 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6940964	  	SA0964	    	 Anatomic Cervical Allograft Spacer 9 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941041	  	SA0041	    	 Anatomic Cervical Allograft Spacer 10 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941064	  	SA0064	    	 Anatomic Cervical Allograft Spacer 10 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941164	  	SA0164	    	 Anatomic Cervical Allograft Spacer 11 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941241	  	SA0241	    	 Anatomic Cervical Allograft Spacer 12 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941264	  	SA0264	    	 Anatomic Cervical Allograft Spacer 12 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941341	  	SA0341	    	 Anatomic Cervical Allograft Spacer 13 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941364	  	SA0364	    	 Anatomic Cervical Allograft Spacer 13 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941441	  	SA0441	    	 Anatomic Cervical Allograft Spacer 14 x 14 x 11mm
	  	 	********	  	  	 	********	  	  	 	********	  
	6941464	  	SA0464	    	 Anatomic Cervical Allograft Spacer 14 x 16 x 14mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Total Facet Shim 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	609002	  	SB0128	    	 2x8x8mm Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609003	  	SB0138	    	 3x8x8mm Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609004	  	SB0148	    	 4x8x8mm Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609404	  	SB0141	    	 4x8x10 Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609405	  	SB0151	    	 5x8x10 Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609406	  	SB0161	    	 6x8x10 Cornerstone Micro
	  	 	********	  	  	 	********	  	  	 	********	  
	609603	  	SB0238	    	 3x8x8mm Cornerstone Micro Wedge
	  	 	********	  	  	 	********	  	  	 	********	  
	609604	  	SB0248	    	 4x8x8mm Cornerstone Micro Wedge
	  	 	********	  	  	 	********	  	  	 	********	  

 Tricortical Block 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	320105	  	320105	    	 Tricortical Block 5mm
	  	 	********	  	  	 	********	  	  	 	********	  
	320106	  	320106	    	 Tricortical Block 6mm
	  	 	********	  	  	 	********	  	  	 	********	  
	320107	  	320107	    	 Tricortical Block 7mm
	  	 	********	  	  	 	********	  	  	 	********	  
	320108	  	320108	    	 Tricortical Block 8mm
	  	 	********	  	  	 	********	  	  	 	********	  
	320109	  	320109	    	 Tricortical Block 9mm
	  	 	********	  	  	 	********	  	  	 	********	  
	320110	  	320110	    	 Tricortical Block 10mm
	  	 	********	  	  	 	********	  	  	 	********	  

 NON-EXCLUSIVE PRODUCTS 

Cornerstone Pinnacle 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	545541	  	545541	    	 MASR Cortical-Cancellous Block 5 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  
	545641	  	545641	    	 MASR Cortical-Cancellous Block 6 x 14 x 11
	  	 	********	  	  	 	********	  	  	 	********	  

 Unicortical Dowel 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	280012	  	280012	    	 Dowel, Unicortical 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	280014	  	280014	    	 Dowel, Unicortical 14mm
	  	 	********	  	  	 	********	  	  	 	********	  
	280016	  	280016	    	 Dowel, Unicortical 16mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Confidential Treatment Requested 

Cornerstone Iliac Block, Tricortical 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	310107	  	310107	    	 Iliac Block, Tricortical 7mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310108	  	310108	    	 Iliac Block, Tricortical 8mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310109	  	310109	    	 Iliac Block, Tricortical 9mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310110	  	310110	    	 Iliac Block, Tricortical 10mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310112	  	310112	    	 Iliac Block, Tricortical 12mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310114	  	310114	    	 Iliac Block, Tricortical 14mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310115	  	310115	    	 Iliac Block, Tricortical 15mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310116	  	310116	    	 Iliac Block, Tricortical 16mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310118	  	310118	    	 Iliac Block, Tricortical 18mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310120	  	310120	    	 Iliac Block, Tricortical 20mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  
	310225	  	310225	    	 Iliac Block, Tricortical 25mm x 15mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Bicortical Block 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	862010	  	862010	    	 Bicortical Block 10mm x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	862012	  	862012	    	 Bicortical Block 12mm x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	862014	  	862014	    	 Bicortical Block 14mm x 20mm
	  	 	********	  	  	 	********	  	  	 	********	  
	862512	  	862512	    	 Bicortical Block 12mm x 25mm
	  	 	********	  	  	 	********	  	  	 	********	  
	862514	  	862514	    	 Bicortical Block 14mm x 25mm
	  	 	********	  	  	 	********	  	  	 	********	  
	862516	  	862516	    	 Bicortical Block 16mm x 25mm
	  	 	********	  	  	 	********	  	  	 	********	  
	872007	  	872007	    	 Bicortical Block 7mm
	  	 	********	  	  	 	********	  	  	 	********	  
	872008	  	872008	    	 Bicortical Block 8mm
	  	 	********	  	  	 	********	  	  	 	********	  

 Unicortical Block 
  

																	
	MDT CFN	  	RTI P/N	    	Description	  	Current Fee	 	  	New Fee	 	  	Change	 
	850612	  	850612	    	 Unicortical Block 6 x 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	850712	  	850712	    	 Unicortical Block 7 x 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	850812	  	850812	    	 Unicortical Block 8 x 12mm
	  	 	********	  	  	 	********	  	  	 	********	  
	850912	  	850912	    	 Unicortical Block 9 x 12mm
	  	 	********	  	  	 	********	  	  	 	********	  

 EXHIBIT B 

	
	 

 

 
  

Osteobiologic Implants 
 RTI BIOLOGICS® 

 

 
  
 About RTI
Biologics, Inc. 
 Strong commitment to advancing science, safety and innovation 

Global leader in tissue-based innovations 
 Precisely shapes allograft tissue for use in surgeries 
 Sterilizes tissue with proprietary, validated sterilization processes 
 that inactivate viruses—including BioCleanse® Tissue Sterilization 
 Process, Tutoplast® Tissue Sterilization Process, and Cancelle® SP DBM 
 Sterilization Process 
 RTI Biologics, Inc. is the
leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue for transplantation through extensive testing and screening, precision
shaping and proprietary, validated sterilization processes. These allograft implants are used in orthopedic, dental, hernia and other specialty surgeries. 
 RTI’s innovations continuously raise the bar of science and safety for biologics—from being the first company to offer precision-tooled bone implants and assembled technology to
maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. These processes sterilize tissue, are clinically successful and are scientifically proven to address donor-to-recipient
disease transmission risk while preserving tissue strength and biocompatibility. They have a proven record of more than four million implants distributed with zero incidence of implant-associated infection. RTI’s worldwide corporate
headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited in the U.S. by the American Association of Tissue Banks. 

Vision 
 We will be recognized as the world leader in transforming donated and natural tissue into safe and innovative biologic solutions. 

Mission 
 We improve lives by using the body to heal the body to achieve life-restoring results. 
 References 
 1 Archibald, LA, et al.,
“Seroprevalence of Bloodborne Viruses Among Cadaveric Donors of Human Tissue: Implications for Tissue Safety.” Presented at EATB 2005. 
 2 Carr, AS, et. al., “Mechanical Testing of Soft Tissue Allografts Sterilized Through the BioCleanse Process.” Unpublished data, 2005. 

1About RTI Biologics 

 

 
  
 Table of
Contents 
 Sterilization Processes Overview 3-4 

General Orthopedic Conventional Allografts 
 Chips and Cubes 5 
 Blocks and Dowels 6 

Wedges and Strips 7 
 Shafts 8 
 Reconstructive Large Segmental
Allografts 
 Heads and Condyles 9 
 Proximal and Distal Grafts 10 
 Whole Bones 11

 Osteoinductive Demineralized Bone Grafts 

DBM Powder 12 
 BioReadyTM DBM Putty 12 
 BioSet® DBM
Allograft Paste 13 
 BioAdaptTM Foam 13 

Precision Machined Spine Spacers 
 Cortical Cervical Spacer 14 
 PROVEN 

QUALITY 
 Table of Contents 2 

 

 
  
 The Path
from Recovery to Implantation 
 Donor Screening 

Serological & Microbiological Testing 
 Tissue before processing 
 Tissue shaped into final
form 
 Through its innovations, RTI Biologics, Inc. 

(RTI) continuously raises the bar of science and 
 safety for biologics – from being the first company to 
 offer precision-tooled bone implants and assembled 

technology, to inventing fully validated sterilization 

processes that include viral inactivation steps. Three 

such processes–the BioCleanse®Tissue Sterilization 

Process, the Tutoplast® Tissue Sterilization Process 

and Cancelle® DBM Sterilization Process – have a 

proven combined record of more than four million 
 implants distributed with zero incidence of implant-associated 
 infection. Validation studies have been 
 performed
for each process based on tissue type 
 using appropriate challenge microorganisms. 

Serological Testing (for every donor): 
 •HCV Antibody 
 •HTLV-I & HTLV-II
Antibody 
 •HBV Surface Antigen 
 •Syphilis 
 •HIV 1 & 2 Antibody

 •HIV-I/NAT 
 •HBV Total Core Antibody 
 •HCV/NAT

 After consent/authorization for donation is obtained, donor history 

screening and laboratory testing is performed in accordance 

with FDA regulations and AATB Standards. 
 Screening for Patient Safety 
 A complete donor
risk assessment interview must be performed for every 
 donor including: 

Cause of death: Donors are only accepted if cause of death is 

established. 
 Donor Risk Assessment: 
 RTI receives donated
tissue from independently licensed recovery agencies 
 which screen for safety prior to recovery, including
conducting an interview 
 with the family/next of kin and a behavioral/lifestyle risk assessment. 

Following receipt of tissue from the recovery agency, RTI evaluates 

records from the recovery agency and performs the following donor risk 

assessment: 
 Medical record/hospital records review 
 Medical
examiner/coroner’s report (autopsy report, when available) 
 Laboratory, pathology and radiology reports

 The final determination of donor eligibility is made by RTI’s medical director – 

a licensed physician – utilizing all available, relevant information. 

Testing for Patient Safety 
 An extensive panel of serological and microbiological tests are performed. 
 These results are subject to stringent acceptance criteria in order to release 
 the donor tissue. 
 In addition to serological
testing on the donor’s blood, microbiological testing 
 is used throughout the process (where appropriate)
to screen for potential 
 contamination and to provide confirmation of tissue suitability for transplant.

 3 Sterilization Processes Overview 

 

 
  

BioCleanse® Tissue Sterilization Process 
 Bone and sports medicine soft tissue 
 Low
temperature chemical process 
 BIOCLEANSE® 

TISSUE STERILIZATION PROCESS 
 Tissue sterilized to SAL 10-6 
 Bone grafts are
terminally sterilized by a validated method. Sports medicine tendons are not terminally irradiated. 

Cancelle® SP DBM Sterilization Process 
 DBM pastes and putties 
 Bone undergoes
demineralization 
 Low-temperature terminal irradiation 

CANCELLE®SP 
 DBM STERILIZATION PROCESS 
 Sterile finished graft

 For most DBM-based implants**, the irradiation dose is applied terminally to achieve an SAL of 10-6.

 BioCleanse® Tissue Sterilization Process 

RTI Biologics’ allograft constructs/spacers and sports medicine soft tissue implants are sterilized to Sterility
Assurance Level 10-6 through its patented BioCleanse Tissue Sterilization Process, an automated, pharmaceutical grade process. BioCleanse sterilization is used on grafts that provide a natural biologic scaffold in orthopedic, spine and sports
medicine procedures. 
 How does the BioCleanse Process work? 

The BioCleanse system sterilizes tissue to SAL 10-6 using a complex, proprietary combination of mechanical and chemical
processes, working in conjunction with each other. The mechanical component applies oscillating positive and negative pressure in the presence of the chemical agents (including detergents and sterilants), which gently perfuse the tissue. This
combination removes blood and lipids, and inactivates or removes pathogenic microorganisms. Repeated water rinses throughout the process remove debris, and final water rinses remove residual chemicals, leaving the tissue biocompatible. The
BioCleanse Process does not sterilize using irradiation. 
 Even if other safeguards fail, RTI’s BioCleanse
technology sterilizes both bone and soft tissue to SAL 10-6. This SAL was established using worst case testing scenarios which included Achilles tendon (because of its dense nature) and spores (because they are the most difficult microorganisms to
remove). 
 Cancelle® SP DBM Sterilization Process 

DBM pastes and putties are sterilized through the Cancelle SP Process, which is a validated bone matrix sterilization
process designed to preserve protein activity. Their osteoinductive (OI) potential*is verified by 100% lot testing after sterilization. In their final form, the DBM products serve as bone void fillers in many applications, including spinal, general
orthopedic and joint reconstruction surgeries. 
 How does the Cancelle SP Process work? 

Cancelle SP is a proprietary process that sterilizes DBM while simultaneously allowing it to maintain its osteoinductive*
potential. Through a combination of oxidative treatments and acid or alcohol washes, debris is removed and pathogens are inactivated. Cleansing rinses remove residual chemicals, maintaining biocompatibility, and low temperature, low dose gamma
irradiation preserves the utility of the graft. For most DBM-based products**, the irradiation dose is applied terminally to achieve a sterility assurance level (SAL) of 10-6. 
 *DBM or representative finished implant is either assayed in vivo in the modified athymic nude rat for bone formation or in vitro for endogenous BMP-2 as a surrogate test marker for
osteoinductive potential. Because the combination of various proteins is responsible for osteoinductive potential, when assayed in vitro, DBM is also screened for the presence of BMP-7. Findings from an in vitro assay or animal model are not
necessarily predictive of human clinical results. 
 **Refer to implant package insert for specific processing
information. 
 Sterilization Processes Overview 4 

 

 
  
 General
Orthopedic Conventional Allografts 
 Chips and Cubes 

Sterilized through the BioCleanse® Process 
 Terminal sterilization after the BioCleanse Process achieves SAL 10-6 and 
 labeled STERILE 
 Chips and Cubes Sterilization:
BioCleanse® 
 Code 
 Description Preservation 
 1-4mm Chips 100005

 Cancellous Chips (1-4mm) 5cc FD 100015 

Cancellous Chips (1-4mm) 15cc FD 100030 
 Cancellous Chips (1-4mm) 30cc FD 100060 

Cancellous Chips (1-4mm) 60cc FD 100090 
 Cancellous Chips (1-4mm) 90cc FD 
 4-10mm Chips
100405 
 Cancellous Chips (4-10mm) 5cc FD 100415 

Cancellous Chips (4-10mm) 15cc FD 100430 
 Cancellous Chips (4-10mm) 30cc FD 100460 

Cancellous Chips (4-10mm) 60cc FD 100490 
 Cancellous Chips (4-10mm) 90cc FD 1-4mm 
 Chips
100505 
 Cancellous Chips (1-4mm) 5cc FZ 100515 

Cancellous Chips (1-4mm) 15cc FZ 100530 
 Cancellous Chips (1-4mm) 30cc FZ 4-10mm 
 Chips
100605 
 Cancellous Chips (4-10mm) 5cc FZ 100615 

Cancellous Chips (4-10mm) 15cc FZ 100630 
 Cancellous Chips (4-10mm) 30cc FZ 4-6mm 
 Cubes
100205 
 Cancellous Cubes (4-6mm) 5cc FD 100215 

Cancellous Cubes (4-6mm) 15cc FD 100230 
 Cancellous Cubes (4-6mm) 30cc FD 6-10mm 
 Cubes
100305 
 Cancellous Cubes (6-10mm) 5cc FD 100315 

Cancellous Cubes (6-10mm) 15cc FD 100330 
 Cancellous Cubes (6-10mm) 30cc FD 

Cortical/Cancellous Blends 110115 
 Cortical Cancellous Chips 40/60 MIX (1-3mm) 
 15cc
FD 110130 
 Cortical Cancellous Chips 
 40/60 MIX (1-3mm) 30cc FD 
 FD=Freeze Dried

 4 - 10mm Chips 
 1 - 4mm Chips 
 6 - 10mm Cubes 

4 - 6mm Cubes 
 Cortical/ Cancellous Blend 
 BIOCLEANSE 

5 General Orthopedic Conventional Allografts 

 

 
  
 General
Orthopedic Conventional Allografts 
 Blocks and Dowels 

Pre-cut to select heights and footprints 
 Sterilized through the BioCleanse Process 

Terminal sterilization after the BioCleanse Process achieves SAL 10-6 and 

labeled STERILE 
 Blocks Sterilization: BioCleanse® 
 Code
Description HxLxW Preservation 
 D08562 Unicortical Block 6x12x12mm FD 

D08572 Unicortical Block 7x12x12mm FD 
 D08582 Unicortical Block 8x12x12mm FD 
 D08592
Unicortical Block 9x12x12mm FD 
 D08502 Unicortical Block 10x12x12mm FD 

D08706 Bicortical Block 6x15x12mm FD 
 D08707 Bicortical Block 7x15x12mm FD 
 D08708
Bicortical Block 8x15x12mm FD 
 D08709 Bicortical Block 9x15x12mm FD 

Blocks HxLxW D08600 
 Bicortical Block 10x20x9mm FD D08602 
 Bicortical
Block 12x20x9mm FD D08604 
 Bicortical Block 14x20x9mm FD D08650 

Bicortical Block 10x25x9mm FD D08652 
 Bicortical Block 12x25x9mm FD D08654 
 Bicortical
Block 14x25x9mm FD D03205 
 Ilium Tricortical Block 5x12x14mm FD D03206 

Ilium Tricortical Block 6x12x14mm FD D03207 
 Ilium Tricortical Block 7x12x14mm FD D03208 
 Ilium
Tricortical Block 8x12x14mm FD D03209 
 Ilium Tricortical Block 9x12x14mm FD D03210 

Ilium Tricortical Block 10x12x14mm FD D03107 
 Ilium Tricortical Block 7x 315x 310mm FD 

D03108 Ilium Tricortical Block 8x 315x
310mm FD 
 D03109 Ilium Tricortical Block 9x 315x 310mm FD 
 D03110 Ilium
Tricortical Block 10x 315x 310mm FD 
 D03112 Ilium Tricortical Block 12x 315x 310mm FD 

D03114 Ilium Tricortical Block 14x 315x
310mm FD 
 D03115 Ilium Tricortical Block 15x 315x 310mm FD 
 D03116 Ilium
Tricortical Block 16x 315x 310mm FD D03118 
 Ilium Tricortical Block 18x 315x 310mm FD D03120 

Ilium Tricortical Block 20x 315x
310mm FD D03125 
 Ilium Tricortical Block 25x 330x 314mm FD Dowels HxD D02812 
 Unicortical Dowel 12x15-35mm FD D02814 

Unicortical Dowel 14x15-35mm FD D02816 
 Unicortical Dowel 16x15-35mm FD D02818 

Unicortical Dowel 18x15-35mm FD 
 Unicortical 
 Block (Cervical) 

12 x 12 
 H W L 
 Bicortical 

Block (Lumbar) 
 20 x 9 
 L W H 

W2 H L W1 
 Ilium Tricortical 
 Block (Lumbar) 

315 x 310 

W L H 
 Bicortical 
 Block 

(Cervical) 
 15 x 12 
 W1 H L W2 

Ilium Tricortical 
 Block (Cervical) 
 12 x 14 

Unicortical 
 Dowel (Lumbar) 
 15-35mm Dia. 

H D 
 BIOCLEANSE 
 General Orthopedic Conventional
Allografts 6 

 

 
  
 General
Orthopedic Conventional Allografts 
 Wedges 

Sterilized through the BioCleanse® Process 
 Terminal sterilization after the BioCleanse Process achieves SAL 10-6 and 
 labeled STERILE 
 L H 

Measurements Recorded: 
 Maximum length 3 50mm 
 Maximum height 
 Minimum width 3 40mm 
 Angle measured on small end 

BIOCLEANSE 
 HTO Wedge Sterilization: BioCleanse® 
 Code
Description (Height) Preservation 
 180672 HTO Wedge 6 degrees, 7.5mm FD 

180872 HTO Wedge 8 degrees, 10.0mm FD 
 181072 HTO Wedge 10 degrees, 12.5mm FD 
 181272 HTO
Wedge 12 degrees, 15.0mm FD 
 181472 HTO Wedge 14 degrees, 17.5mm FD 

190672 HTO Wedge 6 degrees, 7.5mm FZ 
 190872 HTO Wedge 8 degrees, 10.0mm FZ 
 191072 HTO
Wedge 10 degrees, 12.5mm FZ 
 191272 HTO Wedge 12 degrees, 15.0mm FZ 

191472 HTO Wedge 14 degrees, 17.5mm FZ 
 Strips 
 Sterilized through the BioCleanse®
Process 
 Terminal sterilization after the BioCleanse Process achieves SAL 10-6 

and labeled STERILE 
 T1 T2 W L 
 Measurements Recorded: 

Maximum width 
 Minimum length >24mm 
 Maximum thickness >9mm

 Minimum thickness 
 BIOCLEANSE 
 Ilium Tricortical Strip Sterilization:
BioCleanse® 
 Code Description (Width) Preservation 

339030 Ilium Strip Tricortical 28-45mm FZ 
 339050 Ilium Strip Tricortical 46-57mm FZ 
 339060
Ilium Strip Tricortical >58mm FZ 
 330030 Ilium Strip Tricortical 28-45mm FD 

330050 Ilium Strip Tricortical 46-57mm FD 
 330060 Ilium Strip Tricortical >58mm FD 

FD=Freeze Dried 
 FZ=Frozen 
 7 General Orthopedic Conventional
Allografts 

 

 
  
 General
Orthopedic Conventional Allografts 
 Shafts 

Pre-cut to select lengths to reduce OR prep time 
 Sterilized through the BioCleanse Process 

Terminal sterilization after the BioCleanse Process achieves SAL 10-6 and 

labeled STERILE 
 Femoral Shafts Sterilization: BioCleanse® 

Code Description (Length) Preservation 
 639010 Femoral Shaft 98-130mm FZ 
 639015 Femoral
Shaft 131-165mm FZ 
 639020 Femoral Shaft 166-202mm FZ 

632010 Femoral Shaft 98-130mm FD 
 632015 Femoral Shaft 131-165mm FD 
 632020 Femoral
Shaft 166-202mm FD 
 Hemi Femoral Shafts 

639110 Hemi Femoral Shaft 98mm-130mm FZ 
 639115 Hemi Femoral Shaft 131mm-165mm FZ 
 639120
Hemi Femoral Shaft 166mm-202mm FZ 
 632110 Hemi Femoral Shaft 98mm-130mm FD 

632115 Hemi Femoral Shaft 131mm-165mm FD 
 632120 Hemi Femoral Shaft 166mm-202mm FD 
 Humeral
Shafts 
 699060 Humeral Shaft 50mm-100mm FZ 

699010 Humeral Shaft 101mm-150mm FZ 
 691060 Humeral Shaft 50mm-100mm FD 
 692010 Humeral
Shaft 101mm-150mm FD 
 Tibial Shafts 
 789060 Tibial Shaft 50mm-75mm FZ 
 789010 Tibial
Shaft 76mm-102mm FZ 
 789015 Tibial Shaft 103mm-152mm FZ 

781060 Tibial Shaft 50mm-75mm FD 
 782010 Tibial Shaft 76mm-102mm FD 
 782015 Tibial
Shaft 103mm-152mm FD 
 Fibula Shafts Sterilization: BioCleanse® 

Code Description (Length) Preservation 
 669060 Fibula Shaft 50mm-75mm FZ 
 669080 Fibula
Shaft 76mm-98mm FZ 
 669010 Fibula Shaft 99mm-125mm FZ 

661060 Fibula Shaft 50mm-75mm FD 
 661080 Fibula Shaft 76mm-98mm FD 
 662010 Fibula
Shaft 99mm-125mm FD 
 FD=Freeze Dried 
 FZ=Frozen 
 Femoral Shaft 

ML AP L 
 Hemi Femoral Shaft 
 ML AP L 

Humeral Shaft 
 AP ML L 
 Tibial Shaft 

AP L 
 Measurements Recorded: 
 Length 

AP diameter and ML diameter 
 Minimum cortical-wall thickness of 3mm 
 BIOCLEANSE

 Fibula Shaft 
 ML AP L 
 Measurements Recorded: 

Length 
 AP diameter and ML diameter 
 Minimum cortical-wall
thickness of 1.5mm 
 BIOCLEANSE 
 General Orthopedic Conventional Allografts 8 

 

 
  

Reconstructive Large Segmental Allografts 
 Heads and Condyles 
 Existing cartilage still
attached (except femoral head) 
 Sterilized through the BioCleanse® Process 

Terminal sterilization after the BioCleanse Process achieves SAL 10-6 

and labeled STERILE 
 Femoral Head Sterilization: BioCleanse® 
 Code
Description Preservation 
 620100 Femoral Head w/o Cartilage FZ 

Humeral Head Left Right Description Preservation 
 680001 680002 
 Humeral Head FZ 

Distal Tibial Condyle 
 Left 
 Right 

Description 
 Preservation 
 770301 

770302 
 Distal Tibial Condyle 
 FZ 

Femoral Head 
 Humeral Heads 
 Distal Tibial Condyles 

BIOCLEANSE 
 FZ=Frozen 
 9 Reconstructive Large Segmental
Allografts 

 

 
  

Reconstructive Large Segmental Allografts 
 Proximal and Distal Grafts 
 Existing cartilage
still attached 
 Sterilized through the BioCleanse Process 

Terminal sterilization after the BioCleanse Process achieves SAL 10-6 

and labeled STERILE 
 Femur Sterilization: BioCleanse® 
 Left Right
Description Length Preservation 
 640207 640208 Distal Femur Short 150-250mm FZ 

640217 640218 Distal Femur Long 251-350mm FZ 
 640107 640108 Proximal Femur Short 150-250mm FZ 

640117 640118 Proximal Femur Long 251-350mm FZ 
 Humerus 
 Left Right Description Length
Preservation 
 670101 670102 Proximal Humerus Short 130-200mm FZ 

670111 670112 Proximal Humerus Long 201-270mm FZ 
 670201 670202 Distal Humerus Short 130-200mm FZ 

670211 670212 Distal Humerus Long 201-270mm FZ 
 Tibia 
 Left Right Description Length Preservation

 760201 760202 Distal Tibia Short 150-200mm FZ 

760211 760212 Distal Tibia Long 201-300mm FZ 
 760101 760102 Proximal Tibia Short 150-200mm FZ 

760111 760112 Proximal Tibia Long 201-300mm FZ 
 Distal 
 Femur 

Proximal 
 Femur 
 Proximal 

Humerus 
 Distal 
 Humerus 

Measurements Recorded: 
 Distal Femur 
 Length 

ML measurement of distal condyle 
 AP measurement of distal condyle 
 Shaft’s
outer diameter 
 Cortical-wall thickness 

Proximal Femur w/Head 
 Length 
 Femoral head outer diameter 

Shaft’s outer diameter 
 Cortical-wall thickness 
 Proximal Humerus

 Length 
 Shaft’s outer diameter 
 Cortical-wall
thickness 
 Proximal condyle’s outer diameter 

Distal Humerus 
 Length 
 Shaft’s outer diameter 

Cortical-wall thickness 
 BIOCLEANSE 
 Measurements Recorded: 

Distal Tibia 
 Length 
 ML measurement of distal condyle

 AP measurement of distal condyle 
 Shaft’s outer diameter 
 Cortical-wall
thickness 
 Proximal Tibia 
 Length 
 ML measurement of proximal condyle

 AP measurement of proximal condyle 
 Shaft’s outer diameter 
 Cortical-wall
thickness 
 Distal Tibia 
 Proximal 
 Tibia 

BIOCLEANSE 
 FZ=Frozen 
 Reconstructive Large Segmental
Allografts 10 

 

 
  

Reconstructive Large Segmental Allografts 
 Whole Bones 
 Existing cartilage still attached

 Sterilized through the BioCleanse® Process 

Terminal sterilization after the BioCleanse Process achieves SAL 10-6 

and labeled STERILE 
 Femur Sterilization: BioCleanse® 
 Left Right
Description Length Preservation 
 640001 640002 Whole Femur Variable FZ 

Humerus 
 Left Right Description Length Preservation 
 670001
670002 Whole Humerus Variable FZ 
 Tibia 

Left Right Description Length Preservation 
 760001 760002 Whole Tibia Variable FZ 
 Fibula

 Left Right Description Length Preservation 

650001 650002 Whole Fibula Variable FZ 
 Radius 
 Left Right Description Length Preservation

 730001 730002 Whole Radius Variable FZ 

Ulna 
 Left Right Description Length Preservation 
 790001
790002 Whole Ulna Variable FZ 
 Measurements Recorded: 

Whole Ulna Whole Humerus Length Length 
 ML measurement of proximal condyle 
 Shaft’s
outer diameter 
 AP measurement of proximal condyle 

Proximal head outer diameter 
 Shaft’s outer diameter 
 ML measurement of
distal condyle 
 Whole Tibia 
 AP measurement of distal condyle 
 Length

 ML measurement of proximal condyle 
 Whole Radius 
 AP measurement of proximal condyle

 Length 
 Shaft’s outer diameter 
 ML measurement of
proximal condyle 
 ML measurement of distal condyle 

ML measurement of distal condyle 
 Shaft’s outer diameter 
 Whole Fibula

 Length 
 Whole Femur 
 ML measurement of proximal condyle

 Length 
 ML measurement of distal condyle 
 ML measurement
of distal condyle 
 Shaft’s outer diameter 

Shaft’s outer diameter 
 Femoral head outer diameter 
 AP measurement of
distal condyle 
 FZ=Frozen 
 Whole Ulna 
 Whole Radius 

Whole Femur 
 Whole Humerus 
 Whole Tibia 

Whole Fibula 
 BIOCLEANSE 
 11 Reconstructive Large Segmental
Allografts 

 

 
  

Osteoinductive Demineralized Bone Grafts 
 DBM Powder 
 Osteoinductive* (OI) potential is
verified by 100% lot testing after sterilization 
 Sterilized through the Cancelle® SP DBM Sterilization
Process using low-temperature, 
 low dose gamma irradiation to achieve SAL 10-6 

DBM Powder Sterilization: Cancelle® SP 
 Code Description Preservation 
 004805 DBM Powder
5cc FD 
 004810 DBM Powder 10cc FD 
 004815 DBM Powder 15cc FD 
 CANCELLE SP 

DBM Powder 
 FD=Freeze Dried 
 BioReadyTM DBM Putty

 Ready-to-use, 100% allograft 
 Pliable without becoming hard or setting 

Osteoinductive* (OI) potential is verified by 100% lot testing after sterilization 

Sterilized through the Cancelle® SP DBM Sterilization Process using low-temperature, 

low dose gamma irradiation to achieve SAL 10-6 
 Putty Sterilization: Cancelle® SP 
 Code
Description Preservation 
 D00100 BioReadyTM DBM Putty 0.5cc Pre-hydrated 

D00101 BioReadyTM DBM Putty 1cc Pre-hydrated 
 D00102 BioReadyTM DBM Putty 2cc Pre-hydrated 

D00105 BioReadyTM DBM Putty 5cc Pre-hydrated 
 D00110 BioReadyTM DBM Putty 10cc Pre-hydrated 

Putty with Chips 
 Code Description Preservation 
 D00300
BioReadyTM DBM Putty with Chips 0.5cc Pre-hydrated 
 D00301 BioReadyTM DBM Putty with Chips 1cc
Pre-hydrated 
 D00302 BioReadyTM DBM Putty with Chips 2cc Pre-hydrated 

D00305 BioReadyTM DBM Putty with Chips 5cc Pre-hydrated 

D00310 BioReadyTM DBM Putty with Chips 10cc Pre-hydrated 

D00320 BioReadyTM DBM Putty with Chips 20cc Pre-hydrated 

*DBM or representative finished implant is either assayed in vivo in the modified athymic nude rat for bone formation or
in vitro for endogenous BMP-2 as a 
 surrogate test marker for osteoinductive potential. Because the combination
of various proteins is responsible for osteoinductive potential, when assayed in vitro, 
 DBM is also screened
for the presence of BMP-7. Findings from an in vitro assay or animal model are not necessarily predictive of human clinical results. 
 CANCELLE SP 
 Osteoinductive Demineralized Bone
Grafts 12 

 

 
  

Osteoinductive Demineralized Bone Grafts 
 BioSet® DBM Allograft Paste 
 Can be hydrated
with fluid of choice 
 Sets once implanted 

Osteoinductive* (OI) potential is verified by 100% lot testing after 

sterilization 
 Sterilized through the Cancelle® SP DBM Sterilization Process using low-temperature, 
 low dose gamma irradiation to achieve SAL 10-6 

BioSet® DBM Allograft Paste Sterilization: Cancelle® SP 

Code Description Preservation 
 005700 BioSet® RT Allograft Paste, Syringe, 0.5cc DR 
 005701 BioSet® RT Allograft Paste, Syringe, 1cc DR 
 005705 BioSet® RT Allograft Paste, Syringe, 5cc DR 
 005710 BioSet® RT Allograft Paste, Syringe, 10cc DR 
 005800 BioSet® Allograft Paste, Syringe, 0.5cc FZ 
 005801 BioSet® Allograft Paste, Syringe, 1cc FZ 

005805 BioSet® Allograft Paste, Syringe, 5cc FZ 

005810 BioSet® Allograft Paste, Syringe, 10cc FZ 

006702 BioSet® IC, RT Allograft Paste, 2cc DR 
 006705 BioSet® IC, RT Allograft Paste, 5cc DR 

006710 BioSet® IC, RT Allograft Paste, 10cc DR 

006720 BioSet® IC, RT Allograft Paste, 20cc DR 

006805 BioSet® IC Moldable Allograft Paste, Syringe, 5cc FZ 

006810 BioSet® IC Moldable Allograft Paste, Syringe, 10cc FZ 

006820 BioSet® IC Moldable Allograft Paste, Syringe, 20cc FZ 

007820 BioSet® IC Allograft Full Disc, 20 x 3mm, 1cc FZ 

007890 BioSet® IC Allograft Full Disc, 90 x 5mm, 32cc FZ 

007830 BioSet® IC Allograft Full Disc, 30 x 3mm, 2cc FZ 

007845 BioSet® IC Allograft Full Disc, 45 x 5mm, 5cc FZ 

007875 BioSet® IC Allograft Partial Disc, 75 x 5mm, 15cc FZ 

007891 BioSet® IC Allograft Partial Disc, 90 x 5mm, 22cc FZ 

008850 BioSet® IC Moldable Strip, 50mm (2 each), 6cc FZ 

008890 BioSet® IC Moldable Strip, 90mm (2 each), 10cc FZ 

DR=Dried 
 FZ=Frozen 
 BioSet® RT Allograft Paste

 BioSet® 
 Allograft 
 Paste 

BioSet® IC, RT Allograft Paste 
 BioSet® IC 
 Allograft 

Full Disc 
 BioSet® IC 
 Allograft 

Partial Disc 
 BioSet® IC 
 Moldable Strip 

CANCELLE SP 
 *These products induced bone formation when evaluated using the modified athymic nude rat assay. 
 Findings from an animal model are not necessarily predictive of human clinical results. 
 13 Osteoinductive Demineralized Bone Grafts 

 

 
  

Osteoinductive Demineralized Bone Grafts 
 BioAdaptTM Foam 
 Can be hydrated with fluid of
choice 
 Pre-shaped DBM that expands with hydration to provide a contoured fit to the 

bony defect 
 Osteoinductive* (OI) potential is verified by 100% lot testing after sterilization 
 Sterilized through the BioCleanse® Process and Cancelle® SP DBM Sterilization 
 Process using low-temperature, low dose gamma irradiation to achieve SAL 10-6 
 BioAdaptTM Foam Sterilization: BioCleanse®, Cancelle® SP 
 Code Description L x W x H, Volume Preservation 

DU0110 BioAdaptTM Foam, Skinny Strips 100 x 10 x 8mm, 16cc DR 

DU0125 BioAdaptTM Foam, Large Strip 100 x 25 x 5mm, 12cc DR 

DU0025 BioAdaptTM Foam, Medium Strip 50 x 25 x 5mm, 6cc DR 

DU0015 BioAdaptTM Foam, Small Strip 15 x 15 x 8mm, 2cc DR 

DU0060 BioAdaptTM Foam, Disc 60 (diam.) x 5mm, 14cc DR 

Precision Machined Spine Spacers 
 Cortical Cervical Spacer 
 Available in 12x14mm
(small) and 14x16mm (large) footprints 
 Available in parallel and lordotic (7°) profiles 

Sterilized through the BioCleanse® Process 
 Terminal Sterilization after BioCleanse achieves SAL 10-6 and labeled STERILE 
 12mm (AP) x 14mm (ML) Sterilization: BioCleanse® 
 Code Description Preservation 
 D0P146 Cortical
Cervical Spacer, Parallel - Small 6mm FD 
 D0P147 Cortical Cervical Spacer, Parallel - Small 7mm FD 

D0P148 Cortical Cervical Spacer, Parallel - Small 8mm FD 

D0P149 Cortical Cervical Spacer, Parallel - Small 9mm FD 

D0P140 Cortical Cervical Spacer, Parallel - Small 10mm FD 

D0L146 Cortical Cervical Spacer, Lordotic - Small 6mm FD 

D0L147 Cortical Cervical Spacer, Lordotic - Small 7mm FD 

D0L148 Cortical Cervical Spacer, Lordotic - Small 8mm FD 

D0L149 Cortical Cervical Spacer, Lordotic - Small 9mm FD 

D0L140 Cortical Cervical Spacer, Lordotic - Small 10mm FD 

14mm (AP) x 16mm (ML) 
 Code Description Preservation 
 D0P166 Cortical
Cervical Spacer, Parallel - Large 6mm FD 
 D0P167 Cortical Cervical Spacer, Parallel - Large 7mm FD 

D0P168 Cortical Cervical Spacer, Parallel - Large 8mm FD 

D0P169 Cortical Cervical Spacer, Parallel - Large 9mm FD 

D0P160 Cortical Cervical Spacer, Parallel - Large 10mm FD 

D0L166 Cortical Cervical Spacer, Lordotic - Large 6mm FD 

D0L167 Cortical Cervical Spacer, Lordotic - Large 7mm FD 

D0L168 Cortical Cervical Spacer, Lordotic - Large 8mm FD 

D0L169 Cortical Cervical Spacer, Lordotic - Large 9mm FD 

D0L160 Cortical Cervical Spacer, Lordotic - Large 10mm FD 

Skinny Strips 
 Large 
 Strip 

Medium 
 Strip 
 Small Strip 

Disc 
 BIOCLEANSE 
 CANCELLE SP 

*DBM or representative finished implant is either assayed in vivo in the modified athymic 

nude rat for bone formation or in vitro for endogenous BMP-2 as a surrogate test marker 

for osteoinductive potential. Because the combination of various proteins is responsible 

for osteoinductive potential, when assayed in vitro, DBM is also screened for the presence 

of BMP-7. Findings from an in vitro assay or animal model are not necessarily predictive 

of human clinical results. 
 Cortical Cervical Spacer 
 BIOCLEANSE 

DR=Dried 
 FD=Freeze Dried 
 Osteoinductive Demineralized Bone
Grafts 14 

 

 
  
 PROVEN

 QUALITY 
 To order, call RTI directly: 800.624.7238. 
 RTI
BIOLOGICS® 
 11621 Research Circle 
 Alachua, FL 32615 
 Toll Free: 877.343.6832

 Fax: 386.418.0342 
 www.rtibiologics.com 
 Accredited by American
Association of Tissue Banks 
 ISO 13485 Certified 

• AdvaMed Member 
 REIMBURSEMENT INFO: Call 877.839.7152 

BioCleanse® and Cancelle® are U.S. registered trademarks of RTI Biologics, Inc. 

Tutoplast® is a U.S. registered trademark of Tutogen Medical GmbH. 

©2013 RTI Biologics, Inc. 6056 R3 02-13-13 

 EXHIBIT C 
  

			
	Global Business Conduct Policy	  	 Page
 1
 of 8

  
 

 
 Global Business Conduct Standards Policy 

ON INTERACTIONS WITH CUSTOMERS 
 Introduction 

Our Mission is to make and sell devices that alleviate pain, restore health and extend life. We recognize that healthcare professionals – those best
suited to understand the needs of their patients, the performance of medical devices in the clinical setting and unmet treatment needs – are critical partners in our ability to fulfill our Mission. We collaborate with physicians to create new
products and therapies and to improve existing products. We provide world-class training and education on the safe and effective use of our products and therapies to healthcare professionals. We sponsor scientific research conducted by healthcare
professionals to gather clinical evidence related to our products. All of these interactions are for the ultimate benefit of patients. 
 In no instance
will Medtronic offer or provide a payment to a Customer as an unlawful inducement to purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe a Medtronic product. We define “Customer” to include any institution
or individual, other than an individual patient, including any medical or healthcare professional or entity, in a position to purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Medtronic products. Medtronic also
considers persons employed by a Customer, a close family member of a Customer (including spouse or life partner, their children and parents of the Customer) or an organization affiliated with a Customer (meaning that it is controlled by or under
common control with the Customer or if the Customer is on the Board of the organization, receives material compensation from, or has an investment interest in the organization) to be within scope when determining whether an entity or individual
should be treated as a “Customer” under our policies. 
 We are committed to adhering to applicable laws regarding physician-initiated use of our
products and respect a physician’s right to make independent medical decisions when treating patients. Our marketing, education and promotional activities are consistent with these commitments, and we comply with governing laws regarding
appropriate promotion of our products. 
 Index 

Standard 1 | General Provisions 
 Standard 2 |
Discounts and Evaluation Products 
 Standard 3 | Donations, Research and Educational Grants 

Standard 4 | Educational Items and Gifts 

Standard 5 | Business Meetings 
 Standard 6 |
Services Arrangements 
 Standard 7 | Training and Education 

Standard 8 | Third-Party Conferences 

Standard 9 | Activities Benefiting Patient Care 

Statement of Principles 
 Partnership between industry and its
Customers must be based on solid ethical principles, as it presents the potential for conflicts of interest. These conflicts, both real and perceived, can affect patient and stakeholder confidence in clinicians, products, companies – and the
entire industry. To sustain and enhance medical innovation through principled cooperation so that patients continue to benefit from advances in medical care, Medtronic is guided by two central principles: 

Preserve the integrity of the physician-patient relationship 

The relationship between physician and patient is a uniquely trusting one because of the special role that physicians play in saving and enhancing human life.
Appropriate safeguards and regulations are necessary to ensure these relationships are not compromised by the cooperation between a physician and industry in the development and testing of new products, or the training and education of other
physicians on the safe and effective use of products. 
 Remain transparent 

To provide patients and physicians with information to make informed treatment decisions, and to develop trust and minimize actual and perceived conflicts,
Medtronic is committed to transparency and appropriate disclosure of policies regarding its relationships with Customers. We believe also that promoting greater transparency into collaboration with Customers will help people better understand the
critical role that these interactions play in innovation, advancing patient care, and ultimately, saving and improving lives. 

			
	Global Business Conduct Policy	  	 Page
 2
 of 8

  

 Commitment to Ethics and Compliance 

Medtronic has adopted and fully embraces certain local industry codes of ethics, for example, the AdvaMed Code, the Eucomed Code, and many others. The
Medtronic Global Anti-Corruption Policy (“ACP”) sets forth guiding principles across Medtronic for avoiding any corrupt interactions with Customers. The Medtronic Global Business Conduct Standards (“BCS”) give more specific
instructions for common categories of interactions with Customers. Where additional local requirements or exceptions are necessary for conforming this common approach to local rules, or additional information is needed for local operation of the
BCS, those local provisions are provided in the BCS Playbook (in the U.S.) and the BCS International Procedures. Medtronic requires its employees, and others acting on its behalf to follow the ACP, BCS, and applicable BCS Playbook or BCS
International Procedures, as well as all other applicable laws, regulations, company policies and industry standards whenever interacting with Customers. Medtronic will address violations of the BCS and related policies promptly and with appropriate
corrective action. See the Global Code of Conduct and BCS Violations Procedure. 
 The BCS provides a framework to guide interactions across the globe with
Customers that purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Medtronic products. Because it cannot account for every situation, exceptions to this policy may be approved where the action contemplated does not
raise legal, regulatory or ethical concerns. 
 Standard 1 | General Provisions 

Core Rule. In no instance will Medtronic offer or provide a payment or any other item of value to a Customer as an unlawful inducement to purchase,
lease, recommend, use, arrange for the purchase or lease of, or prescribe a Medtronic product. To ensure that all Customer interactions are legal and ethical, they must be consistent with Medtronic’s Business Conduct Standards. 

Scope of Business Conduct Standards. The BCS are mandatory for interactions involving a transfer of anything of value from Medtronic to a Customer (a
“Customer Interaction”). If you are unsure of the scope of the BCS, you must consult with Legal or Compliance before entering into a transaction or initiating a discussion with a Customer. 

Business Conduct Standards are Country-Specific. Customers remain subject to the regulations of the country where they are located (healthcare
organizations) or where they work (healthcare professionals), irrespective of where the interaction occurs. All Medtronic employees, distributors and agents are expected to become familiar with the BCS and other rules applicable to an individual
Customer before initiating an interaction, regardless of the employee’s geographic location. If you plan to enter into an agreement or other interaction with a Customer who works in a country outside your geography, please contact your
compliance or legal contact prior to any negotiation with the Customer. Your compliance or legal contact will help you determine what is required before entering into such interaction. 

Compliance with the BCS is required. All Medtronic employees involved in Customer interactions are expected to know and comply with the Global
Anti-Corruption Policy, the BCS and the applicable BCS International Procedures (outside the U.S.) or BCS Playbook (U.S.), and any other applicable laws, regulations, company policies, procedures and interpretative guidance. As a requirement of
working at Medtronic, all employees are expected to know and follow the BCS. Managers are responsible for ensuring that their reports comply with the BCS and any BCS-related requirements such as mandatory training. Medtronic distributors and agents
must be required by contract to comply with the Medtronic Anti-Corruption Policy and with applicable principles of the BCS. See the Medtronic International Distributor and Sales Agent Appointment, Contracting and Management Policy. 

If Medtronic is restricted from doing something, so are its employees and third party intermediaries. If these Standards restrict Medtronic’s
interactions with a Customer, Medtronic employees and third party intermediaries are likewise restricted, even if no reimbursement request is made to Medtronic. This means that Medtronic employees or agents may not give prohibited items to Customers
even if they pay for them from their own personal funds. 
 BCS Violations. Employees who violate the BCS are subject to discipline, up to and
including termination. See the Global Code of Conduct and BCS Violations Procedure. 
 Interpretation of Business Conduct Standards. Any employee
with questions about the BCS should contact his/her Manager or Legal or Compliance. Distributors and agents should contact their Medtronic business contacts. Legal and Compliance are responsible for final interpretations of the BCS. 

Reporting Concerns and Prohibition against Retaliation. Any employee, agent or business consultant who is concerned that others may be engaging in, or
requiring that the employee, agent or business consultant engage in, conduct that is inconsistent with the BCS, should discuss the concern with a Manager, the Human Resources department, Legal/Compliance, or contact the confidential Medtronic Voice
Your Concern Line at www.VoiceYourConcernLine.com. This website includes phone numbers for the Voice Your Concern Line in the U.S. (1-800-488-3125) and other countries. Reports can be made in many different languages. Retaliation against any
individual for making a good faith report of a potential BCS violation is prohibited. 
 Method of Payment to Customers. Except as specified below,
payments to, or on behalf of, or reimbursed to a Customer must be made by a Medtronic bank transfer only (except for countries where payments are made by check). Whenever possible and practical, payment for travel expenses incurred by a Customer
(e.g. lodging, meals, or transportation) must be paid directly to the vendor (e.g., the hotel, airline and travel agency). When reimbursement is made to the Customer, original receipts or other supporting documentation are required. When a Customer
is expected to pay directly for reimbursable travel expenses, the Customer should be provided with modest per-diem spending guidelines in advance. 

			
	Global Business Conduct Policy	  	 Page
 3
 of 8

  

 Exceptions and Amendments to the BCS. Because the BCS cannot account for every situation, exceptions
to the BCS may be approved where the action contemplated does not raise legal, regulatory or ethical concerns, following the appropriate Business Conduct Exceptions Process. 

BCS Spending Limits. Spending limits are established for business-related expenditures on modest meals, refreshments and lodging; reasonable travel and
occasional educational items provided to Customers. In addition, employees are expected to follow any applicable Customer-related restrictions. These include, for example, more restrictive laws or employer policies. See the Authorization Levels in
the Worldwide Finance Manual to determine the level of authorization necessary to approve payments. For specific spending limits, see the BCS International Procedures or Playbook. 

Proper Reporting of Expenses. Payments and all other benefits transmitted to Customers or on behalf of Customers must be timely reported to Medtronic
using the applicable expense reporting system and attributed to individual Customers accurately and completely. 
 Modest Meals and Refreshments. We
may provide modest meals as an occasional business courtesy so long as the meal is incidental to the purpose of the business interaction, provided in a manner and setting conducive to the exchange of information and attended by a Medtronic
representative. We will not pay for meals for an individual Customer not in attendance at the meeting. We will not pay for or provide excessive alcohol at business meetings, as excessive alcohol undermines the legitimacy of the business meeting.
Such meals or refreshments may be provided to Customers in conjunction with: 
  

	 	•	 	Standard 5 | Business Meetings 

  

	 	•	 	Standard 6 | Services Arrangements 

  

	 	•	 	Standard 7 | Training and Education 

  

	 	•	 	Standard 8 | Third-Party Conferences 

 No Entertainment. Medtronic does not provide or pay the
costs for a Customer’s participation in entertainment or recreational events. 
 No Subsidy of Spouses, Partners or Guests. Medtronic may not
pay for meals, other hospitality, travel or lodging for a spouse, partner or other guest of a Customer. 
 Reasonable Travel. Depending on the local
rules, Medtronic may be able to pay reasonable travel costs for Customers in conjunction with: 
  

	 	•	 	Standard 5 | Business Meetings 

  

	 	•	 	Standard 6 | Services Arrangements 

  

	 	•	 	Standard 7 | Training and Education 

  

	 	•	 	Standard 8 | Third-Party Conferences (generally not for U.S. healthcare professionals) 

 As a general
rule, economy class travel should be used on all flights. The appropriateness of business class travel for Customers, according to Medtronic policy, shall only be considered for certain longer flights in accordance with local policy (see the
International Procedures or BCS Playbook). Medtronic will not pay for upgrades, provide Customers cash in lieu of a ticket or pay any costs associated with a private plane. 

Locations and Lodging for Customer Interactions. Depending on the local rules, Medtronic may be able to provide modest lodging for Customers in
conjunction with the following interactions: 
  

	 	•	 	Standard 5 | Business Meetings 

  

	 	•	 	Standard 6 | Services Arrangements 

  

	 	•	 	Standard 7 | Training and Education 

  

	 	•	 	Standard 8 | Third-Party Conferences (generally not for U.S. healthcare professionals) 

 When Medtronic
is responsible for selecting location and lodging for a Customer interaction, it must be selected based upon program requirements, convenience of attendees, and cost savings to Medtronic. Where most or all of the Customer attendees are from the same
country, the interaction should be held in that country unless there is a legitimate business purpose to hold the meeting elsewhere. 
  

	 	•	 	Medtronic training and education programs requiring “hands-on” training in surgical procedures should be held at Bakken Educational Centers, surgical training facilities, medical institutions or other
facilities appropriate for such purposes. 

  

	 	•	 	Medtronic manufacturing or research and development facilities may be appropriate locations for business or consultant meetings. 

Requisition and BCS Approval Procedure. Approval processes involving evaluation by qualified, non-sales personnel are required for many Customer
interactions (for example consulting agreements, donations and grants all require advance approval according to local processes). See the International Procedures or Playbook for more information. Where an approval process is required by these
Standards, Medtronic personnel may not proceed or make a commitment to a Customer before obtaining all required approvals. Failure to obtain the necessary approval may result in a BCS violation. 

Training on anti-corruption and the Business Conduct Standards is mandatory for all Medtronic employees interacting with Medtronic’s Customers.
Third Party Intermediaries, such as distributors, consultants or agents are also subject to training requirements. Minimum training requirements are specified on the Legal/Compliance website. Such training may occur at the time of hire, annually, or
at such other times as may be required. For questions about required training, contact Legal or Compliance. 

			
	Global Business Conduct Policy	  	 Page
 4
 of 8

  

 Standard 2 | Discounts and Evaluation Products 

With proper documentation and in compliance with applicable legal and regulatory requirements and other Medtronic policies and guidelines such as pricing and
rebate guidelines, Medtronic may provide products to Customers at a reduced or no charge, including: 
  

	 	•	 	Demonstration products/Samples 

  

	 	•	 	Products or other allowances provided under a Medtronic warranty 

  

	 	•	 	Products provided at discounted pricing 

  

	 	•	 	Products sold under rebate programs 

  

	 	•	 	Pricing programs that include multiple products 

  

	 	•	 	No-charge evaluation products 

  

	 	•	 	No-charge replacement products provided as a result of a regulatory action 

  

	 	•	 	Discounts that are applied for a particular purpose 

 Notification to Customers should be provided when
a product or accessory is sold at a discount or provided or loaned to a Customer at no charge. This requirement can be met through a purchase agreement, invoice or other notice that reflects the discounted price or zero charge and is provided to the
Customer. 
 For evaluation purposes, only a reasonable number of single-use or disposable products should be provided to a Customer. Products that
are covered by pricing arrangements such as discounts, rebates, and warranties are not “evaluation” products. 
 Provision of capital equipment
or multiple-use products free of charge must be accompanied by a written agreement addressing, among other things, term of use and return or purchase of the equipment at the end of the term, if less than the useful life of the equipment. This
requirement does not apply to equipment or products that have been determined by Legal to have “no independent value.” Be sure to check BCS International Procedures and Playbook for additional local requirements. 

Discounts, warranties, multi-line discount programs, no-charge products and accessories and other pricing arrangements should adhere to local pricing policies
and procedures or be reviewed by Medtronic legal counsel before being offered. 
 Standard 3 | Donations, Research and Educational Grants 

Purpose. Medtronic may make monetary and product donations for appropriate scientific, educational, health care, or other charitable purposes. Donations
are limited to certain institutions or organizations and are not always allowed for individuals who are Customers; see the appropriate country-specific guidance for more detail. 

The donation or grant may not be connected to the purchase of Medtronic products and cannot be made to influence the judgment of an individual Customer
related to the institution. 
 Types of Grants and Donations 

Educational Grants. Medtronic makes a variety of charitable contributions, including educational grants. Educational grants can include supporting an
endowed chair at an academic institution, the education of fellows in recognized medical training programs, programs that educate the public on health care topics, and support for educational and policy making conferences and meetings. Educational
grants are provided to institutions; not individual people. Refer to Third Party Conferences (BCS 8) for the support of medical congresses or conferences that relate to Medtronic products and therapies. 

Fellowships / Scholarships. Medtronic may provide educational donations to recognized medical training institutions or professional societies for
fellowships and scholarship awards (to underwrite appropriate related costs such as travel, tuition, lodging, meals, etc.) in fields associated with Medtronic products and therapies, so long as they relate to a bona fide educational need of the
fellow and his or her institution. 
 The selection of fellows should be within the discretion of the teaching institutions at which they will be trained.
Donations must be provided to either the teaching institution or the fellow’s home institution (where and to the extent that the teaching institution charges tuition or costs to the home institution for the fellowship program), not to
individual fellows. Grants may not be tied to an institution’s purchase of Medtronic’s products, or otherwise be based on an institution’s past or potential future, undefined use of Medtronic’s products or services.  

Scientific Research Grants. Medtronic funds scientific research including, for example, donations to support basic scientific research and general
research grants to study new therapeutic uses of approved devices. However, Medtronic will not use such research for the purpose of unlawfully promoting uses of our products and therapies that have not been approved. Generally, the funding of
research protocols related to Medtronic products and therapies should be carried out as an agreement under BCS 6 rather than a donation under this Business Conduct Standard. Other guidelines and requirements may apply to decisions for funding such
research protocols, such as the need for review by appropriate Medtronic scientific personnel or an External Research Program board. 
 Fundraising
Events. Medtronic may support a healthcare organization’s fundraising event (for example, a golf outing or a formal gala) when the grantee is a registered charity and at least a portion of the donation qualifies for a charitable tax
deduction. The tickets may be used by Medtronic employees or Medtronic guests who are not Customers, or they may be given back to the charity. See the International Procedures or U.S. BCS Playbook for more details. 

			
	 Global Business Conduct Policy
  
	  	 Page
 5
 of 8

  

 Prior Approval. All Customer-related grants and donations require prior approval under BCS approval
procedures before a commitment may be made to the recipient. Donation / grant requests must be reviewed to ensure that a funding proposal has a permissible purpose, regardless of the volume or value of purchases made by, or anticipated from, the
recipient and that funding is not used as a reward for prior sales or inducement for future sales. In general, it is not appropriate to provide retrospective financial support for research, educational or other projects already completed. Donations
made to privately owned medical institutions require careful review to ensure appropriate project budgeting for use of funds. 
 Standard 4 | Educational
Items and Gifts 
 Except in the very limited circumstances below, the giving of gifts to Customers is generally prohibited. Medtronic may occasionally
provide items that have a genuine educational function or benefit patients, such as textbooks or anatomical models, if they are modest in value and in accordance with the national and local laws, regulations and industry and professional codes of
conduct of the country where the Customer is located. It is never appropriate to give items such as cash or cash equivalents, or personal items (e.g., clothing, perfume, iPods, iPads, iPhones, etc.). 

Medtronic adheres to industry codes of ethics regarding whether it is appropriate to provide gifts to a Customer or a Customer’s close family member.
Consult the BCS International Procedures or Playbook for country-specific standards on items that may be appropriate to give to Customers as well as monetary limits on such gifts. 

The description and purpose of items given to Customers should be documented and approved on an expense report or through a comparable authorization process.

 Standard 5 | Business Meetings 
 We conduct business
meetings with Customers to discuss features or other important aspects of Medtronic products or therapies, product-related service concerns, sales terms, contracts, patient access to therapies and other business topics. We do not use business
meetings to promote our products or therapies in a manner that would be inappropriate under local law. 
 Business Purpose. A business meeting is
defined as a meeting held with one or more Medtronic employees or independent sales representatives and a Customer for one of the following business purposes: 
  

	 	•	 	discussion of product features; instruction on the use or other aspects of Medtronic products, therapies or services; 

  

	 	•	 	product or service-related concerns; 

  

	 	•	 	sales terms; 

  

	 	•	 	contracts; 

  

	 	•	 	coding and reimbursement; 

  

	 	•	 	patient access to therapies; or 

  

	 	•	 	other bona fide scientific, educational or business topics relevant to Medtronic. 

 Often, these meetings occur
at or close to the Customer’s place of business and require either time away from the clinic or a commitment of the Customer’s non-working time. We host such business meetings only at settings that are conducive to bona fide scientific,
educational or business discussions. In addition to providing occasional modest meals and refreshments in connection with such meetings, when necessary we may pay for reasonable travel costs and modest lodging of meeting attendees. Costs for such
meetings must be in accordance with the respective country limits. 
 Plant tours and other such product- or manufacturing-oriented business meetings
with Customers must follow the processes that have been previously reviewed and approved by Compliance/Legal. See the applicable BCS International Procedures or Playbook for more detail. 

For more guidance on meals provided in the context of a third-party conference or training session, see BCS 7 or BCS 8, as appropriate.  

Entertainment. Medtronic may not provide or pay for any entertainment or recreational event, such as golfing, attendance at sporting events, theatre,
etc. for a Customer. This includes paying for, contributing to or holding parties for Customers for the purpose of celebrating a non-business event, such as a holiday, retirement, promotion, etc. 

Expense Reporting. For payment of meals/transport, it is the responsibility of the involved employee and the employee’s manager to confirm the
appropriateness of the type and amount of the event. The description and purpose of meals and related transportation should be documented and approved on an expense report or through a comparable authorization process. 

BCS Spending Limits. For detailed information on meal limits, please see the BCS International Procedures or Playbook. 

Standard 6 | Services Arrangements 
 Business Purpose and
Need. Services agreements with Customers must be entered into only where a specific, legitimate business purpose and need for services in the areas of training and education; product research and development; advisory services; or clinical
research is identified in advance and documented. For example: 
  

	 	•	 	Agreements to obtain services from Customers must match the business need of a specific project for required services. 

			
	Global Business Conduct Policy	  	 Page
 6
 of 8

  

	 	•	 	Research or Clinical Trial Agreements to conduct non-clinical or clinical research, including post-market outcome studies, must be based on a demonstrable need for data. 

 

	 	•	 	Intellectual Property agreements must be based on a Customer having made, or the expectation that a Customer will make, a novel, significant, or innovative contribution to the development of a product, technology,
process or method. 

 Limitations. The use of Customer service providers is limited: 

 

	 	•	 	Customer service providers may not be paid to endorse or otherwise recommend the purchase, use or ordering of Medtronic products. 

  

	 	•	 	Customer service providers may be retained to speak, write and present training and education programs, but are subject to local legal restrictions on product promotion. 

See the BCS International Procedures and Playbook for more detail on the process required to be followed in advance of entering into discussions with a
Customer about a potential agreement. 
 Selection of Customer service providers must be on the basis of the Customer’s qualifications,
expertise and capacity to address the identified purpose. While it is possible that the qualifications for a task could include experience with, usage of, or familiarity with a Medtronic product or therapy, the selection of a Customer service
provider may not be used to reward past usage or constitute an unlawful inducement. 
 Compensation may not exceed the fair market value of services
provided. Fair market value must be assessed in accordance with requirements of the country where the Customer normally practices (in the case of an individual Customer) or is located (in the case of an institutional Customer). Compensation must be
structured on a measurable basis, such as payment based on a daily, hourly or per-project rate, deliverables or milestones. Compensation paid to a Customer service provider may not be based on the volume or value of the Customer’s past, present
or anticipated business. 
 Services agreements must be in writing, must describe all services to be provided, must be approved in advance following
the appropriate process and signed by the parties, including an appropriate Medtronic approver as indicated in the BCS International Procedures or Playbook, and entered into prior to the start of services and payment. Agreements providing for
general services or services on an as-needed basis with payment prior to receipt of services (“retainer agreements”) are prohibited. In addition to the written agreement, the responsible business person must maintain accurate files
documenting the services or intellectual property received in exchange for Medtronic’s payments. 
 Any reimbursement for reasonable travel
expenses should be paid, whenever possible and practical, directly to the hotel, airline, and travel agency and not to the Customer. If not paid directly, any reimbursement should be supported by original receipts or other supporting
documentation. No payments for the Customer’s family members are permitted. Medtronic should not arrange for the travel or lodging of a Customer’s guests or family members. 

Consultant Meetings. The venue and circumstances for meetings with consultants should be appropriate to the subject matter of the consultation.
Hospitality that occurs in conjunction with a consultant meeting should be modest, in accordance with the respective country limits, and should be subordinate in time and focus to the primary purpose of the meeting. 

Medtronic must comply with applicable national and local laws with regard to the disclosure, transparency or approval requirements to any third parties
associated with engaging Customers as service providers. See the BCS International Procedures and Playbook for local requirements as well as the detail on compensating for travel time. 

Standard 7 | Training and Education 
 Purpose. Medtronic
may organize sessions with Customers for the purpose of instruction, education and training to explain the safe and effective use of Medtronic products. This education and training includes “hands on” product training as well as education
on topics associated with the appropriate use of our products, therapies and related services and support programs. This may involve training and education on: 
  

	 	•	 	how to use or implant a Medtronic product; 

  

	 	•	 	indications or therapies appropriate for use of a Medtronic product; 

  

	 	•	 	the technical features, properties, quality and/or design characteristics of a Medtronic product; 

  

	 	•	 	disease states treated by Medtronic products; 

  

	 	•	 	the benefits and risks of use of the product and appropriate precautions for use; 

  

	 	•	 	the appropriate use of the product in the continuum of care; and 

  

	 	•	 	product-related reimbursement support and economic outcomes. 

 Training and education must generally constitute
a substantial majority of the program on each program day. 
 Appropriate Setting. Training and education programs are to be conducted in appropriate
settings - places that are conducive to the program’s training and education purpose, convenient for the attendees and reasonable in cost. See the BCS International Procedures or Playbook for more detail on appropriate training locations. 

Travel Expenses. Where appropriate, we subsidize Customers’ expenses to travel to Medtronic-conducted training and education programs. Lodging,
setting, meals and refreshments provided in conjunction with training and education programs must be modest and in accordance with the applicable country limits and must not overshadow the training and education purpose of the program. 

			
	Global Business Conduct Policy	  	 Page
 7
 of 8

  

 Payments to Customers to conduct Medtronic training and education sessions and reimbursement of travel
expenses must be under a written agreement and in accordance with BCS 6. Medtronic may not pay an honorarium fee for simply attending a Medtronic training and education event. 

Prior Approval. Training and education programs involving Customer travel must be reviewed and approved according to a written process that requires
prior approval of the course content, agenda (covering all events from arrival to departure), budget, location/venue types and numbers of attendees and faculty. Agenda items may not include uses of our products or therapies that would be
inappropriate under local law, nor may agendas include entertainment or recreation. 
 Faculty may include qualified Medtronic sales personnel, other
Medtronic technical experts, as well as healthcare professionals with the proper qualifications and expertise to conduct the training and education. 

Standard 8 | Third-Party Conferences 
 Purpose. Medtronic
may support independent educational, scientific and policymaking conferences and professional meetings that promote scientific knowledge, advance the practice of medicine and enhance the delivery of effective healthcare if they are generally
recognized and respected within the medical community and relate to our products and therapies. The rules and practices in supporting third party conferences vary greatly by geography, but regardless of region, Medtronic never provides funding
support for purposes of rewarding a Customer’s past purchases or improperly influencing future ones. 
 Rules for Funding Conferences by Medtronic U.S.

 Conferences in the U.S. – Medtronic’s funding must be consistent with the rules of the body accrediting the educational activity. This
means: 
  

	 	•	 	Faculty selection and content development must be at the sole discretion of the conference organizer; 

  

	 	•	 	Medtronic does not directly support the attendance of U.S. Customers at U.S. conferences by paying admission fees, honoraria or travel and lodging. 

However, Medtronic may provide grants to conference organizers to reduce overall conference costs, defray faculty costs and expenses, support modest meals or
receptions and allow attendance by healthcare professionals-in-training, or Medtronic may give a grant to a training institution to allow an HCP-in-training to attend a third-party conference or professional meeting. 

Conferences outside the U.S. – Proposed sponsorship of such conferences requires review under the BCS process in the geography of the conference
site. See the BCS Playbook for further detail, including the rules on U.S. Customers attending third-party conferences occurring outside the U.S. 
 Rules
for Funding Conferences by Medtronic International 
 Where permitted under national and local laws, regulations and professional codes of conduct, and with
prior approval, Medtronic may provide financial support to cover the cost of conference attendance by individuals who are Customers. Such financial support should be limited to the conference registration fee and reasonable travel, meals and
accommodation costs relating to attendance at the event. Medtronic must ensure full compliance with national and local laws with regard to the disclosure or approval requirements associated with such sponsorship and where no such requirements are
prescribed, shall nevertheless maintain appropriate transparency, for example, by requiring prior written notification of the sponsorship is made to the hospital administration, the individual Customer’s superior or other locally-designated
competent authority. 
 Note that Eucomed has established a process to approve conferences occurring in Europe which Medtronic will use as a guide for
determining conference support. See the International Procedures for further detail. 
 Standard 9 | Activities Benefiting Patient Care 

Reimbursement Support. Patient access to our products and therapies depends on the availability of timely and complete coverage, reimbursement, and
health economic information. Where appropriate, Medtronic may provide this information to Customers, payors and patients, provided such reimbursement support is accurate, objective and related to Medtronic products, therapies, procedures and
services. We may also collaborate with Customers, patients and organizations representing their interests, to achieve government and commercial payor coverage and adequate reimbursement levels that allow patients to access Medtronic products and
therapies. 
 Medtronic-provided reimbursement support may never suggest mechanisms for either billing for services that are not medically necessary or that
facilitate fraudulent practices to achieve inappropriate reimbursement. 
 Other Activities to Support Patient Access. Medtronic also undertakes
other activities to support patient access to our products and therapies to improve patient outcomes. Medtronic may engage in market development activities and conduct educational and awareness programs with its customers. In addition, Medtronic may
provide health and disease management programs that include the provision of items, services and provider and patient health management tools such as critical pathways, remote monitoring and patient compliance and education support. 

			
	Global Business Conduct Policy	  	 Page
 8
 of 8

  

 Last updated: 23 May 2012 

Additional information 
 Contact Us 

Contact the Audit Committee and/or Board of Directors 

Related Links 
  

	 	•	 	Investor Relations 

  

	 	•	 	SEC Filings 

 © 2014 Medtronic, Inc. 

 EXHIBIT D 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks (********) denote omissions. 

 

					
	 

 Alachua, Florida
	  	Policy	  	 Document No.: 3418
 Revision No.:
R0
 Supercedes: N/A
 Effective Date:
11/28/05

	Title: RTI Domestic Return Policy

 This return policy is applicable in all cases where grafts are supplied by RTI Biologics, Inc. (RTI) to a healthcare facility.

 RTI cannot accept grafts for return unless RTI has issued a Return Authorization Number. Please do not return grafts without this number. 

The healthcare facility is responsible for all shipping costs. 

FROZEN TISSUE 
 Frozen Tissue will not
be accepted for return by RTI except under the following conditions: 
  

	 	1.	The healthcare facility informs RTI within 48 hours of initial receipt that the graft(s) did not meet receiving requirements. 

Authorized returns of frozen tissue must be returned in an unopened (without violation of tamper evident tape) 5-day RTI validated cooler
received at RTI within the 5-day time span. 
 A ******** restocking fee will apply to all accepted returns unless related to a valid
complaint or per contract agreement. 
  

	 	2.	The grafts did not meet storage condition requirements. 

  

	 	3.	The healthcare facility becomes aware of a latent defect – (A defect that is not discoverable by reasonable or customary inspection). 

In any of the above instances, a complaint investigation may be initiated. 

FREEZE DRIED TISSUE 
 Freeze-dried
tissue will be accepted for return by RTI only if the following conditions are met: 
  

	 	1.	The healthcare facility informs RTI, within 5 days of initial receipt, that the graft (s) did not meet receiving requirements. 

Authorized graft returns must be in their original, sealed packaging. 

A ******** restocking fee will apply to all accepted returns unless related to a valid complaint with exception of HTO Wedges, consignment
tissue, or contract agreement. 
  

	 	2.	The grafts did not meet storage condition requirements. 

  

	 	3.	The healthcare facility becomes aware of a latent defect – (A defect that is not discoverable by reasonable or customary inspection). 

  
  

Page 1 of 2 
  

For Use By Affiliates of RTI 
 This
document contains proprietary information. It may not be reproduced or disclosed without prior written approval. 
 >>THE USER OF
THIS DOCUMENT IS RESPONSIBLE FOR CHECKING THE CURRENT EFFECTIVE DATE BEFORE USING THIS DOCUMENT>> 
 Printed 02/27/14 

 Confidential Treatment Requested 

 

					
	 

 Alachua, Florida
	  	Policy	  	 Document No.: 3418
 Revision No.:
R0

	Title:

 CREDIT 

No credit will be issued until and unless the evaluation of the returned graft (s) indicates the return/complaint is valid. Restocking
fees will be subtracted from applicable credit. 
 PROCEDURES 
  

	 	•	 	For any RTI tissue-related return or complaint, contact the RTI Customer Service Department at 800-624-7238 to receive a Return Authorization Number. 

 

	 	•	 	All returns require: 

  

	 	•	 	tissue ID number (s) (Note: If the tissue number is unknown, all possible tissue numbers that could be applicable for that graft must be provided). 

 

	 	•	 	original packaging 

  

	 	•	 	Detailed explanation of the reason for the return. 

  

	 	•	 	Credit cannot be issued without this information. 

  

	 	•	 	No credit will be issued until the evaluation of returned tissue indicates the return/complaint is valid. The healthcare facility has the right to request a copy of the return evaluation report in case of dispute.

  

	 	•	 	When returning the tissue, the Return Authorization Number must be marked on the outside of the shipping package before shipping to RTI. 

 

	 	•	 	Return Authorization Numbers will remain open for ten business days from issuance. After 10 days, if the graft(s) have not been received, contact will be made with the healthcare facility to inquire about the return. If
no response is received, the Return Authorization will be cancelled, the return will not be accepted, and no applicable credit issued. 

  

	 	•	 	All opened grafts much be treated as potential biohazards and must be shipped according to applicable shipping guidelines. The graft (s) must be placed in a doubled leak-proof bag labeled and designed for bio
hazardous material. The outer (second) bag should be protected from potential contamination. The double-bagged product should then be placed into a sturdy outer package of corrugated fiberwood, wood, metal or rigid plastic of a minimum size of
7x4x2. This can be a plain cardboard box of FedEx Clinical Pack. 

  

	 	•	 	Any opened grafts that have been exposed to a known infectious disease will need to be packaged in conjunction with IATA, DOT, FAA, OSHA and CDC packing instruction guidelines for shipping known infectious disease
substances, and this information must be conveyed to customer services. 

  

			
	Ship To:	    	RTI Biologics, Inc.
		    	 Attn: Returns
 11621 Research
Circle

		    	Alachua, FL 32615

  
  

Page 2 of 2 
  

For Use By Affiliates of RTI 
 This
document contains proprietary information. It may not be reproduced or disclosed without prior written approval. 
 >>THE USER OF
THIS DOCUMENT IS RESPONSIBLE FOR CHECKING THE CURRENT EFFECTIVE DATE BEFORE USING THIS DOCUMENT>> 
 Printed 02/27/14 

 EXHIBIT E 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks (********) denote omissions. 

Exhibit E 
  

																			
	 Agreement Qtr
	  	1	  	2	  	3	  	4	  	5	  	6	  	7	  	8	  	9
	 Calendar Qtr
	  	Nov-Jan
2014	  	Feb-April
2014	  	May-July
2014	  	Aug-Oct
2014	  	Nov-Jan
2015	  	Feb-April
2015	  	May-July
2015	  	Aug-Act
2015	  	Nov-Jan
2016
	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********
	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********
	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********	  	********EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 
 $175,000,000

 CREDIT AGREEMENT 
 dated as of

 March 7, 2014 
 among 

ARGO GROUP INTERNATIONAL HOLDINGS, LTD., 

ARGO GROUP US, INC., 
 ARGO
INTERNATIONAL HOLDINGS LIMITED, and 
 ARGO UNDERWRITING AGENCY LIMITED, 

as Borrowers, 
 The Lenders Party
Hereto 
 JPMORGAN CHASE BANK, N.A., 

as Administrative Agent, 
 WELLS
FARGO BANK, N.A., 
 as Syndication Agent 

and 
 U.S. BANK NATIONAL
ASSOCIATION, 
 as Documentation Agent 
  

 
 J.P. MORGAN
SECURITIES LLC, 
 and 
 WELLS
FARGO SECURITIES, LLC, 
 as Joint Bookrunners and Joint Lead Arrangers 

 TABLE OF CONTENTS 
  

					
	 	  	Page	 
	 ARTICLE I Definitions
	  	 	1	  
		
	 SECTION 1.01. Defined Terms
	  	 	1	  
	 SECTION 1.02. Classification of Loans and Borrowings
	  	 	24	  
	 SECTION 1.03. Terms Generally
	  	 	24	  
	 SECTION 1.04. Accounting Terms; GAAP
	  	 	25	  
	 SECTION 1.05. Foreign Currency Calculations
	  	 	25	  
		
	 ARTICLE II The Credits
	  	 	26	  
		
	 SECTION 2.01. Commitments
	  	 	26	  
	 SECTION 2.02. Loans and Borrowings
	  	 	26	  
	 SECTION 2.03. Requests for Revolving Borrowings
	  	 	27	  
	 SECTION 2.04. [Intentionally Omitted]
	  	 	28	  
	 SECTION 2.05. [Intentionally Omitted]
	  	 	28	  
	 SECTION 2.06. Letters of Credit
	  	 	28	  
	 SECTION 2.07. Funding of Borrowings
	  	 	33	  
	 SECTION 2.08. Interest Elections
	  	 	33	  
	 SECTION 2.09. Termination and Reduction and Increase of Commitments
	  	 	35	  
	 SECTION 2.10. Repayment of Loans; Evidence of Debt
	  	 	36	  
	 SECTION 2.11. Prepayment of Loans
	  	 	37	  
	 SECTION 2.12. Fees
	  	 	37	  
	 SECTION 2.13. Interest
	  	 	38	  
	 SECTION 2.14. Alternate Rate of Interest
	  	 	39	  
	 SECTION 2.15. Increased Costs
	  	 	40	  
	 SECTION 2.16. Break Funding Payments
	  	 	42	  
	 SECTION 2.17. Taxes
	  	 	42	  
	 SECTION 2.18. Payments Generally; Pro Rata Treatment; Sharing of Set-offs
	  	 	47	  
	 SECTION 2.19. Mitigation Obligations; Replacement of Lenders
	  	 	49	  
	 SECTION 2.20. Joint and Several Liability of the Borrowers
	  	 	50	  
	 SECTION 2.21. Defaulting Lenders
	  	 	52	  
	 SECTION 2.22. Extension of Maturity Date
	  	 	53	  
		
	 ARTICLE III Representations and Warranties
	  	 	55	  
		
	 SECTION 3.01. Organization; Powers
	  	 	55	  
	 SECTION 3.02. Authorization; Enforceability
	  	 	55	  
	 SECTION 3.03. Governmental Approvals; No Conflicts
	  	 	55	  
	 SECTION 3.04. Financial Condition; No Material Adverse Change
	  	 	56	  
	 SECTION 3.05. Properties
	  	 	56	  
	 SECTION 3.06. Litigation
	  	 	56	  
	 SECTION 3.07. Compliance with Laws and Agreements
	  	 	56	  
	 SECTION 3.08. Investment Company Status
	  	 	56	  

  
 i 

					
	 SECTION 3.09. Taxes
	  	 	57	  
	 SECTION 3.10. ERISA
	  	 	57	  
	 SECTION 3.11. Insurance Licenses
	  	 	57	  
	 SECTION 3.12. Subsidiaries
	  	 	57	  
	 SECTION 3.13. Material Agreements
	  	 	57	  
	 SECTION 3.14. Disclosure
	  	 	58	  
	 SECTION 3.15. Solvency
	  	 	58	  
	 SECTION 3.16. Foreign Pension Plan
	  	 	58	  
	 SECTION 3.17. Anti-Corruption Laws and Sanctions
	  	 	58	  
		
	 ARTICLE IV Conditions
	  	 	59	  
		
	 SECTION 4.01. Effective Date
	  	 	59	  
	 SECTION 4.02. Each Credit Event
	  	 	60	  
		
	 ARTICLE V Affirmative Covenants
	  	 	61	  
		
	 SECTION 5.01. Financial Statements; Ratings Change and Other Information
	  	 	61	  
	 SECTION 5.02. Notices of Material Events
	  	 	63	  
	 SECTION 5.03. Existence; Conduct of Business
	  	 	64	  
	 SECTION 5.04. Payment of Obligations
	  	 	64	  
	 SECTION 5.05. Maintenance of Properties; Insurance
	  	 	64	  
	 SECTION 5.06. Books and Records; Inspection Rights
	  	 	64	  
	 SECTION 5.07. Compliance with Laws
	  	 	65	  
	 SECTION 5.08. Use of Proceeds and Letters of Credit
	  	 	65	  
		
	 ARTICLE VI Negative Covenants
	  	 	65	  
		
	 SECTION 6.01. Indebtedness
	  	 	65	  
	 SECTION 6.02. Liens
	  	 	67	  
	 SECTION 6.03. Fundamental Changes
	  	 	67	  
	 SECTION 6.04. Investments and Acquisitions
	  	 	68	  
	 SECTION 6.05. Swap Agreements
	  	 	68	  
	 SECTION 6.06. Restricted Payments
	  	 	69	  
	 SECTION 6.07. Transactions with Affiliates
	  	 	69	  
	 SECTION 6.08. Restrictive Agreements
	  	 	69	  
	 SECTION 6.09. Maximum Leverage Ratio
	  	 	70	  
	 SECTION 6.10. Tangible Net Worth
	  	 	70	  
	 SECTION 6.11. Sale and Leaseback Transactions
	  	 	70	  
	 SECTION 6.12. Rating
	  	 	70	  
		
	 ARTICLE VII Events of Default
	  	 	70	  
		
	 ARTICLE VIII The Administrative Agent
	  	 	73	  
		
	 ARTICLE IX Miscellaneous
	  	 	75	  

  
 ii 

					
	 SECTION 9.01. Notices
	  	 	75	  
	 SECTION 9.02. Waivers; Amendments
	  	 	77	  
	 SECTION 9.03. Expenses; Indemnity; Damage Waiver
	  	 	79	  
	 SECTION 9.04. Successors and Assigns
	  	 	80	  
	 SECTION 9.05. Survival
	  	 	84	  
	 SECTION 9.06. Counterparts; Integration; Effectiveness
	  	 	84	  
	 SECTION 9.07. Severability
	  	 	85	  
	 SECTION 9.08. Right of Setoff
	  	 	85	  
	 SECTION 9.09. Governing Law; Jurisdiction; Consent to Service of Process
	  	 	85	  
	 SECTION 9.10. WAIVER OF JURY TRIAL
	  	 	86	  
	 SECTION 9.11. Headings
	  	 	86	  
	 SECTION 9.12. Confidentiality
	  	 	86	  
	 SECTION 9.13. Interest Rate Limitation
	  	 	87	  
	 SECTION 9.14. USA PATRIOT Act
	  	 	87	  
	 SECTION 9.15. Conversion of Currencies
	  	 	87	  
	 SECTION 9.16. Appointment and Authorization of Borrower Representative
	  	 	88	  
	 SECTION 9.17. No Fiduciary Duty
	  	 	89	  
	 SECTION 9.18. Termination of Existing Agreement
	  	 	89	  

  
 iii 

 SCHEDULES: 
  

					
	Schedule 1.01	 	—	  	Existing Letters of Credit
	Schedule 1.02	 	—	  	Pricing Schedule
	Schedule 1.03	 	—	  	Trust Preferred Securities
	Schedule 2.01	 	—	  	Commitments
	Schedule 3.11	 	—	  	Licenses
	Schedule 3.12	 	—	  	Subsidiaries
	Schedule 6.01	 	—	  	Existing Indebtedness
	Schedule 6.02	 	—	  	Existing Liens
	Schedule 6.08	 	—	  	Existing Restrictions

 EXHIBITS: 
  

					
	Exhibit A	 	—	  	Form of Assignment and Assumption
	Exhibit B-1	 	—	  	U.S. Tax Compliance Certificate (For Non-U.S. Lenders that are not Partnerships for U.S. Federal; Income Tax Purposes
	Exhibit B-2	 	—	  	U.S. Tax Compliance Certificate (For Non-U.S. Participants that are Partnerships for U.S. Federal; Income Tax Purposes
	Exhibit B-3	 	—	  	U.S. Tax Compliance Certificate (For Non-U.S. Participants that are not Partnerships for U.S. Federal; Income Tax Purposes
	Exhibit B-4	 	—	  	U.S. Tax Compliance Certificate (For Non-U.S. Lenders that are Partnerships for U.S. Federal; Income Tax Purposes

  
 iv 

 CREDIT AGREEMENT dated as of March 7, 2014, among ARGO GROUP INTERNATIONAL HOLDINGS, LTD, a
company organized under the laws of Bermuda, ARGO GROUP US, INC., a Delaware corporation, ARGO INTERNATIONAL HOLDINGS LIMITED, a corporation organized under the laws of the United Kingdom, and ARGO UNDERWRITING AGENCY LIMITED, a corporation
organized under the laws of the United Kingdom, as Borrowers, the LENDERS party hereto from time to time, and JPMORGAN CHASE BANK, N.A., as Administrative Agent. 

WHEREAS, the Borrowers have requested that the Lenders provide a revolving credit facility, and the Lenders are willing to do so on the terms
and conditions set forth herein; 
 NOW THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties
hereto agree as follows: 
 ARTICLE I 

Definitions 
 SECTION
1.01. Defined Terms. As used in this Agreement, the following terms have the meanings specified below: 
 “ABR”,
when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Alternate Base Rate. 

“Acquired Entity or Business” means either (a) the assets constituting a business, division, facility, product line or
line of business of any Person not already a Subsidiary or (b) all of the Equity Interests of any such Person, which Person shall, as a result of such acquisition or merger, become a Wholly-Owned Subsidiary of the Parent (or shall be merged
with and into the Parent or a Wholly-Owned Subsidiary, with the Parent or such Wholly-Owned Subsidiary being the surviving Person). 

“Acquisition” means any transaction, or any series of related transactions, by which any Borrower and/or any of their
Subsidiaries directly or indirectly (i) acquires any ongoing business or all or substantially all of the assets of any Person or division thereof, whether through purchase of assets, merger or otherwise, (ii) acquires (in one transaction
or as the most recent transaction in a series of transactions) Control of at least a majority in ordinary voting power of the securities of a Person which have ordinary voting power for the election of directors or (iii) otherwise acquires
Control of a more than 50% ownership interest in any such Person. 
 “Act” has the meaning assigned to it in
Section 9.14. 
 “Additional Commitment Lender” has the meaning assigned to it in Section 2.22(d). 

  
 1 

 “Adjusted Eurocurrency Rate” means, with respect to any Eurocurrency Borrowing
in Dollars for any Interest Period, an interest rate per annum (rounded upwards, if necessary, to the next 1/16 of 1%) equal to (a) the Eurocurrency Rate for such Interest Period multiplied by (b) the Statutory Reserve Rate. For all other
Eurocurrency Borrowings, “Adjusted Eurocurrency Rate” means the Eurocurrency Rate. 
 “Administrative Agent”
means JPMCB, together with its permitted successors and assigns, in its capacity as administrative agent for the Lenders hereunder. 

“Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent. 

“Advance” means any Loan or any Letter of Credit. 

“Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more
intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 
 “Agreement” means
this Credit Agreement, as amended, restated, modified or supplemented from time to time. 
 “Agreement Currency” shall have
the meaning assigned to such term in Section 9.15(b). 
 “Alternate Base Rate” means, for any day, a rate per annum
equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day (or if such day is not a Business Day, the immediately preceding Business Day) plus
 1⁄2 of 1% and (c) the Adjusted Eurocurrency Rate for a one month Interest Period on such day (or if such day is not a Business Day, the immediately
preceding Business Day) plus 1%, provided that, for the avoidance of doubt, the Adjusted Eurocurrency Rate for any day shall be based on the LIBOR Screen Rate for Dollars for such Interest Period at approximately 11:00 a.m. London time on such day.
Any change in the Alternate Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted Eurocurrency Rate shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds
Effective Rate or the Adjusted Eurocurrency Rate, respectively. 
 “Annual Statement” means the annual statutory financial
statement of any Insurance Subsidiary required to be filed with the insurance commissioner (or similar authority) of its jurisdiction of incorporation, which statement shall be in the form required by such Insurance Subsidiary’s jurisdiction of
incorporation or, if no specific form is so required, in the form of financial statements recommended by the NAIC to be used for filing annual statutory financial statements and shall contain the type of information recommended by the NAIC to be
disclosed therein, together with all exhibits or schedules filed therewith, or, in the case of an Insurance Subsidiary not domiciled in the United States, any comparable statement. 

“Anti-Corruption Laws” means all laws, rules, and regulations of any jurisdiction applicable to the Borrowers or their
Subsidiaries from time to time concerning or relating to bribery or corruption. 
 “Applicable Creditor” has the meaning
assigned to such term in Section 9.15(b). 

  
 2 

 “Applicable Lending Installation” is defined in Section 2.02(e). 

“Applicable Percentage” means, with respect to any Lender, the percentage of the total Commitments represented by such
Lender’s Commitment; provided that in the case of Section 2.21 when a Defaulting Lender shall exist, “Applicable Percentage” shall mean the percentage of the total Commitments (disregarding any Defaulting Lender’s
Commitment) represented by such Lender’s Commitment. If the Commitments have terminated or expired, the Applicable Percentages shall be determined based upon the Commitments most recently in effect, giving effect to any assignments and to any
Lender’s status as a Defaulting Lender at the time of determination. 
 “Applicable Rate” means, for any day, with
respect to any ABR Loan or Eurocurrency Loan or with respect to the facility fees payable hereunder, the applicable rate per annum set forth on Schedule 1.01 under the caption “Eurocurrency Spread”, “Alternative Base Rate Spread”
or “Facility Fee Rate”. 
 “Approved Fund” has the meaning assigned to such term in Section 9.04(b). 

“Argo US” means Argo Group US, Inc., a Delaware corporation. 

“Argo Investment Policy” means the investment policy of the Parent and its Subsidiaries delivered to the Administrative Agent
and the Lenders prior to the Effective Date, together with any amendments or supplements thereto which do not materially alter or change the guidelines or objectives of such policy as exist on the Effective Date, except as approved by the board of
directors of the Parent and would not reasonably be expected to have a Material Adverse Effect. 
 “Asset Disposition”
means any sale, transfer or other disposition (excluding any loss portfolio transfer or any surplus relief transaction (within the meanings prescribed by SAP) through assumption, reinsurance, cancellation and rewriting of insurance business or
otherwise) of any asset of a Borrower or any Subsidiary in a single transaction or in a series of related transactions (other than the sale of inventory or products in the ordinary course of business, the sale of obsolete or worn out property in the
ordinary course of business or the sale of cash, cash equivalents and other investments made in accordance with Section 6.04(a) in the ordinary course of business). 

“Assignment and Assumption” means an assignment and assumption entered into by a Lender and an assignee (with the consent of
any party whose consent is required by Section 9.04), and accepted by the Administrative Agent, in the form of Exhibit A or any other form approved by the Administrative Agent. 

“Availability Period” means the period from and including the Effective Date to but excluding the earlier of the Maturity
Date and the date of termination of the Commitments. 
 “Bankruptcy Event” means, with respect to any Person, such Person
becomes the subject of a bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its
business appointed for it, or, in the good faith determination 

  
 3 

 
of the Administrative Agent, has taken any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any such proceeding or appointment, provided that a Bankruptcy
Event shall not result solely by virtue of any ownership interest, or the acquisition of any ownership interest, in such Person by a Governmental Authority or instrumentality thereof, provided, further, that such ownership interest
does not result in or provide such Person with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Person (or such Governmental Authority or
instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements made by such Person. 
 “Board”
means the Board of Governors of the Federal Reserve System of the United States of America. 
 “Borrower Representative”
shall mean Argo US in its capacity as borrowing agent and Loan administrator for the Borrowers hereunder and under each of the other Credit Documents. 

“Borrowers” means, individually and collectively, the Parent, Argo US, Argo International Holdings Limited, a private limited
liability company organized under the laws of England and Wales and registered under company number: 06543704 and Argo Underwriting Agency Limited, a private limited liability company organized under the laws of England and Wales and registered
under company number: 03741768. 
 “Borrowing” means Revolving Loans of the same Type, made, converted or continued on the
same date and, in the case of Eurocurrency Loans, as to which a single Interest Period is in effect. 
 “Borrowing Request”
means a request by the Borrower Representative for a Revolving Borrowing in accordance with Section 2.03. 
 “Business
Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed; and when used in connection with a Eurocurrency Loan, the term “Business
Day” shall also exclude any day on which banks are not open for general business in London; and, if the Borrowing or LC Disbursements which are the subject of a borrowing, drawing, payment, reimbursement or rate selection are denominated in
Euro, the term “Business Day” shall also exclude any day on which the TARGET2 payment system is not open for the settlement of payments in Euro). 

“Capital Lease Obligations” of any Person means the obligations of such Person to pay rent or other amounts under any lease
of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as capital leases on a balance sheet of such Person under GAAP, and the
amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 

  
 4 

 “Change in Control” means (a) the acquisition of ownership, directly or
indirectly, beneficially or of record, by any Person or group (within the meaning of the Securities Exchange Act of 1934 and the rules of the SEC thereunder as in effect on the date hereof), of Equity Interests representing more than 35% of the
aggregate ordinary voting power represented by the issued and outstanding Equity Interests of the Parent; (b) occupation of a majority of the seats (other than vacant seats) on the board of directors of the Parent by Persons who were neither
(i) nominated by the board of directors of the Parent nor (ii) appointed by directors so nominated; (c) the acquisition of direct or indirect Control of the Parent by any Person or group; (d) except as otherwise expressly
permitted under the terms of this Agreement (including a disposition permitted under Section 6.03(b)), the Parent shall cease to own and control, directly or indirectly, free and clear of all Liens (other than Permitted Encumbrances) all of the
economic and voting rights associated with all of the outstanding Equity Interests of each of its Insurance Subsidiaries or shall cease to have the power, directly or indirectly, to elect all of the members of the board of directors of each of its
Insurance Subsidiaries; (e) except as otherwise expressly permitted under the terms of this Agreement (including a disposition permitted under Section 6.03(b)), Argo US shall cease to own and control, directly or indirectly, free and clear
of all Liens (other than Permitted Encumbrances) all of the economic and voting rights associated with all of the outstanding Equity Interests of each of its Insurance Subsidiaries or shall cease to have the power, directly or indirectly, to elect
all of the members of the board of directors of each of its Insurance Subsidiaries or (f) the Parent shall cease to own and control, directly or indirectly, free and clear of all Liens and other encumbrances all of the economic and voting
rights associated with all of the outstanding Equity Interests of any of the other Borrowers or shall cease to have the power, directly or indirectly, to elect all of the members of the board of directors of any of the other Borrowers. 

“Change in Law” means the occurrence after the date of this Agreement or, with respect to any Lender, such later date on
which such Lender becomes a party to this Agreement, (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation or application
thereof by any Governmental Authority or (c) compliance by any Lender or the Issuing Bank (or, for purposes of Section 2.15(b), by any lending office of such Lender or by such Lender’s or the Issuing Bank’s holding company, if
any) with any request, guideline or directive (whether or not having the force of law) of any Governmental Authority made or issued after the date of this Agreement; provided that, notwithstanding anything herein to the contrary, (x) the
Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines, requirements and directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the
Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall be deemed to be a “Change
in “Law”, regardless of the date enacted, adopted, issued or implemented; provided that, notwithstanding anything in this definition to the contrary, the enactment of the changes to the UK bank levy contained in the draft Finance Bill 2014
provisions as published on December 10, 2013 shall be deemed not to be a “Change in Law” regardless of the date of their enactment or entry into effect. 

“Change of Tax Law” means any change in (or in the interpretation, administration or application of) any law relating to
Taxes or any Treaty, or in any published practice or published concession of any relevant Governmental Authority. 

  
 5 

 “Charges” has the meaning set forth in Section 9.13. 

“Code” means the Internal Revenue Code of 1986, as amended from time to time. 

“Collateral” means all property with respect to which any security interest has been granted (or purported to be granted)
pursuant to any Security Document. 
 “Collateral Account” means a depositary account or securities custody account
constituting Collateral and with respect to which a Control Agreement has been entered into and is in effect. 

“Commitment” means, with respect to each Lender, the commitment of such Lender to make Revolving Loans and to acquire
participations in Letters of Credit hereunder, expressed as an amount representing the maximum aggregate amount of such Lender’s Revolving Credit Exposure hereunder, as such commitment may be (a) reduced or increased from time to time
pursuant to Section 2.09 and (b) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04. The initial amount of each Lender’s Commitment is set forth on Schedule 2.01, or in
the Assignment and Assumption pursuant to which such Lender shall have assumed its Commitment, as applicable. The initial aggregate amount of the Lenders’ Commitments is $175,000,000. 

“Communications” has the meaning assigned to it in Section 9.01(d). 

“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or
that are franchise Taxes or branch profits Taxes. 
 “Control” means the possession, directly or indirectly, of the power
to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 

“Control Agreement” means one or more agreements, in form and substance reasonably satisfactory to the Administrative Agent,
among a Borrower, a securities intermediary or depository institution holding Collateral (which shall be JPMorgan Chase Bank, N.A. or an Affiliate thereof), and the Administrative Agent with respect to collection and control of all financial assets
or deposits held in the applicable securities custody or depository account maintained by such Borrower with such institution in the United States of America. 

“Credit Documents” means this Agreement, any Security Document, after the execution and delivery thereof pursuant to the
terms of this Agreement, each promissory note delivered pursuant to Section 2.10(e), each Security Document, each other document or agreement executed and delivered from time to time by any of the Borrowers in connection with or pursuant to the
terms of this Agreement or any other Credit Document, each amendment or waiver hereof or thereof, and each other document related to the Credit Documents which is from time to time designated as a Credit Document by any Borrower and the
Administrative Agent. 

  
 6 

 “Default” means any event or condition which constitutes an Event of Default or
which upon notice, lapse of time or both would, unless cured or waived, become an Event of Default. 
 “Defaulting Lender”
means any Lender that (a) has failed, within two Business Days of the date required to be funded or paid, to (i) fund any portion of its Loans, (ii) fund any portion of its participations in Letters of Credit or (iii) pay over to
any Lender Party any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in writing that such failure is the result of such Lender’s good faith
determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied, (b) has notified any Borrower or any Lender Party in writing, or has made a public statement to
the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such Lender’s good faith determination that a
condition precedent (specifically identified and including the particular default, if any) to funding a loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed,
within three Business Days after request by a Lender Party, acting in good faith, to provide a certification in writing from an authorized officer of such Lender that it will comply with its obligations (and is financially able to meet such
obligations) to fund prospective Loans and participations in then outstanding Letters of Credit under this Agreement, provided that such Lender Party shall cease to be a Defaulting Lender pursuant to this clause (c) upon such Lender’s
receipt of such certification in form and substance satisfactory to it and the Administrative Agent, or (d) has become the subject of a Bankruptcy Event. 

“Designated Person” means a person or entity. 

“Dollar Equivalent” means, on any date of determination (a) with respect to any amount in Dollars, such amount, and
(b) with respect to any amount in any Foreign Currency, the equivalent in Dollars of such amount, determined by the Administrative Agent pursuant to Section 1.05 using the Exchange Rate with respect to such Foreign Currency at the time in
effect under the provisions of such Section. 
 “Dollars” or “$” refers to lawful money of the United
States of America. 
 “Effective Date” means the date on which the conditions specified in Section 4.01 are satisfied
(or waived in accordance with Section 9.02). 
 “Electronic Signature” means an electronic sound, symbol, or process
attached to, or associated with, a contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record. 

“Electronic System” means any electronic system, including e-mail, e-fax, Intralinks®,ClearPar® and any other Internet or extranet-based site, whether such electronic system is owned, operated or hosted by the Administrative
Agent and the Issuing Bank and any of its respective Related Parties or any other Person, providing for access to data protected by passcodes or other security system. 

“Environmental Laws” means all applicable laws, rules, regulations, codes, ordinances, orders, decrees, judgments,
injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to the environment, preservation or reclamation of natural resources, the management, release or threatened release of
any Hazardous Material. 

  
 7 

 “Environmental Liability” means any liability, contingent or otherwise
(including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Parent or any Subsidiary directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the
generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or
(e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing; provided that the definition of “Environmental Liability” shall not include any
liability arising out of any insurance policy issued by the Parent, the Borrowers or any Subsidiary thereof. 
 “Equity
Interests” means shares of capital stock, partnership interests, membership interests in a limited liability company, beneficial interests in a trust or other equity ownership interests in a Person (in each case, whether voting or
non-voting or common or preferred), and in each case, any warrants, options or other rights entitling the holder thereof to purchase or acquire any such equity interest. 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time. 

“ERISA Affiliate” means any trade or business (whether or not incorporated) that, together with any Borrower, is treated as a
single employer under Section 414(b) or (c) of the Code or, solely for purposes of Section 302 of ERISA and Section 412 of the Code, is treated as a single employer under Section 414 of the Code. 

“ERISA Event” means (a) any “reportable event”, as defined in Section 4043 of ERISA or the regulations
issued thereunder with respect to a Plan (other than an event for which the 30 day notice period is waived); (b) the existence with respect to any Plan of an “accumulated funding deficiency” (as defined in Section 412 of the Code
or Section 302 of ERISA), whether or not waived; (c) the filing pursuant to Section 412(d) of the Code or Section 303(d) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan;
(d) the incurrence by any Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan; (e) the receipt by any Borrower or any ERISA Affiliate from the PBGC or a plan
administrator of any notice relating to an intention to terminate any Plan or Plans or to appoint a trustee to administer any Plan; (f) the incurrence by any Borrower or any of its ERISA Affiliates of any liability with respect to the
withdrawal or partial withdrawal from any Plan or Multiemployer Plan; or (g) the receipt by any Borrower or any ERISA Affiliate of any notice, or the receipt by any Multiemployer Plan from any Borrower or any ERISA Affiliate of any notice,
concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in reorganization, within the meaning of Title IV of ERISA. 

  
 8 

 “Euro” or “€” means the single currency unit of the
Participating Member States. 
 “Eurocurrency”, when used in reference to any Loan or Borrowing, refers to whether such
Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Adjusted Eurocurrency Rate. 

“Eurocurrency Rate” means, with respect to (a) any Eurocurrency Borrowing and for any applicable Interest Period, the
London interbank offered rate administered by ICE Benchmark Administration (or any other Person that takes over the administration of such rate) for the applicable currency for a period equal in length to such Interest Period as displayed on pages
LIBOR01 or LIBOR02 of the Reuters screen or, in the event such rate does not appear on a Reuters page or screen, on any successor or substitute page on such screen that displays such rate, or on the appropriate page of such other information service
that publishes such rate as shall be selected by the Administrative Agent from time to time in its reasonable discretion (the “LIBOR Screen Rate”) at approximately 11:00 a.m., London time, on the Quotation Date for such Interest
Period; provided, that, if the LIBOR Screen Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement; and further provided that if a LIBOR Screen Rate shall not be available at the applicable
time for a period equal in length to such Interest Period, then the Eurocurrency Rate shall be the Interpolated Rate at such time, subject to Section 2.14 in the event that the Administrative Agent shall conclude that it shall not be possible
to determine such Interpolated Rate (which conclusion shall be conclusive and binding absent manifest error). 
 “Event of
Default” has the meaning assigned to such term in Article VII. 
 “Exchange Rate” means on any day, for purposes
of determining the Dollar Equivalent of any currency other than Dollars, the rate at which such currency may be exchanged into Dollars at 11:00 a.m. Local Time on such day on the Reuters Currency pages, if available, for such currency. In the event
that such rate does not appear on any Reuters Currency pages, the Exchange Rate shall be determined by reference to such other publicly available service for displaying exchange rates as may be agreed upon by the Administrative Agent and the
Borrowers, or, in the absence of such an agreement, such Exchange Rate shall instead be the arithmetic average of the spot rates of exchange of the Administrative Agent in the market where its foreign currency exchange operations in respect of such
currency are then being conducted, at or about such time as the Administrative Agent shall elect after determining that such rates shall be the basis for determining the Exchange Rate, on such date for the purchase of Dollars for delivery two
Business Days later; provided that if at the time of any such determination, for any reason, no such spot rate is being quoted, the Administrative Agent may use any reasonable method it deems appropriate to determine such rate, and such
determination shall be conclusive absent manifest error. 
 “Exchange Rate Date” means, if on such date any outstanding
Loan or Letter of Credit is (or any Loan or Letter of Credit that has been requested at such time would be) denominated in a currency other than Dollars, each of: 

(a) the last Business Day of each calendar month, 

  
 9 

 (b) if an Event of Default has occurred and is continuing, any Business Day designated as an
Exchange Rate Date by the Administrative Agent in its sole discretion, and 
 (c) each date (with such date to be reasonably determined by
the Administrative Agent) that is on or about the date of (i) a Borrowing Request or an Interest Election Request with respect to any Revolving Borrowing or (ii) each request for the issuance, amendment, renewal or extension of any Letter
of Credit. 
 “Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be
withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized
under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes,
(b) in the case of a Lender, U.S. Federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which
(i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Parent under Section 2.19(b)) or (ii) such Lender changes its lending office, except in each case to the extent
that, pursuant to Section 2.17, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender acquired the applicable interest in a Loan or Commitment or to such Lender immediately before
it changed its lending office, (c) Taxes attributable to such Recipient’s failure to comply with Section 2.17(f) or (g), (d) any U.S. Federal withholding Taxes imposed under FATCA, and (e) in the case of a Lender, UK
income tax deductible at source from interest payable to or for the account of such Lender with respect to an applicable participation in a Loan (i) if on the date on which the payment of interest falls due the payment could have been made to
the relevant Lender without a deduction on account of UK income tax if the Lender had been a Qualifying Treaty Lender but on that date that Lender is not or has ceased to be a Qualifying Treaty Lender other than as a result of a Change of Tax Law
occurring after the date it became a Lender, or (ii) if such Lender acquired such participation in the Loan or Commitment by way of an Assignment and Assumption (other than pursuant to an assignment request by the Parent under
Section 2.19(b)), except to the extent that, pursuant to Section 2.17, amounts with respect to such Taxes were payable to such Lender’s assignor immediately before such Lender acquired the applicable participation in the Loan or
Commitment. 
 “Existing Letter of Credit” means the letters of credit identified on Schedule 1.01. 

“Existing Termination Date” has the meaning assigned to it in Section 2.22(a). 

“Extending Lender” has the meaning assigned to it in Section 2.22(b). 

“Extension Date” has the meaning assigned to it in Section 2.22(a). 

“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor
version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreement entered into pursuant to Section 1471(b)(1) of the Code. 

  
 10 

 “Federal Funds Effective Rate” means, for any day, the weighted average (rounded
upwards, if necessary, to the next 1/100 of 1%) of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the next succeeding Business Day by the Federal
Reserve Bank of New York, or, if such rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of 1%) of the quotations for such day for such transactions received by the
Administrative Agent from three Federal funds brokers of recognized standing selected by it. 
 “Financial Officer” means
the chief financial officer, principal accounting officer, treasurer or controller of any Borrower. 
 “Foreign Currency”
means Euros or Sterling. 
 “Foreign Lender” means (a) if the applicable Borrower is a U.S. Person, a Lender, with
respect to such Borrower, that is not a U.S. Person, and (b) if the applicable Borrower is not a U.S. Person, a Lender, with respect to such Borrower, that is resident or organized under the laws of a jurisdiction other than that in which such
Borrower is resident for tax purposes. 
 “Foreign Pension Plan” means any plan, fund (including, without limitation, any
superannuation fund) or other similar program established or maintained outside the United States by a Borrower or any Subsidiary primarily for the benefit of employees of such Borrower or any one or more of the Subsidiaries residing outside the
United States, which plan, fund or other similar program provides, or results in, retirement income, a deferral of income in contemplation of retirement or payments to be made upon termination or severance of employment, and which plan is not
subject to ERISA or the Code. 
 “GAAP” means generally accepted accounting principles in the United States of America.

 “Governmental Authority” means the government of the United States of America, any other nation or any political
subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity, including any insurance commissioner or other insurance regulatory authority, exercising executive,
legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government. 

“Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the
guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the
guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the
payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the 

  
 11 

 
payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay
such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided, that the term Guarantee shall not include endorsements
for collection or deposit in the ordinary course of business. The amount of any Guarantee made by any guarantor shall be deemed to be the lower of (a) an amount equal to the stated or determinable amount of the primary obligation in respect of
which such Guarantee is made and (b) the maximum amount for which such guarantor may be liable pursuant to the terms of the instrument embodying such Guarantee, unless (in the case of a primary obligation that is not Indebtedness) such primary
obligation and the maximum amount for which such guarantor may be liable are not stated or determinable, in which case the amount of such Guarantee shall be such guarantor’s maximum reasonably anticipated liability in respect thereof as
determined by the Borrowers in good faith. 
 “Hazardous Materials” means all explosive or radioactive substances or wastes
and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances
or wastes of any nature regulated pursuant to any Environmental Law. 
 “HMRC DT Treaty Passport scheme” means the Board of
H.M. Revenue and Customs Double Taxation Treaty Passport scheme. 
 “Indebtedness” of any Person means, without
duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person upon which interest charges are
customarily paid, (d) all obligations of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of
property or services (excluding current accounts payable incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be
secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all Capital Lease Obligations of such
Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (j) all obligations, contingent or otherwise, of such Person in respect of bankers’
acceptances, (k) all Off-Balance Sheet Liabilities and (l) all Trust Preferred Securities and similarly structured indebtedness. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership
in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that
such Person is not liable therefor. 
 “Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or
with respect to any payment made by or on account of any obligation of any Borrower under any Credit Document and (b) to the extent not otherwise described in (a), Other Taxes. 

  
 12 

 “Industry Loss Warranty” means an agreement, whether in the form of a
reinsurance agreement or a Swap Agreement or other similar agreement entered into by any Insurance Subsidiary in accordance with its customary insurance or reinsurance underwriting procedures, which creates a payment obligation arising from an
industry wide loss. 
 “Ineligible Institution” has the meaning assigned to it in Section 9.04(b). 

“Insurance Subsidiary” means any Subsidiary which is licensed by any Governmental Authority to engage in the insurance
business including, without limitation, issuing Primary Policies and/or entering into Reinsurance Agreements.  
 “Interest
Election Request” means a request by the Borrower Representative to convert or continue a Revolving Borrowing in accordance with Section 2.08. 

“Interest Payment Date” means (a) with respect to any ABR Loan, the last day of each March, June, September and December
and (b) with respect to any Eurocurrency Loan, the last day of the Interest Period applicable to the Borrowing of which such Loan is a part and, in the case of a Eurocurrency Borrowing with an Interest Period of more than three months’
duration, each day prior to the last day of such Interest Period that occurs at intervals of three months’ duration after the first day of such Interest Period. 

“Interest Period” means, with respect to any Eurocurrency Borrowing, the period commencing on the date of such Borrowing and
ending on the numerically corresponding day in the calendar month that is one, two, three or six months thereafter, as the Borrower Representative may elect; provided, that (i) if any Interest Period would end on a day other than a
Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day
and (ii) any Interest Period pertaining to a Eurocurrency Borrowing that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period)
shall end on the last Business Day of the last calendar month of such Interest Period. For purposes hereof, the date of a Borrowing initially shall be the date on which such Borrowing is made and thereafter shall be the effective date of the most
recent conversion or continuation of such Borrowing. 
 “Interpolated Rate” means, at any time, for any Interest Period,
the rate per annum determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the applicable Screen
Rate for the longest period (for which the applicable Screen Rate is available for the applicable currency) that is shorter than the impacted Interest Period and (b) the applicable Screen Rate for the shortest period (for which such Screen Rate
is available for the applicable currency) that exceeds the Impacted Interest Period, in each case, at such time. 
 “IRS”
means the United States Internal Revenue Service. 
 “Issuing Bank” means JPMCB, in its capacity as the issuer of
Letters of Credit hereunder, and its successors in such capacity as provided in Section 2.06(i). The Issuing Bank may, in its discretion, arrange for one or more Letters of Credit to be issued by Affiliates of the Issuing Bank, in which case
the term “Issuing Bank” shall include any such Affiliate with respect to Letters of Credit issued by such Affiliate. 

  
 13 

 “JPMCB” means JPMorgan Chase Bank, N.A., a national banking association, and its
successors. 
 “LC Disbursement” means a payment made by the Issuing Bank pursuant to a Letter of Credit. 

“LC Exposure” means, at any time, the sum of (a) the Dollar Equivalent of the aggregate undrawn amount of all
outstanding Letters of Credit at such time plus (b) the Dollar Equivalent of the aggregate amount of all LC Disbursements that have not yet been reimbursed by or on behalf of the Borrowers at such time. The LC Exposure of any Lender at any time
shall be its Applicable Percentage of the total LC Exposure at such time. 
 “Lenders” means the Persons listed on Schedule
2.01 and any other Person that shall have become a party hereto pursuant to an Assignment and Assumption or as provided in Section 2.09(d), other than any such Person that ceases to be a party hereto pursuant to an Assignment and Assumption.

 “Lender Parent” means, with respect to any Lender, any Person as to which such Lender is, directly or indirectly, a
subsidiary. 
 “Lender Party” means the Administrative Agent, the Issuing Bank and each other Lender. 

“Letter of Credit” means any letter of credit issued pursuant to this Agreement. 

“Leverage Ratio” means at any time, the ratio of Total Debt at such time to Total Capitalization at such time. 

“Lien” means, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge, hypothecation, encumbrance,
charge or security interest in, on or of such asset, (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having substantially the same economic effect
as any of the foregoing) relating to such asset and (c) in the case of securities, any purchase option, call or similar right of a third party with respect to such securities. 

“Loans” means the loans made by the Lenders to the Borrowers pursuant to this Agreement. 

“Local Time” means (a) with respect to a Loan or Borrowing denominated in Dollars, Chicago time and (b) with
respect to a Loan or Borrowing denominated in any Foreign Currency, London time. 
 “Material Adverse Effect” means a
material adverse effect on (a) the business, assets, operations or financial condition of the Parent and the Subsidiaries taken as a whole, (b) the ability of the Borrowers, taken as a whole, to perform any of their payment or other
material obligations under this Agreement or any other Credit Document or (c) the material rights of or benefits available to the Administrative Agent or the Lenders under this Agreement or any other Credit Document. 

  
 14 

 “Material Indebtedness” means Indebtedness (other than the Loans and Letters of
Credit), or obligations in respect of one or more Swap Agreements, of any one or more of the Borrowers and the Subsidiaries in an aggregate principal amount exceeding $20,000,000. For purposes of determining Material Indebtedness, the
“principal amount” of the obligations of a Borrower or any Subsidiary in respect of any Swap Agreement at any time shall be the maximum aggregate amount (giving effect to any legally enforceable netting agreements) that such Borrower or
such Subsidiary would be required to pay if such Swap Agreement were terminated at such time. 
 “Maturity Date” means
March 7, 2018, subject to extension pursuant to Section 2.22. 
 “Maximum Rate” has the meaning set forth in
Section 9.13. 
 “Multiemployer Plan” means a multiemployer plan as defined in Section 4001(a)(3) of ERISA. 

“NAIC” means the National Association of Insurance Commissioners or any successor thereto, or in lieu thereof, any other
association, agency or other organization performing substantially similar advisory, coordination or other like functions among insurance departments, insurance commissions and similar governmental authorities of the various states of the United
States of America toward the promotion of uniformity in the practices of such governmental authorities. 
 “Net Income”
means, for any computation period, with respect to the Parent on a consolidated basis with its Subsidiaries, cumulative net income earned during such period (determined before the deduction of minority interests) as determined in accordance with
GAAP. 
 “Net Worth Maintenance Agreement” means net worth maintenance agreements and similar agreements entered into by
any Borrower or any of its respective Subsidiaries with respect to any Wholly-Owned Subsidiary. 
 “Non-Extending Lender”
has the meaning assigned to it in Section 2.22(b). 
 “Non-Replaced Lender” has the meaning assigned to it in
Section 2.22(e). 
 “Notice Date” has the meaning assigned to it in Section 2.22(b). 

“Obligations” means all unpaid principal of and accrued and unpaid interest on the Loans, all LC Exposure, all accrued and
unpaid fees and all expenses, reimbursements, indemnities and other obligations and indebtedness (including interest and fees accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether
allowed or allowable in such proceeding), obligations and liabilities of any of the Borrowers to any of the Lenders, the Administrative Agent, any LC Issuer or any indemnified 

  
 15 

 
party under this Agreement, individually or collectively, existing on the Effective Date or arising thereafter, direct or indirect, joint or several, absolute or contingent, matured or unmatured,
liquidated or unliquidated, secured or unsecured, arising by contract, operation of law or otherwise, arising or incurred under this Agreement or any of the other Credit Documents or in respect of any of the Loans made or reimbursement or other
obligations incurred or any of the Letters of Credit or other instruments at any time evidencing any thereof. 
 “Off-Balance Sheet
Liability” of a Person means (a) any repurchase obligation or liability of such Person with respect to accounts or notes receivable sold by such Person, (b) any liability under any Sale and Leaseback Transaction other than Capital
Lease Obligations, (c) any liability under any so-called “synthetic lease” arrangement or transaction entered into by such Person, or (d) any obligation arising with respect to any other transaction which is the functional
equivalent of or takes the place of borrowing but which does not constitute a liability on the balance sheets of such Person. 

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection
between such Recipient and the jurisdiction imposing such Taxes (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a
security interest under, engaged in any other transaction pursuant to or enforced any Credit Document, or sold or assigned an interest in any Loan or Credit Document). 

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that
arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Credit Document, except any such Taxes that
are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 2.19). 

“Parent” means Argo Group International Holdings, Ltd., a company formed under the laws of Bermuda. 

“Participant” has the meaning set forth in Section 9.04(c). 

“Participant Register” has the meaning assigned to such term in Section 9.04(c). 

“Participating Member State” means any member state of the European Communities that adopts or has adopted the Euro as its
lawful currency in accordance with the legislation of the European Community relating to the Economic and Monetary Union. 

“PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing
similar functions. 
 “Permitted Acquisition” means the acquisition by the Parent or a Wholly-Owned Subsidiary thereof of
an Acquired Entity or Business (including by way of merger of such Acquired Entity or Business with and into the Parent (so long as the Parent is the surviving corporation) or a Wholly-Owned Subsidiary thereof (so long as the Wholly-Owned Subsidiary
is the surviving corporation); provided that (a) in the case of the acquisition of the Equity Interests 

  
 16 

 
of any Person (including by way of merger), such Person shall own no Equity Interests of any other Person (excluding de minimis amounts) unless either (i) such Person owns 100% of the Equity
Interests of such other Person or (ii) (x) such Person and its Wholly-Owned Subsidiaries own at least 80% of the consolidated assets of such other Person and its Subsidiaries and (y) any non-Wholly-Owned Subsidiary of such Person was
a non-Wholly-Owned Subsidiary prior to the date of such Permitted Acquisition of such Person; (b) the Acquired Entity or Business acquired pursuant to the respective Permitted Acquisition is in a business permitted by Section 6.03(c); and
(c) in the case of a stock acquisition, such acquisition shall have been approved by the board of directors of the Acquired Entity or Business. 

“Permitted Encumbrances” means: 

(a) Liens imposed by law for Taxes that are not yet due or are being contested in compliance with Section 5.04; 

(b) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s and other like Liens imposed by law, arising in
the ordinary course of business and securing obligations that are not overdue by more than 30 days or are being contested in compliance with Section 5.04; 

(c) pledges and deposits made in the ordinary course of business for insurance regulatory or licensing purposes or in compliance with
workers’ compensation, unemployment insurance and other social security laws or regulations; 
 (d) deposits required for insurance
regulatory or licensing purposes or to secure the performance of bids, trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of
business; 
 (e) judgment liens in respect of judgments that do not constitute an Event of Default under clause (k) of Article VII; 

(f) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of
business that do not secure any monetary obligations and do not materially detract from the value of the affected property or interfere with the ordinary conduct of business of a Borrower or any Subsidiary; and 

(g) licenses, sublicenses, leases or subleases granted to other Persons not materially interfering with the conduct of the business of a
Borrower or any Subsidiary; 
 (h) Liens incurred pursuant to ordinary course investing, clearing and settling activities; 

(i) bankers’ Liens, rights of setoff and other similar Liens not granted to secure specific Indebtedness existing solely with respect to
cash and cash equivalents on deposit in one or more accounts maintained by a Borrower or any Subsidiary, in each case granted in the ordinary course of business in favor of the bank or banks with which such accounts are maintained; 

  
 17 

 (j) any Lien on any property or asset of the Borrowers or any Subsidiary existing on the date
hereof and set forth in Schedule 6.02; provided that (i) such Lien shall not apply to any other property or asset of the Borrowers or any Subsidiary and (ii) such Lien shall secure only those obligations which it secures on the date
hereof and extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof; 
 (k) any Lien
existing on any property or asset prior to the acquisition thereof by a Borrower or any Subsidiary or existing on any property or asset of any Person that becomes a Subsidiary after the date hereof prior to the time such Person becomes a Subsidiary;
provided that (i) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be, (ii) such Lien shall not apply to any other property or assets of the
Borrowers or any Subsidiary and (iii) such Lien shall secure only those obligations which it secures on the date of such acquisition or the date such Person becomes a Subsidiary, as the case may be; 

(l) Liens securing Indebtedness at no time exceeding $25,000,000 in outstanding aggregate principal amount; 

(m) [Reserved]; and 
 (n) Liens
upon assets subject to, and arising out of, Sale and Leaseback Transactions permitted by Section 6.11 and Permitted Purchase Money Indebtedness at no time exceeding $100,000,000 in outstanding aggregate principal amount; 

provided that the term “Permitted Encumbrances” shall not, with respect to clauses (a)-(i) above, include any Lien securing
Indebtedness. 
 “Permitted Purchase Money Indebtedness” means, with respect to any Person, any Indebtedness, whether
secured or unsecured, including Capital Lease Obligations, incurred by such Person to finance the acquisition of fixed assets, so long as (a) at the time of such incurrence, no Default has occurred and is continuing or would result from such
incurrence, (b) such Indebtedness has a scheduled maturity and is not due on demand and (c) such Indebtedness does not exceed the lower of the fair market value or the cost of the applicable fixed assets on the date acquired. 

“Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company,
partnership, Governmental Authority or other entity. 
 “Plan” means any employee pension benefit plan (other than a
Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which a Borrower or any ERISA Affiliate is (or, if such plan were terminated, would under
Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA. 
 “Primary
Policies” means any insurance policies issued by any Insurance Subsidiary. 

  
 18 

 “Prime Rate” means the rate of interest per annum publicly announced from time
to time by JPMCB as its prime rate in effect at its office located at 270 Park Avenue, New York, New York; each change in the Prime Rate shall be effective from and including the date such change is publicly announced as being effective. 

“Qualifying Treaty Lender” means a Lender which (a) is beneficially entitled to the interest payable under any Credit
Document and (b) is treated as a resident of a Treaty State for the purposes of the relevant Treaty and (c) does not carry on a business in the United Kingdom through a permanent establishment with which the Lender’s participation in
the Loans or Commitment is effectively connected and (d) is entitled to claim the benefits of such Treaty with respect to payments made by any U.K. Borrower hereunder. 

“Quotation Date” means, with respect to any Eurocurrency Borrowing and any Interest Period, (i) if the currency is Euro,
the day two TARGET Days before the first day of such Interest Period and (iii) if the currency is Dollars or Sterling, the day two Business Days prior to the commencement of such Interest period (or such day as the Administrative Agent shall
determine is the day on which it is market practice in the relevant interbank market for prime banks to give quotations for deposits in the currency of such Borrowing for delivery on the first day of such Interest Period). 

“Rating” has the meaning set forth in Schedule 1.01. 

“Recipient” means, as applicable, (a) the Administrative Agent, (b) any Lender and (c) any Issuing Bank. 

“Register” has the meaning set forth in Section 9.04(b). 

“Reinsurance Agreements” means any agreement, contract, treaty, certificate or other arrangement whereby a Borrower or any
Subsidiary agrees to assume from or reinsure an insurer or reinsurer all or part of the liability of such insurer or reinsurer under a policy or policies of insurance issued by such insurer or reinsurer. 

“Related Parties” means, with respect to any specified Person, such Person’s Affiliates and the respective directors,
officers, employees, agents, advisors and representatives of such Person and such Person’s Affiliates. 
 “Removal Effective
Date” has the meaning assigned to it in Article VIII. 
 “Required Lenders” means, at any time, subject to
Section 2.21, Lenders having Revolving Credit Exposures and unused Commitments representing at least a majority of the sum of the total Revolving Credit Exposures and unused Commitments at such time. 

“Restricted Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to
any Equity Interests in the Parent or any Subsidiary, or any payment (whether in cash, securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or
termination of any such Equity Interests in the Parent or any Subsidiary or any option, warrant or other right to acquire any such Equity Interests in the Parent or any Subsidiary. 

  
 19 

 “Revolving Credit Exposure” means, with respect to any Lender at any time, the
sum of the outstanding principal amount of such Lender’s Revolving Loans and its LC Exposure at such time. 
 “Revolving
Loan” means a Loan made pursuant to Section 2.01. 
 “S&P” means Standard & Poor’s Ratings
Services, a Standard & Poor’s Financial Services LLC business. 
 “Sale and Leaseback Transaction” means any
sale or other transfer of property by any Person with the intent to lease such property as lessee. 
 “Sanctions” means
economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or
the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom. 

“Sanctioned Country” means, at any time, a country or territory which is the subject or target of any Sanctions. 

“Sanctioned Person” means, at any time, (a) any Person listed in any Sanctions-related list of Designated Persons
maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating,
organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person. 
 “SAP” means, with
respect to any Insurance Subsidiary, the statutory accounting practices prescribed or permitted by the insurance commissioner (or other similar authority) as of the date hereof in the jurisdiction of incorporation of such Insurance Subsidiary for
the preparation of annual statements and other financial reports by insurance companies of the same type as such Insurance Subsidiary. 

“SEC” means the Securities and Exchange Commission of the United States of America or any succeeding Governmental Authority
thereto. 
 “Secured Letter of Credit” means a Letter of Credit issued at the request of a Borrower which has been
designated as a “Secured Letter of Credit” in the applicable Letter of Credit Application. 
 “Security
Agreement” means, individually and collectively, each security agreement or other collateral document, each in form and substance satisfactory to the Administrative Agent, entered into between the Administrative Agent and a Borrower
pursuant hereto. 
 “Security Documents” means the Security Agreement, each Control Agreement and each other document or
instrument pursuant to which security or collateral is from time to time provided for the obligations of the Borrowers hereunder. 

  
 20 

 “Significant Insurance Subsidiary” means any Significant Subsidiary which is an
Insurance Subsidiary. 
 “Significant Subsidiary” of a Person means a “significant subsidiary” as defined in Rule
1 02(w) of Regulation S-X of the SEC (17 CFR Part 210). Unless otherwise expressly provided, all references herein to a “Significant Subsidiary” shall mean a Significant Subsidiary of any of the Borrowers; provided that any entity that is
a Significant Subsidiary on the Effective Date or becomes a Significant Subsidiary thereafter shall remain a Significant Subsidiary for all purposes of this Agreement. 

“Solvent” means, when used with respect to a Person, that (a) the fair saleable value of the assets of such Person is in
excess of the total amount of the present value of its liabilities (including for purposes of this definition all liabilities (including loss reserves as determined by such Person), whether or not reflected on a balance sheet prepared in accordance
with GAAP and whether direct or indirect, fixed or contingent, secured or unsecured, disputed or undisputed), (b) such Person is able to pay its debts or obligations in the ordinary course as they mature and (c) such Person does not have
unreasonably small capital to carry out its business as conducted and as proposed to be conducted. “Solvency” shall have a correlative meaning. 

“Special Purpose Entity” means any Subsidiary formed after the date hereof for the sole purpose of incurring Indebtedness,
which Subsidiary (a) promptly remits to a Borrower the net proceeds of any such Indebtedness by way of loan or otherwise and (b) has received from the Parent and its Subsidiaries aggregate capital contributions or other payments
in respect of the Equity Interests thereof not exceeding five percent of the total assets of such Subsidiary. 
 “Specified
Amount” has the meaning set forth in the definition of Total Debt. 
 “Statutory Reserve Rate” means a fraction
(expressed as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the aggregate of the maximum reserve percentages (including any marginal, special, emergency or supplemental reserves) expressed
as a decimal established by the Board to which the Administrative Agent is subject with respect to the Adjusted Eurocurrency Rate, for eurocurrency funding (currently referred to as “Eurocurrency Liabilities” in Regulation D of the
Board). Such reserve percentages shall include those imposed pursuant to such Regulation D. Eurocurrency Loans shall be deemed to constitute eurocurrency funding and to be subject to such reserve requirements without benefit of or credit for
proration, exemptions or offsets that may be available from time to time to any Lender under such Regulation D or any comparable regulation. The Statutory Reserve Rate shall be adjusted automatically on and as of the effective date of any change in
any reserve percentage. 
 “Sterling” or “£” means the lawful currency of the United Kingdom of
Great Britain and Northern Ireland. 
 “Subordinated Indebtedness” means Indebtedness the payment of which is subordinated
to any of the obligations of the applicable Borrower or Borrowers hereunder or in connection herewith, including without limitation the obligations of the Borrowers in respect of the Trust Preferred Securities. 

  
 21 

 “subsidiary” means, with respect to any Person (the “parent”)
at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial
statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing more than
50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held, or (b) that is, as of such date, otherwise
Controlled, by the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent. 

“Subsidiary” means any subsidiary of the Parent. 

“Subsidiary Rating” has the meaning set forth in Schedule 1.01 

“Substantial Portion” means, with respect to the property of the Parent and its Subsidiaries, property which represents more
than 10% of the consolidated assets of the Parent and its Subsidiaries as would be shown in the consolidated financial statements of the Parent and its Subsidiaries as at the beginning of the twelve-month period ending with the last day of the
fiscal quarter or year end for which financial statements have most recently been delivered pursuant to Section 5.01(a) or (b), as applicable, preceding the date upon which such determination is made. 

“Swap Agreement” means any agreement with respect to any swap, forward, future or derivative transaction or option or similar
agreement involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments or securities, or economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any
similar transaction or any combination of these transactions; provided that no phantom stock or similar plan providing for payments only on account of services provided by current or former directors, officers, employees or consultants of a
Borrower or the Subsidiaries shall be a Swap Agreement. 
 “Tangible Net Worth” means, with respect to the Parent, an
amount equal to (a) the Parent’s total shareholder’s equity determined in accordance with GAAP, minus (b) the aggregate book value of the intangible assets, including goodwill, all determined on a consolidated basis in accordance
with GAAP; provided, however, that the effect of the application of FASB ASC 320 (formerly known as FAS 115) shall be excluded in the computation of Tangible Net Worth. 

“TARGET2” means the Trans-European Automated Real-time Gross Settlement Express Transfer (TARGET2) payment system (or, if
such payment system ceases to be operative, such other payment system (if any) reasonably determined by the Administrative Agent to be a suitable replacement) for the settlement of payments in Euro. 

“TARGET Day” means any day on which TARGET2 (or, if such payment system ceases to be operative, such other payment system, if
any, determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro. 

  
 22 

 “Taxes” means all present or future taxes, levies, imposts, duties, deductions,
withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 

“Total Capitalization” means an amount equal to the sum of Tangible Net Worth of the Parent plus Total Debt plus (without
duplication) the Specified Amount. 
 “Total Debt” means all Indebtedness of the Parent and its Subsidiaries, on a
consolidated basis, which appears on a balance sheet calculated in accordance with GAAP plus, (a) without duplication (i) the face amount of all outstanding letters of credit in respect of which the Parent or any Subsidiary has any actual
or contingent reimbursement obligation (excluding letters of credit which are issued to support the reinsurance obligations of Subsidiaries of the Parent which have been fully collateralized and fully collateralized letters of credit which are
issued to support the capital requirements at Lloyd’s of London, otherwise known as “Funds at Lloyd’s”), (ii) the maximum aggregate amount (giving effect to any legally enforceable netting agreements) that the Parent and its
Subsidiaries would be required to pay if all Swap Agreements of the Parent and its Subsidiaries with respect to interest on indebtedness for money borrowed were terminated at any date of determination and (iii) the principal amount of all
Guarantees of Indebtedness by the Parent and its Subsidiaries; provided that this clause (iii) shall not include Guarantees between or among the Parent and/or its consolidated Subsidiaries, minus (b) that portion of the outstanding
principal amount of all Trust Preferred Securities and similar long-term hybrid capital that is deemed to constitute equity, as determined in accordance with S&P’s methodology at such time (but only to the extent that such amount does not
exceed 15% of Total Capitalization) the amount described in this clause (b) being the “Specified Amount”. 

“Transactions” means the execution, delivery and performance by the Borrowers of this Agreement and the other Credit
Documents, the borrowing of Loans and other credit extensions hereunder, the use of the proceeds thereof and the issuance of Letters of Credit hereunder. 

“Treaty State” means a jurisdiction which has entered into a double taxation agreement (a “Treaty”) with the United
Kingdom which makes provision for full exemption from Tax imposed by the United Kingdom on interest. 
 “Trust Preferred
Securities” means those securities listed on Schedule 1.03 hereto. 
 “Trust Preferred Security
Indebtedness” means any Indebtedness of a Borrower or a Subsidiary arising under Trust Preferred Securities. 

“Type”, when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans
comprising such Borrowing, is determined by reference to the Adjusted Eurocurrency Rate or the Alternate Base Rate. 
 “UK
Borrower” means any Borrower (i) that is organized or formed under the laws of the United Kingdom or (ii) payments from which under this Agreement or any Loan Document are subject to withholding Taxes imposed by the laws of the
United Kingdom. 

  
 23 

 “Unsecured Letter of Credit” means a Letter of Credit which is not a Secured
Letter of Credit. 
 “U.S. Person” means a “United States person” within the meaning of Section 7701(a)(30)
of the Code. 
 “U.S. Tax Compliance Certificate” has the meaning assigned to such term in Section 2.17(f)(ii)(B)(3).

 “Wholly-Owned Subsidiary” of a Person means (a) any subsidiary all of the outstanding voting securities of which
shall at the time be owned or controlled, directly or indirectly, by such Person or one or more Wholly-Owned Subsidiaries of such Person, or by such Person and one or more Wholly-Owned Subsidiaries of such Person, or (b) any partnership,
limited liability company, association, joint venture or similar business organization 100% of the ownership interests having ordinary voting power of which shall at the time be so owned or controlled (other than in the case of Foreign Subsidiaries,
director’s qualifying shares and/or other nominal amounts of shares required to be held by Persons other than the Parent and its Subsidiaries under applicable law). 

“Withdrawal Liability” means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such
Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. 
 SECTION 1.02. Classification of Loans and
Borrowings. For purposes of this Agreement, Loans may be classified and referred to by class (e.g., a “Revolving Loan”) or by Type (e.g., a “Eurocurrency Loan”) or by class and Type (e.g., a
“Eurocurrency Revolving Loan”). Borrowings also may be classified and referred to by class (e.g., a “Revolving Borrowing”) or by Type (e.g., a “Eurocurrency Borrowing”) or by class and Type (e.g., a
“Eurocurrency Revolving Borrowing”). 
 SECTION 1.03. Terms Generally. The definitions of terms herein shall apply equally
to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “without limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall”. The word “law” shall be construed as referring to
all statutes, rules, regulations, codes and other laws (including official rulings and interpretations thereunder having the force of law or with which affected Persons customarily comply), and all judgments, orders and decrees, of all Governmental
Authorities. Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time
amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, restatements, supplements or modifications set forth herein), (b) any definition of or reference to any statute, rule or regulation shall be
construed as referring thereto as from time to time amended, supplemented or otherwise modified (including by succession of comparable successor laws), (c) any reference herein to any Person shall be construed to include such Person’s
successors and assigns (subject to any restrictions on assignment set forth herein) and, in the case 

  
 24 

 
of any Governmental Authority, any other Governmental Authority that shall have succeeded to any or all functions thereof, (d) the words “herein”, “hereof” and
“hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (e) all references herein to Articles, Sections, Exhibits and Schedules shall be
construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement and (f) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all
tangible and intangible assets and properties, including cash, securities, accounts and contract rights. 
 SECTION 1.04. Accounting
Terms; GAAP. Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time; provided that, if the Borrower Representative notifies
the Administrative Agent that the Borrowers request an amendment to any provision hereof to eliminate the effect of any change occurring after the date hereof in GAAP or in the application thereof on the operation of such provision (or if the
Administrative Agent notifies the Borrower Representative that the Required Lenders request an amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such change in GAAP or in the
application thereof, then such provision shall be interpreted on the basis of GAAP as in effect and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in
accordance herewith. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made, (i) without
giving effect to any election under Financial Accounting Standards Board Accounting Standards Codification 825 (or any other Financial Accounting Standard having a similar result or effect) to value any Indebtedness or other liabilities of any
Borrower or any Subsidiary at “fair value”, as defined therein, and (ii) in a manner such that any obligations relating to a lease that, in accordance with GAAP as in effect on the Effective Date, would be accounted for by the Parent
as an operating lease shall be accounted for as obligations relating to an operating lease and not as obligations relating to a Capitalized Lease (and shall not constitute Indebtedness hereunder). 

SECTION 1.05. Foreign Currency Calculations. (a) For purposes of determining the Dollar Equivalent of any Advance denominated in a
Foreign Currency or any related amount, the Administrative Agent shall determine the Exchange Rate as of the applicable Exchange Rate Date with respect to each Foreign Currency in which any requested or outstanding Advance or Letter of Credit is
denominated and shall apply such Exchange Rates to determine such amount (in each case after giving effect to any Advance to be made or repaid on or prior to the applicable date for such calculation). 

(b) For purposes of any determination hereunder (including determinations under Section 6.01, 6.02, 6.04, 6.09 or 6.10 or under Article
VII), all amounts incurred, outstanding or proposed to be incurred or outstanding in currencies other than Dollars shall be translated into Dollars at the appropriate currency Exchange Rate; provided that no Default shall arise as a result of
any limitation set forth in Dollars in Section 6.01 or 6.02 being exceeded solely as a result of changes in Exchange Rates from those rates applicable at the time or times Indebtedness or Liens were initially consummated in reliance on the
exceptions under such Sections. For purposes of any determination under Section 6.04, 6.09 or 6.10, the amount of each investment, asset disposition or other applicable transaction denominated in a currency other than Dollars shall be
translated into Dollars at the applicable Exchange Rate. Such Exchange Rates shall be determined in good faith by the Borrowers. 

  
 25 

 ARTICLE II 

The Credits 
 SECTION
2.01. Commitments. Subject to the terms and conditions set forth herein, each Lender agrees to make Revolving Loans denominated in Dollars and Foreign Currencies to the Borrowers from time to time during the Availability Period in an
aggregate principal amount that will not result in (a) such Lender’s Revolving Credit Exposure exceeding such Lender’s Commitment, (b) the sum of the total Revolving Credit Exposures exceeding the total Commitments, or
(c) the sum of the total Revolving Credit Exposures exceeding the total Commitments. Within the foregoing limits and subject to the terms and conditions set forth herein, the Borrowers may borrow, prepay and reborrow Revolving Loans. 

SECTION 2.02. Loans and Borrowings. (a) Each Revolving Loan shall be made as part of a Borrowing consisting of Revolving Loans
made by the Lenders ratably in accordance with their respective Commitments. The failure of any Lender to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that the Commitments
of the Lenders are several and no Lender shall be responsible for any other Lender’s failure to make Loans as required hereby. 
 (b)
Subject to Section 2.14, (i) each Revolving Borrowing denominated in Dollars shall be comprised entirely of ABR Loans or Eurocurrency Loans as the Borrower Representative may request in accordance herewith and (ii) each Revolving
Borrowing denominated in a Foreign Currency shall be comprised entirely of Eurocurrency Loans. Each Lender at its option may make any Eurocurrency Loan by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan;
provided that any exercise of such option shall not affect the obligation of the Borrowers to repay such Loan in accordance with the terms of this Agreement. 

(c) At the commencement of each Interest Period for any Eurocurrency Revolving Borrowing, such Borrowing shall be in an aggregate amount that
is an integral multiple of $1,000,000 (or, for any Foreign Currency Borrowing, an approximate equivalent thereof as determined by the Administrative Agent) and not less than $1,000,000 (or, for any Foreign Currency Borrowing, an approximate
equivalent thereof as determined by the Administrative Agent). At the time that each ABR Revolving Borrowing is made, such Borrowing shall be in an aggregate amount that is an integral multiple of $1,000,000 and not less than $1,000,000;
provided that an ABR Revolving Borrowing may be in an aggregate amount (i) that is equal to the entire unused balance of the total Commitments or (ii) that is required to finance the reimbursement of an LC Disbursement as
contemplated by Section 2.06(e). Borrowings of more than one Type may be outstanding at the same time; provided that there shall not at any time be more than a total of twelve Eurocurrency Revolving Borrowings outstanding.
Notwithstanding the foregoing, Loans which are not denominated in Dollars may be made in amounts and increments in the applicable Foreign Currency satisfactory to the Administrative Agent. 

  
 26 

 (d) Notwithstanding any other provision of this Agreement, the Borrowers shall not be entitled to
request, or to elect to convert or continue, any Borrowing if the Interest Period requested with respect thereto would end after the Maturity Date. 

(e) Notwithstanding any other provision of this Agreement, each Lender at its option may make any ABR Loan or Eurocurrency Loan by causing any
domestic or foreign office, branch or Affiliate of such Lender (an “Applicable Lending Installation”) to make such Loan that has been designated by such Lender to the Administrative Agent. All terms of this Agreement shall apply to
any such Applicable Lending Installation of such Lender and the Loans and any Notes issued hereunder shall be deemed held by each Lender for the benefit of any such Applicable Lending Installation. Each Lender may, by written notice to the
Administrative Agent and the Borrower Representative, designate replacement or additional Applicable Lending Installations through which Loans will be made by it and for whose account Loan payments are to be made. Any exercise of such option shall
not affect the obligation of the Borrowers to repay such Loan in accordance with the terms of this Agreement. 
 SECTION 2.03. Requests
for Revolving Borrowings. To request a Revolving Borrowing, the Borrower Representative shall notify the Administrative Agent of such request by telephone (a) in the case of a Eurocurrency Borrowing, not later than 10:00 a.m., Local Time,
three Business Days before the date of the proposed Borrowing or (b) in the case of an ABR Borrowing, not later than 10:00 a.m., Local Time, one Business Day before the date of the proposed Borrowing. Each such telephonic Borrowing Request
shall be irrevocable and shall be confirmed promptly by hand delivery or telecopy (or by electronic communication if, after the date hereof, arrangements for doing so shall be approved by the Administrative Agent) to the Administrative Agent of a
written Borrowing Request in a form approved by the Administrative Agent and signed by the Borrower Representative. Each such telephonic and written Borrowing Request shall specify the following information in compliance with Section 2.02: 

(i) the Borrower to which the proceeds of the requested Borrowing shall be disbursed; 

(ii) the aggregate amount of the requested Borrowing; 

(iii) the currency (which may be Dollars or a Foreign Currency) in which such Borrowing is to be denominated; 

(iv) the date of such Borrowing, which shall be a Business Day; 

(v) in the case of a Borrowing denominated in Dollars, whether such Borrowing is to be an ABR Borrowing or a Eurocurrency
Borrowing; 
 (vi) in the case of a Eurocurrency Borrowing, the initial Interest Period to be applicable thereto, which shall
be a period contemplated by the definition of the term “Interest Period”; and 

  
 27 

 (vii) the location and number of the account of a Borrower to which funds are to
be disbursed, which shall comply with the requirements of Section 2.07. 
 If no election as to the Type of Revolving Borrowing is specified, then the
requested Revolving Borrowing shall be an ABR Borrowing, unless such Revolving Borrowing is denominated in a Foreign Currency, in which case such Revolving Borrowing shall be a Eurocurrency Borrowing. If no Interest Period is specified with respect
to any requested Eurocurrency Revolving Borrowing, then the Borrower Representative shall be deemed to have selected an Interest Period of one month’s duration. Promptly following receipt of a Borrowing Request in accordance with this Section,
but in any event prior to 11:00 a.m., Local Time on the date received if received before 10:00 a.m. Local Time, the Administrative Agent shall advise each applicable Lender of the details thereof and of the amount of such Lender’s Loan to be
made as part of the requested Borrowing. 
 SECTION 2.04. [Intentionally Omitted]. 

SECTION 2.05. [Intentionally Omitted]. 

SECTION 2.06. Letters of Credit. (a) General. Subject to the terms and conditions set forth herein, the Borrower
Representative may request the issuance of Letters of Credit denominated in Dollars or Foreign Currencies for the joint and several account of the Borrowers, in a form reasonably acceptable to the Administrative Agent and the Issuing Bank (which
form may include having such Letters of Credit, though issued for the joint and several account of the Borrowers, reflect on their face Subsidiaries of the Parent as the account party and name as the beneficiaries thereof commercial counterparties
or creditors of such Subsidiaries), at any time and from time to time during the Availability Period. In the event of any inconsistency between the terms and conditions of this Agreement and the terms and conditions of any form of letter of credit
application or other agreement submitted by any Borrower to, or entered into by any Borrower with, the Issuing Bank relating to any Letter of Credit, the terms and conditions of this Agreement shall control. Upon the effectiveness of this Agreement,
the Existing Letter of Credit shall, without any further action by any party, be deemed to have been issued as a Letter of Credit hereunder on the date of such effectiveness and shall for all purposes hereof be treated as a Letter of Credit under
this Agreement. 
 (b) Notice of Issuance, Amendment, Renewal, Extension; Certain Conditions. To request the issuance of a Letter of
Credit (or the amendment, renewal or extension of an outstanding Letter of Credit), the Borrower Representative shall hand deliver or telecopy (or transmit by electronic communication, if arrangements for doing so have been approved by the Issuing
Bank) to the Issuing Bank and the Administrative Agent (reasonably in advance of the requested date of issuance, amendment, renewal or extension) a notice requesting the issuance of a Letter of Credit, or identifying the Letter of Credit to be
amended, renewed or extended, and specifying the date of issuance, amendment, renewal or extension (which shall be a Business Day), the date on which such Letter of Credit is to expire (which shall comply with paragraph (c) of this Section),
the amount of such Letter of Credit, the name and address of the beneficiary thereof, whether such Letter of Credit will be a Secured Letter of Credit or an Unsecured Letter of Credit and such other information as shall be necessary to prepare,
amend, renew or extend such Letter of Credit. If requested by the Issuing Bank, the Borrower Representative also shall 

  
 28 

 
submit a letter of credit application on the Issuing Bank’s standard form in connection with any request for a Letter of Credit. A Letter of Credit shall be issued, amended, renewed or
extended by the Issuing Bank only if (and upon issuance, amendment, renewal or extension of each Letter of Credit each Borrower shall be deemed to represent and warrant that), after giving effect to such issuance, amendment, renewal or extension
(i) the LC Exposure shall not exceed the Dollar Equivalent of an amount equal to 10% of the aggregate amount of the Commitments and (ii) the sum of the total Revolving Credit Exposures shall not exceed the total Commitments. 

(c) Expiration Date. Unless approved by the Issuing Bank and each Lender, each Letter of Credit shall expire at or prior to the close of
business on the date one year or less after the date of the issuance of such Letter of Credit (or, in the case of any renewal or extension thereof, one year or less after such renewal or extension); provided that any Letter of Credit will
include, if requested, customary “evergreen” provisions; provided further that (i) no Letter of Credit shall have a expiry date more than one year after the Maturity Date, (ii) the Issuing Bank shall be under no obligation
to renew or extend any Letter of Credit after the Maturity Date and (iii) with respect to of any Letter of Credit expiring after the Maturity Date, the Borrowers shall cash collateralize such Letter of Credit on or before the date five
(5) Business Days prior to the Maturity Date in the manner and to the extent described in Section 2.06(j). 
 (d)
Participations. By the issuance of a Letter of Credit (or an amendment to a Letter of Credit increasing the amount thereof) and without any further action on the part of the Issuing Bank or the Lenders, the Issuing Bank hereby grants to each
Lender, and each Lender hereby acquires from the Issuing Bank, a participation in such Letter of Credit equal to such Lender’s Applicable Percentage of the aggregate amount available to be drawn under such Letter of Credit. In consideration and
in furtherance of the foregoing, each Lender hereby absolutely and unconditionally agrees to pay to the Administrative Agent, for the account of the Issuing Bank, such Lender’s Applicable Percentage of each LC Disbursement made by the Issuing
Bank and not reimbursed by the Borrowers on the date due as provided in paragraph (e) of this Section, or of any reimbursement payment required to be refunded to the Borrowers for any reason. Each Lender acknowledges and agrees that its
obligation to acquire participations pursuant to this paragraph in respect of Letters of Credit is absolute and unconditional and shall not be affected by any circumstance whatsoever, including any amendment, renewal or extension of any Letter of
Credit or the occurrence and continuance of a Default or reduction or termination of the Commitments, and that each such payment shall be made without any offset, abatement, withholding or reduction whatsoever. 

(e) Reimbursement. If the Issuing Bank shall make any LC Disbursement in respect of a Letter of Credit, the Borrowers shall reimburse
such LC Disbursement by paying to the Administrative Agent an amount equal to such LC Disbursement not later than 3:00 p.m., Local Time, on the second Business Day following the date that such LC Disbursement is made, if the Borrower Representative
shall have received notice of such LC Disbursement prior to 10:00 a.m., Local Time, on such date, or, if such notice has not been received by the Borrower Representative prior to such time on such date, then not later than 3:00 p.m., Local Time, on
(i) the second Business Day following the date that the Borrower Representative receives such notice, if such notice is received prior to 10:00 a.m., Local Time, on the day of receipt, or (ii) the Business Day immediately following the
second Business Day after the day that the Borrower Representative receives such notice, if such notice is not received prior to such time on the day 

  
 29 

 
of receipt; provided that the Borrowers may, subject to the conditions to borrowing set forth herein, request in accordance with Section 2.03 that such payment be financed with an ABR
Revolving Borrowing in an equivalent amount and, to the extent so financed, the Borrowers’ obligation to make such payment shall be discharged and replaced by the resulting ABR Revolving Borrowing. If the Borrowers fail to make such payment
when due, such amount shall bear interest at the Alternate Base Rate and the Administrative Agent shall notify each Lender of the applicable LC Disbursement, the payment then due from the Borrowers in respect thereof and such Lender’s
Applicable Percentage thereof. Promptly following receipt of such notice, each Lender shall pay to the Administrative Agent its Applicable Percentage of the payment then due from the Borrowers, in the same manner as provided in Section 2.07
with respect to Loans made by such Lender (and Section 2.07 shall apply, mutatis mutandis, to the payment obligations of the Lenders), and the Administrative Agent shall promptly pay to the Issuing Bank the amounts so received by
it from the Lenders. Promptly following receipt by the Administrative Agent of any payment from the Borrowers pursuant to this paragraph, the Administrative Agent shall distribute such payment to the Issuing Bank or, to the extent that Lenders have
made payments pursuant to this paragraph to reimburse the Issuing Bank, then to such Lenders and the Issuing Bank as their interests may appear. Any payment made by a Lender pursuant to this paragraph to reimburse the Issuing Bank for any LC
Disbursement (other than the funding of ABR Revolving Loans as contemplated above) shall not constitute a Loan and shall not relieve the Borrowers of their obligation to reimburse such LC Disbursement. 

(f) Obligations Absolute. The Borrowers’ obligation to reimburse LC Disbursements as provided in paragraph (e) of this
Section shall be absolute, unconditional and irrevocable, and shall be performed strictly in accordance with the terms of this Agreement under any and all circumstances whatsoever and irrespective of (i) any lack of validity or
enforceability of any Letter of Credit or this Agreement, or any term or provision therein, (ii) any draft or other document presented under a Letter of Credit proving to be forged, fraudulent or invalid in any respect or any statement therein
being untrue or inaccurate in any respect, (iii) payment by the Issuing Bank under a Letter of Credit against presentation of a draft or other document that does not comply with the terms of such Letter of Credit, or (iv) any other event
or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this Section, constitute a legal or equitable discharge of, or provide a right of setoff against, the Borrowers’ obligations
hereunder. Neither the Administrative Agent, the Lenders nor the Issuing Bank, nor any of their Related Parties, shall have any liability or responsibility by reason of or in connection with the issuance or transfer of any Letter of Credit or any
payment or failure to make any payment thereunder (irrespective of any of the circumstances referred to in the preceding sentence), or any error, omission, interruption, loss or delay in transmission or delivery of any draft, notice or other
communication under or relating to any Letter of Credit (including any document required to make a drawing thereunder), any error in interpretation of technical terms or any consequence arising from causes beyond the control of the Issuing Bank;
provided that the foregoing shall not be construed to excuse the Issuing Bank from liability to the Borrowers to the extent of any direct damages (as opposed to consequential damages, claims in respect of which are hereby waived by the
Borrowers to the extent permitted by applicable law) suffered by the Borrowers that are caused by the Issuing Bank’s failure to exercise care when determining whether drafts and other documents presented under a Letter of Credit comply with the
terms thereof. The parties hereto expressly agree that, in the absence of gross negligence or willful misconduct on the part of the Issuing Bank (as finally determined by a court of competent 

  
 30 

 
jurisdiction), the Issuing Bank shall be deemed to have exercised care in each such determination. In furtherance of the foregoing and without limiting the generality thereof, the parties agree
that, with respect to documents presented which appear on their face to be in substantial compliance with the terms of a Letter of Credit, the Issuing Bank may, in its sole discretion, either accept and make payment upon such documents without
responsibility for further investigation, regardless of any notice or information to the contrary, or refuse to accept and make payment upon such documents if such documents are not in strict compliance with the terms of such Letter of Credit. 

(g) Disbursement Procedures. The Issuing Bank shall, promptly following its receipt thereof, examine all documents purporting to
represent a demand for payment under a Letter of Credit. The Issuing Bank shall promptly notify the Administrative Agent and the Borrower Representative by telephone (confirmed by telecopy) of such demand for payment and whether the Issuing Bank has
made or will make an LC Disbursement thereunder; provided that any failure to give or delay in giving such notice shall not relieve the Borrowers of their obligation to reimburse the Issuing Bank and the Lenders with respect to any such LC
Disbursement. 
 (h) Interim Interest. If the Issuing Bank shall make any LC Disbursement, then, unless the Borrowers shall reimburse
such LC Disbursement in full on the date such LC Disbursement is made, the unpaid amount thereof shall bear interest, for each day from and including the date such LC Disbursement is made to but excluding the date that the Borrowers reimburse such
LC Disbursement, at the rate per annum then applicable to ABR Revolving Loans; provided that, if the Borrowers fail to reimburse such LC Disbursement when due pursuant to paragraph (e) of this Section, then Section 2.13(c) shall
apply. Interest accrued pursuant to this paragraph shall be for the account of the Issuing Bank, except that interest accrued on and after the date of payment by any Lender pursuant to paragraph (e) of this Section to reimburse the Issuing
Bank shall be for the account of such Lender to the extent of such payment. 
 (i) Replacement of the Issuing Bank. The Issuing Bank
may be replaced at any time by written agreement among the Borrowers, the Administrative Agent, the replaced Issuing Bank and the successor Issuing Bank. The Administrative Agent shall notify the Lenders of any such replacement of the Issuing Bank.
At the time any such replacement shall become effective, the Borrowers shall pay all unpaid fees accrued for the account of the replaced Issuing Bank pursuant to Section 2.12(b). From and after the effective date of any such replacement,
(i) the successor Issuing Bank shall have all the rights and obligations of the Issuing Bank under this Agreement with respect to Letters of Credit to be issued thereafter and (ii) references herein to the term “Issuing Bank”
shall be deemed to refer to such successor or to any previous Issuing Bank, or to such successor and all previous Issuing Banks, as the context shall require. After the replacement of an Issuing Bank hereunder, the replaced Issuing Bank shall remain
a party hereto and shall continue to have all the rights and obligations of an Issuing Bank under this Agreement with respect to Letters of Credit issued by it prior to such replacement, but shall not be required to issue additional Letters of
Credit. 

  
 31 

 (j) Cash Collateralization. If (i) any Event of Default shall occur and be continuing
and if all outstanding Loans have been declared to be due and payable pursuant to Article VII, then, on the Business Day that the Borrowers receive notice from the Administrative Agent or the Required Lenders demanding the deposit of cash collateral
pursuant to this paragraph, the Borrowers shall deposit in an account with the Administrative Agent, in the name of the Administrative Agent and for the benefit of the Lenders, an amount in cash equal to the LC Exposure as of such date plus any
accrued and unpaid interest thereon; provided that the obligation to deposit such cash collateral shall become effective immediately, and such deposit shall become immediately due and payable, without demand or other notice of any kind, upon
the occurrence of any Event of Default with respect to the Borrowers described in clause (h) or (i) of Article VII or (ii) any Letter of Credit shall have an expiration date after the Maturity Date, on the date five Business Days
prior to the Maturity Date the Borrowers shall deposit in an account with the Administrative Agent, in the name of the Administrative Agent and for the benefit of the Lenders, (A) in the case of Letters of Credit denominated in Dollars, an
amount in cash in Dollars equal to 105% of the face amount of such Letters of Credit and (B) in the case of Letters of Credit denominated in a Foreign Currency, in cash in Dollars equal to 120% of the face amount of such Letter of Credit or, at
the request of the Issuing Bank, in cash in the relevant Foreign Currency equal to 105% of the face amount of such Letter of Credit. Any such deposit shall be held by the Administrative Agent as collateral for the payment and performance of the
obligations of the Borrowers under this Agreement. The Administrative Agent shall have exclusive dominion and control, including the exclusive right of withdrawal, over such account. Other than any interest earned on the investment of such deposits,
which investments shall be made at the option and sole discretion of the Administrative Agent and at the Borrowers’ risk and expense, such deposits shall not bear interest. Interest or profits, if any, on such investments shall accumulate in
such account. Moneys in such account shall be applied by the Administrative Agent to reimburse the Issuing Bank for LC Disbursements for which it has not been reimbursed and, to the extent not so applied, shall be held for the satisfaction of the
reimbursement obligations of the Borrowers for the LC Exposure at such time or, if the maturity of the Loans has been accelerated, be applied to satisfy other obligations of the Borrowers under this Agreement. If the Borrowers are required to
provide an amount of cash collateral hereunder (i) as a result of the occurrence of an Event of Default, such amount (to the extent not applied as aforesaid) shall be returned to the Borrowers within three Business Days after all Events of
Default have been cured or waived and (ii) as a result of the expiration of a Letter of Credit extending past the Maturity Date, such amount (to the extent not applied as aforesaid) shall be returned to the Borrowers within three Business Days
after the surrender or expiration of such Letter of Credit. 
 (k) Collateral for Secured Letters of Credit. If a Borrower requests
that any Letter of Credit be issued as a Secured Letter of Credit pursuant to Section 2.06(b), then at or prior to the time of issuance of such Letter of Credit such Borrower shall deposit in a Collateral Account an amount in cash equal to 100%
of the face amount of such Letter of Credit. If at any time the LC Exposure associated with such Letter of Credit shall exceed the amount in such Collateral Account, such Borrower shall, within three Business Days of receipt of written request
therefor from the Administrative Agent, deposit into such Collateral Account such additional cash as may be required to eliminate such excess. The Administrative Agent shall determine the Dollar Equivalent of the LC Exposure in respect of Secured
Letters of Credit from time to time in its discretion. If at any time the aggregate amount of LC Exposure in respect of Secured Letters of Credit exceeds 105% of the amount of cash collateral on deposit in such Collateral Account, the Borrowers
shall, upon the request of the Administrative Agent, promptly deposit additional cash to such Collateral Account in an amount sufficient to eliminate such excess. 

  
 32 

 SECTION 2.07. Funding of Borrowings. (a) Each Lender shall make each Loan to be made
by it hereunder on the proposed date thereof by wire transfer of immediately available funds by 12:00 noon, Local Time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders. The
Administrative Agent will make such Loans available to the Borrowers by promptly crediting the amounts so received, in like funds, to the account specified pursuant to Section 2.03, which shall be an account of a Borrower maintained with the
Administrative Agent in New York City (or, in the case of Loans denominated in a Foreign Currency, in such other location as may be designated by the Administrative Agent) and designated by the Borrowers in the applicable Borrowing Request;
provided that ABR Revolving Loans made to finance the reimbursement of an LC Disbursement as provided in Section 2.06(e) shall be remitted by the Administrative Agent to the Issuing Bank. 

(b) Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Borrowing that such Lender will
not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with this Section 2.07 and may, in
reliance upon such assumption, make available to the Borrowers a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the
Borrowers severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from and including the date such amount is made available to the Borrowers to but excluding the date of
payment to the Administrative Agent, at (i) in the case of such Lender, (x) the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank
compensation (in the case of a Borrowing denominated in Dollars) or (y) the rate reasonably determined by the Administrative Agent to be the cost to it of funding such amount (in the case of a Borrowing denominated in a Foreign Currency) or
(ii) in the case of the Borrowers, the interest rate applicable to ABR Loans. If such Lender pays such amount to the Administrative Agent, then such amount shall constitute such Lender’s Loan included in such Borrowing. 

SECTION 2.08. Interest Elections. (a) Each Revolving Borrowing initially shall be of the Type specified in the applicable
Borrowing Request and, in the case of a Eurocurrency Revolving Borrowing, shall have an initial Interest Period as specified in such Borrowing Request. Thereafter, the Borrower Representative may elect to convert such Borrowing to a different Type,
in the case of Borrowings denominated in Dollars, or to continue such Borrowing and, in the case of a Eurocurrency Revolving Borrowing, may elect Interest Periods therefor, all as provided in this Section. The Borrower Representative may elect
different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Loans comprising such Borrowing, and the Loans comprising each such portion
shall be considered a separate Borrowing. 
 (b) To make an election pursuant to this Section, the Borrower Representative shall notify the
Administrative Agent of such election by telephone by the time that a Borrowing Request would be required under Section 2.03 if the Borrower Representative were requesting a 

  
 33 

 
Revolving Borrowing of the Type and denominated in the currency resulting from such election to be made on the effective date of such election. Each such telephonic Interest Election Request
shall be irrevocable and shall be confirmed promptly by hand delivery or telecopy to the Administrative Agent of a written Interest Election Request in a form approved by the Administrative Agent and signed by the Borrower Representative. 

(c) Each telephonic and written Interest Election Request shall specify the following information in compliance with Section 2.02: 

(i) the Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to
different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) below shall be specified for each resulting Borrowing); 

(ii) the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day; 

(iii) whether the resulting Borrowing is to be an ABR Borrowing or a Eurocurrency Borrowing; and 

(iv) if the resulting Borrowing is a Eurocurrency Borrowing, the Interest Period to be applicable thereto after giving effect
to such election, which shall be a period contemplated by the definition of the term “Interest Period”; 
 If any such Interest Election Request
requests a Eurocurrency Borrowing but does not specify an Interest Period, then the Borrower Representative shall be deemed to have selected an Interest Period of one month’s duration. 

(d) Promptly following receipt of an Interest Election Request, the Administrative Agent shall advise each applicable Lender of the details
thereof and of such Lender’s portion of each resulting Borrowing. 
 (e) If the Borrower Representative fails to deliver a timely
Interest Election Request with respect to a Eurocurrency Revolving Borrowing prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as provided herein, at the end of such Interest Period such Borrowing
shall be converted to an ABR Borrowing (unless such Borrowing is denominated in a Foreign Currency, in which case such Borrowing shall be continued as a Eurocurrency Borrowing with an Interest Period of one month’s duration commencing on the
last day of such Interest Period). Notwithstanding any contrary provision hereof, if an Event of Default has occurred and is continuing and the Administrative Agent, at the request of the Required Lenders, so notifies the Borrower Representative
then, so long as an Event of Default is continuing (i) no outstanding Revolving Borrowing may be converted to or continued as a Eurocurrency Borrowing, (ii) unless repaid, each Eurocurrency Revolving Borrowing denominated in Dollars shall
be converted to an ABR Borrowing at the end of the Interest Period applicable thereto, and (iii) unless repaid, each Eurocurrency Revolving Borrowing denominated in a Foreign Currency shall be continued as a Eurocurrency Revolving Borrowing
with an Interest Period of one month’s duration. 

  
 34 

 SECTION 2.09. Termination and Reduction and Increase of Commitments. (a) Unless
previously terminated (or extended pursuant to Section 2.22), the Commitments shall terminate on the Maturity Date. 
 (b) The Borrowers
may at any time terminate, or from time to time reduce, the Commitments; provided that (i) each reduction of the Commitments shall be in an amount that is an integral multiple of $1,000,000 and not less than $5,000,000 and (ii) the
Borrowers shall not terminate or reduce the Commitments if, after giving effect to any concurrent prepayment of the Loans in accordance with Section 2.11, the sum of the Revolving Credit Exposures would exceed the total Commitments. 

(c) The Borrower Representative shall notify the Administrative Agent of any election to terminate or reduce the Commitments under paragraph
(b) or (c) of this Section at least three Business Days prior to the effective date of such termination or reduction, specifying such election and the effective date thereof. Promptly following receipt of any notice, the
Administrative Agent shall advise the applicable Lenders of the contents thereof. Each notice delivered by the Borrower Representative pursuant to this Section shall be irrevocable; provided that a notice of termination of the
Commitments delivered by the Borrower Representative may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower Representative (by notice to the
Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Any termination or reduction of the Commitments shall be permanent. Each reduction of the Commitments shall be made ratably among the Lenders, in
each case accordance with their respective Commitments. 
 (d) The Borrower Representative at its option may, from time to time, after the
Effective Date, seek to increase the total Commitments by up to an aggregate amount of $50,000,000 (resulting in maximum total Commitments of $225,000,000) upon at least three (3) Business Days’ prior written notice to the Administrative
Agent, which notice shall specify the amount of any such increase (which shall not be less than $10,000,000 or such lesser amount to which the Administrative Agent may agree) and shall certify that no Default has occurred and is continuing. After
delivery of such notice, the Parent, in its discretion, may offer the increase (which may be declined by any Lender in its sole discretion) in the total Commitments on either a ratable basis to the Lenders or on a non pro-rata basis to one or more
Lenders and/or to other Lenders or entities reasonably acceptable to the Administrative Agent, the Issuing Bank and the Borrower Representative; provided that no increase may be offered to any entity that is an Ineligible Institution. No increase in
the total Commitments shall become effective until the existing or new Lenders extending such incremental Commitment amount and the Borrowers shall have delivered to the Administrative Agent a document in form and substance reasonably satisfactory
to the Administrative Agent pursuant to which (i) any such existing Lender agrees to the amount of its Commitment increase, (ii) any such new Lender agrees to its Commitment and agrees to assume and accept the obligations and rights of a
Lender hereunder, (iii) the Borrowers accept such incremental Commitments, (iv) the effective date of any increase in the Commitments is specified and (v) the Borrowers certify that on such date the conditions for a new Loan set forth
in Section 4.02 are satisfied. Upon the effectiveness of any increase in the total Commitments pursuant hereto, (i) each Lender (new or existing) shall be deemed to have accepted an assignment from the existing Lenders, and the existing
Lenders shall be deemed to 

  
 35 

 
have made an assignment to each new or existing Lender accepting a new or increased Commitment, of an interest in each then outstanding Revolving Loan (in each case, on the terms and conditions
set forth in the Assignment and Assumption) and (ii) the LC Exposure of the existing and new Lenders shall be automatically adjusted such that, after giving effect to such assignments and adjustments, all Revolving Credit Exposure hereunder is
held ratably by the Lenders in proportion to their respective Commitments. Assignments pursuant to the preceding two sentences shall be made in exchange for, and substantially contemporaneously with the payment to the assigning Lenders of, the
principal amount assigned. Payments received by assigning Lenders pursuant to this Section in respect of the principal amount of any Eurocurrency Loan shall, for purposes of Section 2.16 be deemed prepayments of such Loan. Any increase of
the total Commitments pursuant to this Section 2.09(d) shall be subject to receipt by the Administrative Agent from the Borrowers of such supplemental opinions, resolutions, certificates and other documents as the Administrative Agent may
reasonably request. No consent of any Lender (other than the Lenders agreeing to new or increased Commitments) shall be required for any incremental Commitment provided or Loan made pursuant to this Section 2.09(d). 

SECTION 2.10. Repayment of Loans; Evidence of Debt. (a) The Borrowers hereby jointly and severally unconditionally promise to pay
to the Administrative Agent for the account of each Lender the then unpaid principal amount of each Loan on the Maturity Date. 
 (b) Each
Lender shall maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of the Borrowers to such Lender resulting from each Loan made by such Lender, including the amounts of principal and interest payable and
paid to such Lender from time to time hereunder. 
 (c) The Administrative Agent shall maintain accounts in which it shall record
(i) the amount of each Loan made hereunder, the Type thereof and the Interest Period applicable thereto, (ii) the amount of any principal or interest due and payable or to become due and payable from the Borrowers to each Lender hereunder
and (iii) the amount of any sum received by the Administrative Agent hereunder for the account of the Lenders and each Lender’s share thereof. 

(d) The entries made in the accounts maintained pursuant to paragraph (b) or (c) of this Section shall be prima
facie evidence of the existence and amounts of the obligations recorded therein; provided that the failure of any Lender or the Administrative Agent to maintain such accounts or any error therein shall not in any manner affect the
obligation of the Borrowers to repay the Loans in accordance with the terms of this Agreement. 
 (e) Any Lender may request that Loans made
by it be evidenced by a promissory note. In such event, the Borrowers shall prepare, execute and deliver to such Lender a promissory note payable to such Lender (or, if requested by such Lender, to such Lender and its registered assigns) and in a
form approved by the Administrative Agent. Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times (including after assignment pursuant to Section 9.04) be represented by one or more promissory notes in
such form payable to the payee named therein (or, if such promissory note is a registered note, to such payee and its registered assigns). 

  
 36 

 (f) If as of any date a determination is required or authorized to be made under the Credit
Documents the aggregate Revolving Credit Exposure of the Lenders exceeds the aggregate Commitments of the Lenders, the Borrowers shall within two (2) Business Days prepay the Loans in the amount of such excess. To the extent that, after the
prepayment of all Loans an excess of the Credit Exposure over the aggregate Commitments still exists, the Borrowers shall promptly cash collateralize the Letters of Credit in the manner described in Section 2.06(j) in an amount sufficient to
eliminate such excess. 
 (g) The Administrative Agent will determine the Dollar Equivalent of the aggregate LC Exposure and the Dollar
Equivalent of each Loan on each Exchange Rate Date. If at any time the sum of such amounts exceeds 105% of the aggregate Commitments of the Lenders, the Borrowers shall within two (2) Business Days prepay the Loans in an amount sufficient to
reduce the sum of such amounts to no greater than the amount of the aggregate Commitments of the Lenders. To the extent that, after the prepayment of all Loans an excess of the sum of such amounts over the aggregate Commitments still exists, the
Borrowers shall promptly cash collateralize the Letters of Credit in the manner described in Section 2.06(j) in an amount sufficient to eliminate such excess. 

SECTION 2.11. Prepayment of Loans. (a) The Borrowers shall have the right at any time and from time to time to prepay any
Borrowing in whole or in part and without prepayment or penalty, subject to prior notice in accordance with paragraph (b) of this Section. 

(b) The Borrower Representative shall notify the Administrative Agent by telephone (confirmed by telecopy) of any prepayment hereunder
(i) in the case of prepayment of a Eurocurrency Revolving Borrowing, not later than 11:00 a.m., Local Time, three Business Days before the date of prepayment or (ii) in the case of prepayment of an ABR Revolving Borrowing, not later than
11:00 a.m., Local Time, one Business Day before the date of prepayment. Each such notice shall be irrevocable and shall specify the prepayment date and the principal amount of each Borrowing or portion thereof to be prepaid; provided that, if
a notice of prepayment is given in connection with a conditional notice of termination of the Commitments as contemplated by Section 2.09(d), then such notice of prepayment may be revoked if such notice of termination is revoked in accordance
with Section 2.09(d). Promptly following receipt of any such notice relating to a Revolving Borrowing, the Administrative Agent shall advise the applicable Lenders of the contents thereof. Each partial prepayment of any Revolving Borrowing
shall be in an amount that would be permitted in the case of an advance of a Revolving Borrowing of the same Type as provided in Section 2.02. Each prepayment of a Revolving Borrowing shall be applied ratably to the Loans included in the
prepaid Borrowing. Prepayments shall be accompanied by accrued interest to the extent required by Section 2.13. 
 SECTION 2.12.
Fees. (a) Subject to Section 2.21(a), the Borrowers agree to pay to the Administrative Agent for the account of each Lender a commitment fee, which shall accrue at the Applicable Rate on the daily amount of the difference between
the Commitment of such Lender and the Revolving Credit Exposure of such Lender during the period from and including the date hereof to but excluding the date on which such Commitment terminates. Accrued commitment fees shall be payable quarterly in
arrears on the fifth Business Day after receipt by the Borrowers of an invoice with respect to such fees. All commitment fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including
the first day but excluding the last day). 

  
 37 

 (b) Subject to Section 2.21(c), the Borrowers agree to pay (i) to the Administrative
Agent for the account of each Lender a participation fee with respect to its participations in Letters of Credit, equal to (A) in the case of Unsecured Letters of Credit, the Applicable Rate used to determine the interest rate applicable to
Eurocurrency Revolving Loans on the average daily amount available to be drawn under such Unsecured Letter of Credit (excluding any portion thereof attributable to unreimbursed LC Disbursements) and (B) in the case of Secured Letters of Credit,
0.45% per annum on the average daily amount available to be drawn under such Secured Letter of Credit, in each case, during the period from and including the Effective Date to but excluding the later of the date on which such Lender’s
Commitment terminates and the date on which such Lender ceases to have any LC Exposure, and (ii) to the Issuing Bank a fronting fee, which shall accrue at the rate or rates per annum separately agreed upon between the Borrowers and the Issuing
Bank on the average daily amount of the LC Exposure (excluding any portion thereof attributable to unreimbursed LC Disbursements) during the period from and including the Effective Date to but excluding the later of the date of termination of the
Commitments and the date on which there ceases to be any LC Exposure, as well as the Issuing Bank’s standard fees and commissions with respect to the issuance, amendment, cancellation, negotiation, transfer, presentment, renewal or extension of
any Letter of Credit or processing of drawings thereunder. Participation fees and fronting fees accrued through and including the last day of March, June, September and December of each year shall be payable on the fifth Business Day following
receipt by the Borrowers of an invoice thereof, commencing on the first such date to occur after the Effective Date; provided that all such fees shall be payable on the date on which the Commitments terminate and any such fees accruing after
the date on which the Commitments terminate shall be payable on demand. Any other fees payable to the Issuing Bank pursuant to this paragraph shall be payable within 10 days after demand. All participation fees and fronting fees shall be computed on
the basis of a year of 360 days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day). 

(c) The Borrowers agree to pay to the Administrative Agent, for its own account, fees payable in the amounts and at the times separately agreed
upon between the Borrowers and the Administrative Agent. 
 (d) All fees payable hereunder shall be paid on the dates due, in immediately
available funds, to the Administrative Agent (or to the Issuing Bank, in the case of fees payable to it) for distribution, in the case of facility fees and participation fees, to the Lenders. Fees paid shall not be refundable under any
circumstances. 
 SECTION 2.13. Interest. (a) The Loans comprising each ABR Borrowing shall bear interest at the Alternate Base
Rate plus the Applicable Rate. 
 (b) The Loans comprising each Eurocurrency Borrowing shall bear interest at the Adjusted Eurocurrency Rate
for the Interest Period in effect for such Borrowing plus the Applicable Rate. 

  
 38 

 (c) Notwithstanding the foregoing, if any principal of or interest on any Loan or any fee or
other amount payable by any of the Borrowers hereunder is not paid when due, whether at stated maturity, upon acceleration or otherwise, such overdue amount shall bear interest, after as well as before judgment, at a rate per annum equal to
(i) in the case of overdue principal of any Loan, 2% plus the rate otherwise applicable to such Loan as provided in the preceding paragraphs of this Section or (ii) in the case of any other amount, 2% plus the rate applicable to ABR
Loans as provided in paragraph (a) of this Section. 
 (d) Accrued interest on each Loan shall be payable in arrears on each Interest
Payment Date for such Loan, upon the final maturity thereof and upon termination of the Commitments; provided that (i) interest accrued pursuant to paragraph (c) of this Section shall be payable on demand, (ii) in the
event of any repayment or prepayment of any Loan (other than a prepayment of an ABR Loan prior to the end of the Availability Period), accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or
prepayment and (iii) in the event of any conversion of any Eurocurrency Loan prior to the end of the current Interest Period therefor, accrued interest on such Loan shall be payable on the effective date of such conversion. 

(e) All interest hereunder shall be computed on the basis of a year of 360 days, except that (i) interest on Borrowings denominated in
Sterling shall be computed on the basis of a year of 365 days, (ii) interest on Borrowings denominated in any other Foreign Currency for which it is required by applicable law or customary to compute interest on the basis of a year of 365 days
or, if required by applicable law or customary, 366 days in a leap year, shall be computed on such basis, and (iii) interest computed by reference to the Alternate Base Rate at times when the Alternate Base Rate is based on the Prime Rate shall
be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). The applicable Alternate Base Rate or Adjusted
Eurocurrency Rate shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error. 

SECTION 2.14. Alternate Rate of Interest. (a) If prior to the commencement of any Interest Period for a Eurocurrency Borrowing
denominated in any currency: 
 (i) the Administrative Agent determines (which determination shall be conclusive absent
manifest error) that adequate and reasonable means (including by means of an Interpolated Rate) do not exist for ascertaining the Adjusted Eurocurrency Rate for such Interest Period; or 

(ii) the Administrative Agent is advised by the Required Lenders that the Adjusted Eurocurrency Rate for such Interest Period
will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining their Loans (or its Loan) included in such Borrowing for such Interest Period, which notice is accompanied by a written rationale for the
determination of the Required Lenders, which will be shared with the Borrowers; 

  
 39 

 then the Administrative Agent shall give notice thereof to the Borrowers and the Lenders by telephone or telecopy
as promptly as practicable thereafter and, until the Administrative Agent notifies the Borrowers and the Lenders that the circumstances giving rise to such notice no longer exist, (i) any Interest Election Request that requests the conversion
of any Revolving Borrowing to, or continuation of any Revolving Borrowing as, a Eurocurrency Borrowing denominated in such currency shall be ineffective, (ii) such Borrowing shall be converted to or continued as on the last day of the Interest
Period applicable thereto (A) if such Borrowing is denominated in Dollars, an ABR Borrowing or (B) if such Borrowing is denominated in a Foreign Currency, as a Borrowing in respect of which the rate to apply to each Lender’s
participation is an interest rate to include (1) the Applicable Rate for Eurocurrency Loans and (2) the rate notified to the Administrative Agent by such Lender as soon as practicable and in any event before interest is due to be paid in
respect of the applicable Interest Period, to be that which expresses as a percentage rate per annum the cost to such Lender of funding its participation in the applicable Borrowing from whatever source it may reasonably select; and (iii) if
any Borrowing Request requests a Eurocurrency Borrowing in such currency, such Borrowing shall be made as an ABR Borrowing (if such Borrowing is requested to be made in Dollars) or shall be made as a Borrowing bearing interest at the rate described
under (ii)(B) above. 
 (b) If, after the date hereof, any Change in Law shall make it unlawful or impossible for any of the Lenders to honor
its obligations hereunder to make or maintain any Eurocurrency Loan or any ABR Loan as to which the interest rate is determined by reference to the Adjusted Eurocurrency Rate, such Lender shall promptly give notice thereof to the Administrative
Agent and the Administrative Agent shall promptly give notice to the Parent and the other Lenders. Thereafter, until the Administrative Agent notifies the Parent that such circumstances no longer exist, (i) the obligations of the Lenders to
make Eurocurrency Loans or ABR Loans as to which the interest rate is determined by reference to the Adjusted Eurocurrency Rate, and the right of the Borrowers to convert any Loan to a Eurodollar Loan or continue any Loan as a Eurodollar Loan or an
ABR Loan as to which the interest rate is determined by reference to the Adjusted Eurocurrency Rate shall be suspended and thereafter the Borrowers may select only ABR Loans as to which the interest rate is not determined by reference to the
Adjusted Eurocurrency Rate hereunder, (ii) all ABR Loans shall cease to be determined by reference to the Adjusted Eurocurrency Rate and (iii) if any of the Lenders may not lawfully continue to maintain a Eurodollar Loan to the end of the
then current Interest Period applicable thereto, the applicable Loan shall immediately be converted to an ABR Loan as to which the interest rate is not determined by reference to the Adjusted Eurocurrency Rate for the remainder of such Interest
Period. 
 SECTION 2.15. Increased Costs. (a) If any Change in Law shall: 

(i) impose, modify or deem applicable any reserve, special deposit, liquidity or similar requirement (including any compulsory
loan requirement, insurance charge or other assessment) against assets of, deposits with or for the account of, or credit extended by, any Lender (except any such reserve requirement reflected in the Adjusted Eurocurrency Rate) or the Issuing Bank;

 (ii) impose on any Lender or the Issuing Bank or the London interbank market any other condition, cost or expense (other
than Taxes) affecting this Agreement or Eurocurrency Loans made by such Lender or any Letter of Credit or participation therein; or 

  
 40 

 (iii) subject any Recipient to any Taxes (other than (A) Indemnified Taxes,
(B) Taxes described in clauses (b) through (e) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves,
other liabilities or capital attributable thereto; 
 and the result of any of the foregoing shall be to increase the cost to such Lender or such other
Recipient of making, converting into, continuing or maintaining any Loan (or of maintaining its obligation to make any such Loan) or to increase the cost to such Lender, the Issuing Bank or such other Recipient of participating in, issuing or
maintaining any Letter of Credit or to reduce the amount of any sum received or receivable by such Lender, the Issuing Bank or such other Recipient hereunder (whether of principal, interest or otherwise), then the Borrowers will pay to such Lender,
the Issuing Bank or such other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender, the Issuing Bank or such other Recipient, as the case may be, for such additional costs incurred or reduction suffered.

 (b) If any Lender or the Issuing Bank determines that any Change in Law regarding capital or liquidity requirements has or would have the
effect of reducing the rate of return on such Lender’s or the Issuing Bank’s capital or on the capital of such Lender’s or the Issuing Bank’s holding company, if any, as a consequence of this Agreement or the Loans made by, or
participations in Letters of Credit held by, such Lender, or the Letters of Credit issued by the Issuing Bank, to a level below that which such Lender or the Issuing Bank or such Lender’s or the Issuing Bank’s holding company could have
achieved but for such Change in Law (taking into consideration such Lender’s or the Issuing Bank’s policies and the policies of such Lender’s or the Issuing Bank’s holding company with respect to capital adequacy or liquidity),
then from time to time the Borrowers will pay to such Lender or the Issuing Bank, as the case may be, such additional amount or amounts as will compensate such Lender or the Issuing Bank or such Lender’s or the Issuing Bank’s holding
company for any such reduction suffered. 
 (c) A certificate of a Lender or the Issuing Bank setting forth the amount or amounts necessary
to compensate such Lender or the Issuing Bank or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section shall be delivered to the Borrower Representative and shall be conclusive absent manifest
error. The Borrowers shall pay such Lender or the Issuing Bank, as the case may be, the amount shown as due on any such certificate within 10 days after receipt thereof. 

(d) Failure or delay on the part of any Lender or the Issuing Bank to demand compensation pursuant to this Section shall not constitute a
waiver of such Lender’s or the Issuing Bank’s right to demand such compensation; provided that the Borrowers shall not be required to compensate a Lender or the Issuing Bank pursuant to this Section for any increased costs or
reductions incurred more than 270 days prior to the date that such Lender or the Issuing Bank, as the case may be, notifies the Borrower Representative of the Change in Law giving rise to such increased costs or reductions and of such Lender’s
or the Issuing Bank’s intention to claim compensation therefor; provided further that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 270-day period referred to above shall be
extended to include the period of retroactive effect thereof. 

  
 41 

 Notwithstanding the above, a Lender will not be entitled to demand compensation for any increased
cost or reduction set forth in this Section 2.15 at any time if it is not the general practice of such Lender to demand such compensation from similarly situated borrowers in similar circumstances at such time. 

SECTION 2.16. Break Funding Payments. In the event of (a) the payment of any principal of any Eurocurrency Loan other than on the
last day of an Interest Period applicable thereto (including as a result of an Event of Default or as a result of any prepayment pursuant to Section 2.11), (b) the conversion of any Eurocurrency Loan other than on the last day of the
Interest Period applicable thereto, (c) the failure to borrow, convert, continue or prepay any Eurocurrency Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under
Section 2.11(b) and is revoked in accordance therewith) or (d) the assignment of any Eurocurrency Loan other than on the last day of the Interest Period applicable thereto as a result of a request by a Borrower pursuant to
Section 2.19, then, in any such event, the Borrowers shall compensate each Lender for the loss, cost and expense (excluding any loss of anticipated profits or loss of margin) attributable to such event. In the case of a Eurocurrency Loan, such
loss, cost or expense to any Lender shall be deemed to be an amount determined by such Lender to be the excess, if any, of (i) the amount of interest which would have accrued on the principal amount of such Loan had such event not occurred, at
the Adjusted Eurocurrency Rate that would have been applicable to such Loan, for the period from the date of such event to the last day of the then current Interest Period therefor (or, in the case of a failure to borrow, convert or continue, for
the period that would have been the Interest Period for such Loan), over (ii) the amount of interest which would accrue on such principal amount for such period at the interest rate which such Lender would bid were it to bid, at the date of
such event, for Dollar deposits in the applicable currency of a comparable amount and period from other banks in the eurocurrency market. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive
pursuant to this Section and setting forth in reasonable detail the basis for such claim shall be delivered to the Borrower Representative and shall be conclusive absent manifest error. The Borrowers shall pay such Lender the amount shown as
due on any such certificate within 10 days after receipt thereof. 
 SECTION 2.17. Taxes. (a) Payments Free of Taxes. Any
and all payments by or on account of any obligation of any Borrower under any Credit Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith
discretion of an applicable withholding agent) requires the deduction or withholding of any Tax from any such payment by a withholding agent, then the applicable withholding agent shall be entitled to make such deduction or withholding and shall
timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the applicable Borrower shall be increased as necessary so that
after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2.17) the applicable Recipient receives an amount equal to the sum it would have received had
no such deduction or withholding been made. 

  
 42 

 (b) Payment of Other Taxes by the Borrowers. The Borrowers shall timely pay to the
relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for, Other Taxes. 

(c) Evidence of Payments. As soon as practicable after any payment of Taxes by any Borrower to a Governmental Authority pursuant to this
Section 2.17, such Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of
such payment reasonably satisfactory to the Administrative Agent. 
 (d) Indemnification by the Borrowers. The Borrowers shall jointly
and severally indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by
such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the
relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrowers by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender,
shall be conclusive absent manifest error. 
 (e) Indemnification by the Lenders. Each Lender shall severally indemnify the
Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that any Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and
without limiting the obligation of the Borrowers to do so), (ii) any Taxes attributable to such Lender’s failure to comply with the provisions of Section 9.04(c) relating to the maintenance of a Participant Register and (iii) any
Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Credit Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes
were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each
Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Credit Document or otherwise payable by the Administrative Agent to the Lender from any other source against any
amount due to the Administrative Agent under this paragraph (e). 
 (f) Status of Lenders. (i) Any Lender that is entitled to an
exemption from or reduction of withholding Tax with respect to payments made under any Credit Document shall deliver to the Borrowers and the Administrative Agent, at the time or times reasonably requested by the Borrowers or the Administrative
Agent, such properly completed and executed documentation reasonably requested by the Borrowers or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if
reasonably requested by the Borrowers or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrowers or the Administrative Agent as will enable the Borrowers or the
Administrative Agent to determine whether or not such Lender is subject to backup withholding or information 

  
 43 

 
reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set
forth in Section 2.17(f)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or
would materially prejudice the legal or commercial position of such Lender. 
 (ii) Without limiting the generality of the
foregoing, in the event that any Borrower is a U.S. Person, 
 (A) any Lender that is a U.S. Person shall deliver to such
Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of such Borrower or the Administrative Agent), executed originals
of IRS Form W-9 certifying that such Lender is exempt from U.S. Federal backup withholding tax; 
 (B) any Foreign Lender
(with respect to such Borrower) shall, to the extent it is legally entitled to do so, deliver to such Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such
Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of such Borrower or the Administrative Agent), whichever of the following is applicable: 

(1) in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party
(x) with respect to payments of interest under any Credit Document, executed originals of IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “interest” article of such tax
treaty and (y) with respect to any other applicable payments under any Credit Document, IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “business profits” or “other
income” article of such tax treaty; 
 (2) executed originals of IRS Form W-8ECI; 

(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of
the Code, (x) a certificate substantially in the form of Exhibit B-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of such
Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed
originals of IRS Form W-8BEN; or 
 (4) to the extent a Foreign Lender is not the beneficial owner, executed originals of IRS
Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, a U.S. Tax Compliance Certificate substantially in the form of Exhibit B-2 or Exhibit B-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable;
provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate
substantially in the form of Exhibit B-4 on behalf of each such direct and indirect partner; 

  
 44 

 (C) any Foreign Lender (with respect to such Borrower) shall, to the extent it is
legally entitled to do so, deliver to such Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from
time to time thereafter upon the reasonable request of such Borrower or the Administrative Agent), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. Federal withholding
Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit such Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and 

(D) if a payment made to a Lender under any Credit Document would be subject to U.S. Federal withholding Tax imposed by FATCA
if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to such Borrower and the Administrative
Agent at the time or times prescribed by law and at such time or times reasonably requested by such Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the
Code) and such additional documentation reasonably requested by such Borrower or the Administrative Agent as may be necessary for such Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such
Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the
date of this Agreement. 
 (iii) Each Lender agrees that if any form or certification it previously delivered expires or
becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrowers and the Administrative Agent in writing of its legal inability to do so. 

(g) Additional United Kingdom Withholding Tax Matters. 

(i) Without limiting the generality of the foregoing and subject to (ii) below, each Lender and each UK Borrower which
makes a payment to such Lender shall cooperate in completing as soon as reasonably possible any procedural formalities necessary for such UK Borrower to obtain authorization to make such payment without withholding or deduction or subject to a
reduced rate of withholding or deduction for Taxes imposed under the laws of the United Kingdom. 
 (ii) (A) A Lender on the
day on which this Agreement closes that (x) holds a passport under the HMRC DT Treaty Passport scheme and (y) wishes such scheme to apply to this Agreement, shall confirm its scheme reference number and its jurisdiction of tax residence
opposite its name in Schedule 2.01; and 

  
 45 

 (B) a Lender which becomes a Lender hereunder after the day on which this
Agreement closes that (x) holds a passport under the HMRC DT Treaty Passport scheme and (y) wishes such scheme to apply to this Agreement, shall confirm its scheme reference number and its jurisdiction of tax residence to the Borrower
Representative and in the relevant documentation it executes to becomes a Lender, and 
 (C) Upon satisfying either clause
(A) or (B) above, such Lender shall have satisfied its obligation under paragraph (g)(i) above. 
 (iii) If a
Lender has confirmed its scheme reference number and its jurisdiction of tax residence in accordance with paragraph (g)(ii) above, the UK Borrower(s) shall duly complete and file HMRC form DTTP2 with HMRC within 30 days of the date of this Agreement
in respect of a Lender falling within Section 2.17(g)(ii)(A) and within 30 days of the date a Lender falling under Section 2.17(g)(ii)(B) becomes a Lender under this Agreement (a “Borrower DTTP Filing”) with respect to
such Lender, and shall promptly provide such Lender with a copy of such filing; provided that, if: 
 (A) each UK
Borrower making a payment to such Lender has not made a Borrower DTTP Filing in respect of such Lender; or 
 (B) each UK
Borrower making a payment to such Lender has made a Borrower DTTP Filing in respect of such Lender but: 
 (1) such Borrower
DTTP Filing has been rejected by HM Revenue & Customs; or 
 (2) HM Revenue & Customs has not given such
UK Borrower authority to make payments to such Lender without a deduction for tax within 60 days of the date of such Borrower DTTP Filing; 

and in each case, such UK Borrower has notified that Lender in writing of either (1) or (2) above, then such Lender
and such UK Borrower shall co-operate in completing any additional procedural formalities necessary for such UK Borrower to obtain authorization as soon as reasonably possible to make that payment without withholding or deduction for Taxes imposed
under the laws of the United Kingdom. 
 (iv) If a Lender has not confirmed its scheme reference number and jurisdiction of
tax residence in accordance with paragraph (g)(ii) above, no UK Borrower shall make a Borrower DTTP Filing or file any other form relating to the HMRC DT Treaty Passport scheme in respect of that Lender’s Commitment(s) or its participation in
any Loan unless the Lender otherwise agrees. 

  
 46 

 (v) Each UK Borrower shall, promptly on making a Borrower DTTP Filing, deliver a
copy of such Borrower DTTP Filing to the Administrative Agent for delivery to the relevant Lender. 
 (vi) Each Lender shall
promptly notify the Parent and Administrative Agent if it determines in its sole discretion that it ceases to be entitled to claim the benefits of an income tax treaty to which the United Kingdom is a party with respect to payments made by any U.K.
Borrower hereunder. 
 (h) Treatment of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that
it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.17 (including by the payment of additional amounts pursuant to this Section 2.17), it shall pay to the indemnifying party an amount equal
to such refund (but only to the extent of indemnity payments made under this Section 2.17 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest
(other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this
paragraph (g) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to
the contrary in this paragraph (g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (g) the payment of which would place the indemnified party in a less favorable net
after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with
respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party
or any other Person. 
 (i) Survival. Each party’s obligations under this Section 2.17 shall survive the resignation or
replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all obligations under any Credit Document. 

(j) Issuing Bank. For purposes of this Section 2.17, the term “Lender” includes any Issuing Bank and the term
“applicable law” includes FATCA. 
 SECTION 2.18. Payments Generally; Pro Rata Treatment; Sharing of Set-offs.
(a) Each of the Borrowers shall make each payment required to be made by it hereunder (whether of principal, interest, fees or reimbursement of LC Disbursements, or of amounts payable under Section 2.15, 2.16 or 2.17, or otherwise) prior
to 12:00 noon, Local Time, on the date when due, in immediately available funds, without set off or counterclaim. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on
the next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the Administrative Agent at its offices at 10 South Dearborn, Floor 19, Chicago, Illinois 60603 (or, for payments denominated in a
Foreign 

  
 47 

 
Currency, to J.P. Morgan Europe Limited, 125 London Wall, London EC2Y 5AJ), except payments to be made directly to the Issuing Bank as expressly provided herein and except that payments pursuant
to Sections 2.15, 2.16, 2.17 and 9.03 shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly
following receipt thereof. If any payment hereunder shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon
shall be payable for the period of such extension. All payments hereunder of (i) principal or interest in respect of any Loan shall be made in the currency in which such Loan is denominated, (ii) reimbursement obligations shall be made in
the currency in which the Letter of Credit in respect of which such reimbursement obligation exists is denominated or (iii) any other amount due hereunder or under another Credit Document shall be made in Dollars. Any payment required to be
made by the Administrative Agent hereunder shall be deemed to have been made by the time required if the Administrative Agent shall at or before such time have taken the necessary steps to make such payment in accordance with the regulations or
operating procedures of the clearing or settlement system used by the Administrative Agent to make such payment. 
 (b) If at any time
insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, unreimbursed LC Disbursements, interest and fees then due hereunder, such funds shall be applied (i) first, towards payment of
interest and fees then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest and fees then due to such parties, and (ii) second, towards payment of principal and unreimbursed LC Disbursements then
due hereunder, ratably among the parties entitled thereto in accordance with the amounts of principal and unreimbursed LC Disbursements then due to such parties. 

(c) If any Lender shall, by exercising any right of set off or counterclaim or otherwise, obtain payment in respect of any principal of or
interest on any of its Loans or participations in LC Disbursements resulting in such Lender receiving payment of a greater proportion of the aggregate amount of its Loans and participations in LC Disbursements and accrued interest thereon than the
proportion received by any other Lender, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Loans and participations in LC Disbursements of other Lenders without recourse or warranty from
the other Lenders except as contemplated by Section 9.04 in respect of assignments to the extent necessary so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of
and accrued interest on their respective Loans and participations in LC Disbursements; provided that (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations
shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this paragraph shall not be construed to apply to any payment made by any of the Borrowers pursuant to and in
accordance with the express terms of this Agreement or any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or participations in LC Disbursements to any assignee or participant, other
than to the Borrowers or any Subsidiary or Affiliate thereof (as to which the provisions of this paragraph shall apply). Each of the Borrowers consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that
any Lender acquiring a 

  
 48 

 
participation pursuant to the foregoing arrangements may exercise against any of the Borrowers rights of set-off and counterclaim with respect to such participation as fully as if such Lender
were a direct creditor of such Borrower in the amount of such participation. 
 (d) Unless the Administrative Agent shall have received
notice from the Borrower Representative prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the Issuing Bank hereunder that the Borrowers will not make such payment, the Administrative Agent
may assume that the Borrowers have made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Bank, as the case may be, the amount due. In such event, if the Borrowers
have not in fact made such payment, then each of the Lenders or the Issuing Bank, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or Issuing Bank with interest
thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, (i) at the greater of the Federal Funds Effective Rate and a rate determined by the
Administrative Agent in accordance with banking industry rules on interbank compensation (in the case of an amount denominated in Dollars) and (ii) the rate reasonably determined by the Administrative Agent to be the cost to it of funding such
amount (in the case of an amount denominated in a Foreign Currency). 
 (e) If any Lender shall fail to make any payment required to be made
by it pursuant to Section 2.06(d) or (e), 2.07(c), 2.18(d) or 9.03(c), then the Administrative Agent may, in its discretion (notwithstanding any contrary provision hereof), (i) apply any amounts thereafter received by the Administrative
Agent for the account of such Lender and for the benefit of the Administrative Agent or the Issuing Bank to satisfy such Lender’s obligations under such Sections until all such unsatisfied obligations are fully paid, and/or (ii) hold any
such amounts in a segregated account as cash collateral for, and application to, any future funding obligations of such Lender under such Sections; in the case of each of (i) and (ii) above, in any order as determined by the Administrative
Agent in its discretion. 
 SECTION 2.19. Mitigation Obligations; Replacement of Lenders. (a) If any Lender requests compensation
under Section 2.15, or if any of the Borrowers is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17, then such Lender (at the
written request of such Borrower) shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates,
if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.15 or 2.17, as the case may be, in the future and (ii) would not subject such Lender to any
unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrowers hereby agree to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. 

(b) If any Lender requests compensation under Section 2.15, or if any of the Borrowers is required to pay any additional amount to any
Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.17, or if any Lender becomes a Defaulting Lender, then the Borrowers may, at their sole expense and effort, upon notice to such

  
 49 

 
Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in Section 9.04), all its
interests, rights and obligations under this Agreement to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that (i) the Borrower Representative shall
have received the prior written consent of the Administrative Agent (and if a Commitment is being assigned, the Issuing Bank), which consent shall not unreasonably be withheld, (ii) such Lender shall have received payment of an amount equal to
the outstanding principal of its Loans and participations in LC Disbursements, accrued interest thereon, accrued fees and all other amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and accrued interest
and fees) or the Borrowers (in the case of all other amounts), (iii) in the case of any such assignment resulting from a claim for compensation under Section 2.15 or payments required to be made pursuant to Section 2.17, such
assignment will result in a reduction in such compensation or payments and (iv) such assignee shall not be an Ineligible Institution. A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a
waiver by such Lender or otherwise, the circumstances entitling the Borrowers to require such assignment and delegation cease to apply. 

SECTION 2.20. Joint and Several Liability of the Borrowers. 

(a) Each of the Borrowers shall be jointly and severally liable hereunder and under each of the other Credit Documents with respect to all
Loans and all other Obligations, regardless of which of the Borrowers actually receives the proceeds of the Loans or the benefit of any other extensions of credit hereunder, or the manner in which the Borrowers, the Administrative Agent, the Lenders
or the Issuing Bank accounts therefore in their respective books and records. In furtherance and not in limitation of the foregoing, (i) each Borrower’s obligations and liabilities with respect to proceeds of Loans which it receives or
Letters of Credit issued for its account, and related fees, costs and expenses, and (ii) each Borrower’s obligations and liabilities arising as a result of the joint and several liability of Borrowers hereunder with respect to proceeds of
Loans received by, or Letters of Credit issued for the account of, any of the other Borrowers, together with the related fees, costs and expenses, shall be separate and distinct obligations, both of which are primary obligations of such Borrower.
The joint and several liability of each of the Borrowers shall not be impaired or released by (A) the failure of the Administrative Agent, any Lender or the Issuing Bank, any successors or assigns thereof, or any holder of any of the
Obligations to assert any claim or demand or to exercise or enforce any right, power or remedy against any Borrower, any Subsidiary, any other Person or otherwise; (B) any extension or renewal for any period (whether or not longer than the
original period) or exchange of any of the Obligations or the release or compromise of any obligation of any nature of any Person with respect thereto; (C) the surrender, release or exchange of all or any part of any property securing payment,
performance and/or observance of any of the Obligations or the compromise or extension or renewal for any period (whether or not longer than the original period) of any obligations of any nature of any Person with respect to any such property;
(D) any action or inaction on the part of the Administrative Agent, any Lender or the Issuing Bank, or any other event or condition with respect to any other Borrower, including any such action or inaction or other event or condition, which
might otherwise constitute a defense available to, or a discharge of, such Borrower, or a guarantor or surety of or for any or all of the Obligations; and (E) any other act, matter or thing (other than indefeasible payment in full or
performance of the Obligations) which would or might, in the absence of this provision, operate to release, discharge or otherwise prejudicially affect the obligations of such Borrower or any other Borrower. 

  
 50 

 (b) Notwithstanding any provision to the contrary contained herein or in any other of the Credit
Documents, to the extent the joint obligations of a Borrower shall be adjudicated to be invalid or unenforceable for any reason (including, without limitation, because of Section 548 of Chapter 11 of the Bankruptcy Code or under any applicable
state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar U.S. or foreign statute or common law) then the Obligations of each Borrower hereunder shall be limited to the maximum amount that is permissible under applicable
law (whether foreign, federal or state and including, without limitation, the federal Bankruptcy Code). 
 (c) To the extent that any
Borrower shall make a payment under this Section 2.20 of all or any of the Obligations (other than Loans the proceeds of which were received by such Borrower) (a “Surety Payment”) that, taking into account all other Surety
Payments then previously or concurrently made by any other Borrower, exceeds the amount that such Borrower would otherwise have paid if each Borrower had paid the aggregate Obligations satisfied by such Surety Payment in the same proportion that
such Borrower’s “Allocable Amount” (as defined below) (as determined immediately prior to such Surety Payment) bore to the aggregate Allocable Amounts of each of the Borrowers as determined immediately prior to the making of such
Surety Payment, then, following indefeasible payment in full in cash of the Obligations and termination of the Commitments, such Borrower shall be entitled to receive contribution and indemnification payments from, and be reimbursed by, each other
Borrower for the amount of such excess, pro rata based upon their respective Allocable Amounts in effect immediately prior to such Surety Payment. As of any date of determination, the “Allocable Amount” of any Borrower shall be
equal to the maximum amount of the claim that could then be recovered from such Borrower under this Section 2.20 without rendering such claim voidable or avoidable under Section 548 of Chapter 11 of the Bankruptcy Code or under any
applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar U.S. or foreign statute or common law. This Section 2.20(c) is intended only to define the relative rights of Borrowers and nothing set forth in this
Section 2.20(c) is intended to or shall impair the obligations of Borrowers, jointly and severally, to pay any amounts as and when the same shall become due and payable in accordance with the terms of this Agreement, including
Section 2.20(a). Nothing contained in this Section 2.20(c) shall limit the liability of any Borrower to pay the Loans made directly or indirectly to that Borrower and accrued interest, fees and expenses with respect thereto for which such
Borrower shall be primarily liable. The parties hereto acknowledge that the rights of contribution and indemnification hereunder shall constitute assets of the Borrowers to which such contribution and indemnification is owing. The rights of the
indemnifying Borrowers against other Borrowers under this Section 2.20(c) shall be exercisable only upon the full and indefeasible payment of the Obligations and the termination of the Commitments. 

(d) The liability of Borrowers under this Section 2.20 is in addition to and shall be cumulative with all liabilities of each Borrower to
the Administrative Agent and Lenders under this Agreement and the other Credit Documents to which such Borrower is a party, without any limitation as to amount. 

  
 51 

 SECTION 2.21. Defaulting Lenders. Notwithstanding any provision of this Agreement to the
contrary, if any Lender becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender: 

(a) fees shall cease to accrue on the unfunded portion of the Commitment of such Defaulting Lender pursuant to Section 2.12; 

(b) the Commitment and Revolving Credit Exposure of such Defaulting Lender shall not be included in determining whether all Lenders, the
Required Lenders or the Required Lenders have taken or may take any action hereunder (including any consent to any amendment or waiver pursuant to Section 9.02), provided that any waiver, amendment or modification requiring the consent
of all Lenders or each affected Lender which affects such Defaulting Lender differently than other affected Lenders shall require the consent of such Defaulting Lender; 

(c) if any LC Exposure exists at the time a Lender becomes a Defaulting Lender then: 

(i) all or any part of such LC Exposure shall be reallocated among the non-Defaulting Lenders in accordance with their
respective Applicable Percentages but only to the extent (x) the sum of all non-Defaulting Lenders’ Revolving Credit Exposures plus such Defaulting Lender’s LC Exposure does not exceed the total of all non-Defaulting Lenders’
Commitments and (y) the conditions set forth in Section 4.02 are satisfied at such time; and 
 (ii) if the
reallocation described in clause (i) above cannot, or can only partially, be effected, the Borrowers shall within one Business Day following notice by the Administrative Agent cash collateralize such Defaulting Lender’s LC Exposure (after
giving effect to any partial reallocation pursuant to clause (i) above) in accordance with the procedures set forth in Section 2.06(j) for so long as such LC Exposure is outstanding; 

(iii) if the Borrowers cash collateralize any portion of such Defaulting Lender’s LC Exposure pursuant to
Section 2.21(c), the Borrowers shall not be required to pay any fees to such Defaulting Lender pursuant to Section 2.12(b) with respect to such Defaulting Lender’s LC Exposure during the period such Defaulting Lender’s LC
Exposure is cash collateralized; 
 (iv) if the LC Exposure of the non-Defaulting Lenders is reallocated pursuant to
Section 2.21(c), then the fees payable to the Lenders pursuant to Section 2.12 shall be adjusted in accordance with such non-Defaulting Lenders’ Applicable Percentages; or 

(v) if any Defaulting Lender’s LC Exposure is neither cash collateralized nor reallocated pursuant to
Section 2.21(c), then, without prejudice to any rights or remedies of the Issuing Bank or any Lender hereunder, all facility fees that otherwise would have been payable to such Defaulting Lender (solely with respect to the portion of such
Defaulting Lender’s Commitment that was utilized by such LC Exposure) and letter of credit fees payable under Section 2.12(b) with respect to such Defaulting Lender’s LC Exposure shall be payable to the Issuing Bank until such LC
Exposure is cash collateralized and/or reallocated; and 

  
 52 

 (d) so long as any Lender is a Defaulting Lender, the Issuing Bank shall not be required to
issue, amend or increase any Letter of Credit, unless it is satisfied that the related exposure will be 100% covered by the Commitments of the non-Defaulting Lenders and/or cash collateral will be provided by the Borrowers in accordance with
Section 2.21(c), and participating interests in any such newly issued or increased Letter of Credit shall be allocated among non-Defaulting Lenders in a manner consistent with Section 2.21(c)(i) (and Defaulting Lenders shall not
participate therein). 
 (e) If (i) a Bankruptcy Event with respect to a Lender Parent shall occur following the date hereof and for so
long as such event shall continue or (ii) the Issuing Bank has a good faith belief that any Lender has defaulted in fulfilling its obligations under one or more other agreements in which such Lender commits to extend credit, the Issuing Bank
shall not be required to issue, amend or increase any Letter of Credit, unless the Issuing Bank shall have entered into arrangements with a Borrower or such Lender, satisfactory to the Issuing Bank to defease any risk to it in respect of such Lender
hereunder. 
 (f) In the event that the Administrative Agent, the Borrowers and the Issuing Bank each agrees that a Defaulting Lender has
adequately remedied all matters that caused such Lender to be a Defaulting Lender, then the LC Exposure of the Lenders shall be readjusted to reflect the inclusion of such Lender’s Commitment and on such date such Lender shall purchase at par
such of the Loans of the other Lenders as the Administrative Agent shall determine may be necessary in order for such Lender to hold such Loans in accordance with its Applicable Percentage. 

SECTION 2.22. Extension of Maturity Date. 

(a) Requests for Extension. The Parent may, on up to two (2) occasions and by notice to the Administrative Agent (who shall
promptly notify the Lenders) not less than sixty (60) days prior to the then effective Maturity Date (the “Extension Date”), request that each Lender extend such Lender’s Maturity Date for an additional one year from the
Maturity Date then in effect hereunder (the “Existing Termination Date”). 
 (b) Lender Elections to Extend. Each
Lender, acting in its sole and individual discretion, shall, by notice to the Administrative Agent given not later than the date that is ten (10) Business Days after receipt of notice from the Administrative Agent of the Borrower’s request
for an extension (the “Notice Date”) advise the Administrative Agent whether or not such Lender agrees to such extension (each such Lender that determines to so extend its Maturity Date, being an “Extending Lender”
and each Lender that determines not to so extend its Maturity Date, being a “Non-Extending Lender”). In the event that a Lender that does not so advise the Administrative Agent on or before the Notice Date such Lender shall be
deemed to be a Non-Extending Lender. The election of any Lender to agree to such extension shall not obligate any other Lender to so agree. 

  
 53 

 (c) Notification by Administrative Agent. The Administrative Agent shall notify the Parent
of each Lender’s determination under this Section no later than the date fifteen (15) days prior to the Extension Date (or, if such date is not a Business Day, on the next preceding Business Day). 

(d) Additional Commitment Lenders. If (and only if) the Required Lenders have agreed to extend the Maturity Date then in effect
hereunder, the Parent shall have the right at any time prior to the date 30 days prior to the existing Maturity Date applicable to any Non-Extending Lender to replace such Non-Extending Lender with, and add as “Lenders” under this
Agreement, one or more entities that are not Ineligible Institutions with the consent of the Administrative Agent (such consent not to be unreasonably withheld or denied) (each, an “Additional Commitment Lender”) in accordance with
the provisions contained in Section 2.09(d), provided that each of such Additional Commitment Lenders shall have entered into an Assignment and Assumption Agreement pursuant to which such Additional Commitment Lender shall, effective as
of the date of the Assignment and Assumption, accept a new or incremental Commitment which results in there being aggregate Commitments in an amount no greater than the aggregate amount of Commitments before giving effect to assignments contemplated
by this Section 2.22(d). 
 (e) Minimum Extension Requirement. If (and only if) the Required Lenders have agreed so to extend the
Maturity Date then in effect hereunder as described in this Section 2.22, then, effective as of such Extension Date, the Maturity Date of each Extending Lender and each Additional Commitment Lender shall be extended to the date falling
one year after the Existing Termination Date (except that, if such date is not a Business Day, such date shall be the next preceding Business Day) and each Additional Commitment Lender shall thereupon become a “Lender” for all purposes of
this Agreement; provided, however, that there shall be no change in the Maturity Date of any Non-Extending Lender that has not been replaced by an Additional Commitment Lender (each a “Non-Replaced Lender”). 

(f) Conditions to Effectiveness of Extensions. Notwithstanding the foregoing, the extension of the Maturity Date pursuant to this
Section shall not be effective with respect to any Lender unless: 
 (i) no Default shall have occurred and be
continuing on the date of such extension and after giving effect thereto; 
 (ii) the representations and warranties
contained in Article V or any other Credit Document are true and correct on and as of the date of such extension and after giving effect thereto, as though made on and as of such date, except to the extent any such representation or warranty
is stated to relate solely to an earlier date, in which case such representation or warranty shall have been true and correct on and as of such earlier date; 

(iii) since the date of the financial statements most recently delivered pursuant to Section 5.01(a) or (c),
no event, circumstance or development shall have occurred that has had or could reasonably be expected to have a Material Adverse Effect; 

  
 54 

 (iv) the Parent shall have delivered to the Administrative Agent a certificate
dated the Effective Date in form satisfactory to the Administrative Agent as to the satisfaction of the conditions set forth in clauses (i) – (iii) above and other relevant documentation, including legal opinions, reasonably requested
by the Administrative Agent; and 
 (v) on the Maturity Date of each Non-Replaced Lender, the Borrowers shall prepay any
Loans outstanding on such date (and pay any additional amounts required pursuant to Section 2.16) to the extent necessary to repay, nonratably, the Loans of such Non-Replaced Lenders and the Commitment of such Non-Replaced Lenders shall
be terminated. The Applicable Percentages of the remaining Lenders shall be revised accordingly as of such date. 
 (g) Conflicting
Provisions. This Section shall supersede any provisions in Section 2.18 or 9.02 to the contrary. 
 ARTICLE III

 Representations and Warranties 

Each of the Borrowers represents and warrants to the Administrative Agent and the Lenders that: 

SECTION 3.01. Organization; Powers. Each of the Parent and its Subsidiaries is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its organization and has all requisite power and authority to carry on its business as now conducted and, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to
result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every jurisdiction where such qualification is required. 

SECTION 3.02. Authorization; Enforceability. The Transactions are within the Borrowers’ corporate powers and have been duly
authorized by all necessary corporate and, if required, stockholder action. This Agreement has been duly executed and delivered by the Borrowers and constitutes a legal, valid and binding obligation of the Borrowers, enforceable in accordance with
its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or
at law. 
 SECTION 3.03. Governmental Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of,
registration or filing with, or any other action by, any Governmental Authority, except such as have been obtained or made and are in full force and effect, (b) will not violate any applicable law or regulation or the charter, by-laws,
memorandum or articles of association or other organizational documents of the Parent or any of its Subsidiaries or any order of any Governmental Authority applicable to the Parent or any of its Subsidiaries and (c) will not violate or result
in a default under any indenture, agreement or other instrument binding upon the Parent or any of its Subsidiaries or its assets, or give rise to a right thereunder to require any payment to be made by the Parent or any of its Subsidiaries, but only
to the extent that such violation or default could reasonably be expected to result in a Material Adverse Effect. 

  
 55 

 SECTION 3.04. Financial Condition; No Material Adverse Change. (a) The Borrowers have
heretofore furnished to the Lenders the consolidated balance sheet and statements of income, stockholders equity and cash flows (including consolidating statements and schedules) of the Parent as of and for the fiscal years ended December 31,
2012 and December 31, 2013, reported on without qualification by Ernst & Young LLP, independent public accountants. Such financial statements present fairly, in all material respects, the financial position and results of operations
and cash flows of the Parent and its consolidated Subsidiaries as of such dates and for such periods in accordance with GAAP. 
 (b) Since
December 31, 2013, there has been no material adverse change in the business, assets, operations, prospects or financial condition of the Parent and its Subsidiaries, taken as a whole. 

SECTION 3.05. Properties. (a) The Parent and its Subsidiaries have good title to, or valid leasehold interests in, all their real
and personal property material to their business, taken as a whole, except for minor defects in title that do not interfere with their ability to conduct their business as currently conducted or to utilize such properties for their intended
purposes. 
 (b) Each of the Parent and its Subsidiaries owns, or is licensed to use, all trademarks, tradenames, copyrights, patents and
other intellectual property material to its business, and, to the knowledge of the Borrowers, the use thereof by the Parent and its Subsidiaries does not infringe upon the rights of any other Person, except for any such infringements that,
individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.06.
Litigation. There are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or, to the knowledge of the Borrowers, threatened against or affecting the Parent or any of its Subsidiaries
(i) that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or (ii) that involve this Agreement or the Transactions. 

SECTION 3.07. Compliance with Laws and Agreements. Each of the Parent and its Subsidiaries is in compliance with: (i) the charter,
by-laws, memorandum or articles of association or other organizational documents applicable to it and (ii) all laws, regulations and orders of any Governmental Authority applicable to it or its property, except where the failure to do so,
individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.08. Investment
Company Status. Neither the Parent nor any of its Subsidiaries is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940. 

  
 56 

 SECTION 3.09. Taxes. Each of the Parent and its Subsidiaries has timely filed or caused to
be filed all Tax returns and reports required to have been filed and has paid or caused to be paid all Taxes required to have been paid by it, except (a) Taxes that are being contested in good faith by appropriate proceedings and for which the
Parent or such Subsidiary, as applicable, has set aside on its books adequate reserves or (b) to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect. 

SECTION 3.10. ERISA. No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA
Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect. The present value of all accumulated benefit obligations under each Plan (based on the assumptions used for purposes of
Statement of Financial Accounting Standards No. 87) did not, as of the date of the most recent financial statements reflecting such amounts, exceed by more than $10,000,000 the fair market value of the assets of such Plan, and the present value
of all accumulated benefit obligations of all underfunded Plans (based on the assumptions used for purposes of Statement of Financial Accounting Standards No. 87) did not, as of the date of the most recent financial statements reflecting such
amounts, exceed by more than $10,000,000 the fair market value of the assets of all such underfunded Plans. 
 SECTION 3.11. Insurance
Licenses. As of the Effective Date, (i) Schedule 3.11 attached hereto lists all of the jurisdictions in which any Significant Insurance Subsidiary holds active Licenses and is authorized to transact insurance business, (ii) no such
License is the subject of a proceeding for suspension or revocation, there is no sustainable basis for such suspension or revocation, and to any Borrower’s knowledge, no such suspension or revocation has been threatened by any Governmental
Authority, except as could not reasonably be expected to result in a Material Adverse Effect, (iii) Schedule 3.11 also indicates the type or types of insurance in which each such Insurance Subsidiary is permitted to engage with respect to each
License therein listed, and (iv) none of the Significant Insurance Subsidiaries transacts any insurance business, directly or indirectly, in any state other than those enumerated in Schedule 3.11. 

SECTION 3.12. Subsidiaries. As of the Effective Date, the Parent has no Subsidiaries other than those Subsidiaries listed on Schedule
3.12. Schedule 3.12 correctly sets forth, as of the Effective Date, (i) the percentage ownership (direct or indirect) of the Parent in the Equity Interests of its Subsidiaries and also identifies the direct owner thereof, (ii) the
jurisdiction of organization of each such Subsidiary and (iii) with respect to each such Subsidiary, whether such Subsidiary is a Significant Subsidiary or Significant Insurance Subsidiary; provided that the identification of Significant
Subsidiaries on Schedule 3.12 may be provided within thirty (30) days after the Effective Date. Notwithstanding anything in Section 9.02 to the contrary, Schedule 3.12 shall be amended to reflect such Significant Subsidiaries upon
identification thereof as contemplated thereby. 
 SECTION 3.13. Material Agreements. Neither the Parent nor any Subsidiary is in
default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any agreement to which it is a party, which default could reasonably be expected to have a Material Adverse Effect. 

  
 57 

 SECTION 3.14. Disclosure. Each of the Borrowers has disclosed to the Lenders all
agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse
Effect. None of the reports, financial statements, certificates or other information furnished by or on behalf of the Borrowers to the Administrative Agent or any Lender in connection with the negotiation of this Agreement or delivered hereunder
taken as a whole (as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading; provided that, with respect to projected financial information, the Borrowers represent only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it
being understood that projected financial information is as to future events and is not to be viewed as fact and that actual results during the period or periods covered by any such information may differ significantly from the projected results and
such differences may be material). 
 SECTION 3.15. Solvency. The Parent and its Subsidiaries are, on a consolidated basis, Solvent.

 SECTION 3.16. Foreign Pension Plan. Except as, individually or in the aggregate, could not reasonably be expected to result in a
Material Adverse Effect, (i) each Foreign Pension Plan has been maintained in compliance with its terms and in compliance with the requirements of any and all applicable laws, statutes, rules, regulations and orders (including all funding
requirements and the respective requirements of the governing documents for each such Foreign Pension Plan) and has been maintained, where required, in good standing with applicable regulatory authorities, (ii) all contributions required to be
made with respect to a Foreign Pension Plan have been timely made, (iii) no actions or proceedings have been taken or instituted to terminate or wind up a Foreign Pension Plan, and (iv) neither any Borrower nor any Subsidiary has incurred
any obligation in connection with the termination of or withdrawal from any Foreign Pension Plan. The present value of the accrued benefit liabilities (whether or not vested) under each Foreign Pension Plan, determined as of the end of the
Parent’s most recently ended fiscal year on the basis of actuarial assumptions, each of which is reasonable, did not exceed by more than $10,000,000 the current value of the assets of such Foreign Pension Plan allocable to such benefit
liabilities. 
 SECTION 3.17. Anti-Corruption Laws and Sanctions. The Borrowers have implemented and maintain in effect policies and
procedures reasonably designed to ensure compliance in all material respects by the Borrowers, their Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and the Borrowers,
their Subsidiaries and their respective officers and employees and to the knowledge of the Borrowers its directors and agents (under the control of any Borrower or Subsidiary), are in compliance with Anti-Corruption Laws and applicable Sanctions in
all material respects. None of (a) the Borrowers, any Subsidiary or to the knowledge of the Borrowers or such Subsidiary any of their respective directors, officers or employees, or (b) to the knowledge of the Borrowers, any agent (under
the control of any Borrower or Subsidiary) of the Borrowers or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Borrowing or Letter of Credit, use of
proceeds or other transaction contemplated by the Credit Agreement will violate Anti-Corruption Laws or applicable Sanctions. 

  
 58 

 ARTICLE IV 

Conditions 
 SECTION 4.01.
Effective Date. The obligations of the Lenders to make Loans and participate in Letters of Credit and of the Issuing Bank to issue Letters of Credit hereunder shall not become effective until the date on which each of the following conditions
is satisfied (or waived in accordance with Section 9.02): 
 (a) The Administrative Agent (or its counsel) shall have received from each
party hereto either (i) a counterpart of this Agreement signed on behalf of such party or (ii) written evidence satisfactory to the Administrative Agent (which may include telecopy transmission of a signed signature page of this Agreement)
that such party has signed a counterpart of this Agreement. 
 (b) The Administrative Agent shall have received a favorable written opinion
(addressed to the Administrative Agent and the Lenders and dated the Effective Date) of (i) Willkie Farr & Gallagher LLP, US counsel for the Borrowers, (ii) Conyers Dill & Pearman, Bermuda counsel for the Borrowers,
(iii) Willkie Farr & Gallagher (UK) LLP, UK counsel for the Borrowers and (iv) in house counsel to Argo US, in form and substance reasonably satisfactory to the Administrative Agent and covering such other matters relating to the
Borrowers, this Agreement or the Transactions as the Administrative Agent shall reasonably request. The Borrowers hereby request such counsel to deliver such opinion. 

(c) The Administrative Agent shall have received such documents and certificates as the Administrative Agent or its counsel may reasonably
request relating to the organization, existence and good standing of the Borrowers, the authorization of the Transactions and any other legal matters relating to the Borrowers, this Agreement or the Transactions, all in form and substance reasonably
satisfactory to the Administrative Agent and its counsel. 
 (d) The Administrative Agent shall have received a certificate relating to the
solvency of each of the Borrowers in form and substance reasonably satisfactory to the Administrative Agent. 
 (e) The Administrative Agent
shall have received a certificate, dated the Effective Date and signed by the President, a Vice President or a Financial Officer of the Parent, confirming compliance with the conditions set forth in paragraphs (a) and (b) of
Section 4.02, stating (i) the Argo US Rating and (ii) the Subsidiary Rating of each Insurance Subsidiary of Argo US. 
 (f)
All obligations of the Borrowers under their Credit Agreement dated April 30, 2010 with JPMCB as administrative agent and the lenders party thereto (other than any obligations in respect of outstanding letters of credit thereunder which are
continued under this Agreement) shall have been or shall substantially contemporaneously be repaid in full and all commitments to extend credit pursuant to such agreement shall be terminated. 

  
 59 

 (g) The Lenders shall have received audited (without qualification) consolidated financial
statements of Argo Group International Holdings, Ltd. for the fiscal years ended December 31, 2012 and December 31, 2013. 
 (h)
The Administrative Agent shall have received all fees and other amounts due and payable on or prior to the Effective Date, including, to the extent invoiced, reimbursement or payment of all out of pocket expenses required to be reimbursed or paid by
the Borrowers hereunder. 
 The Administrative Agent shall notify the Borrower Representative and the Lenders of the Effective Date, and such notice shall
be conclusive and binding. Notwithstanding the foregoing, the obligations of the Lenders to make Loans and of the Issuing Bank to issue Letters of Credit hereunder shall not become effective unless each of the foregoing conditions is satisfied (or
waived pursuant to Section 9.02) at or prior to 3:00 p.m., Chicago time, on March 15, 2014 (and, in the event such conditions are not so satisfied or waived, the Commitments shall terminate at such time). 

SECTION 4.02. Each Credit Event. The obligation of each Lender to make a Loan on the occasion of any Borrowing, and of the Issuing Bank
to issue, amend, renew or extend any Letter of Credit, is subject to the satisfaction of the following conditions: 
 (a) The representations
and warranties of the Borrowers set forth in this Agreement shall be true and correct in all material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse Effect shall
be true and correct in all respects) on and as of the date of such Borrowing or the date of issuance, amendment, renewal or extension of such Letter of Credit, as applicable, except to the extent such representations and warranties expressly relate
to an earlier date (in which case such representations and warranties shall be true and correct in all material respects (except that any representation or warranty which is already qualified as to materiality or by reference to Material Adverse
Effect shall be true and correct in all respects) as of such earlier date). 
 (b) At the time of and immediately after giving effect to such
Borrowing or the issuance, amendment, renewal or extension of such Letter of Credit, as applicable, no Default shall have occurred and be continuing. 

(c) If a Secured Letter of Credit is being requested, (i) the Borrowers shall have executed a Security Agreement and Control Agreement and
the Administrative Agent shall have received such resolutions, certificates and opinions with respect thereto as the Administrative Agent may reasonably request and (ii) the Borrowers shall have cash collateralized such Letter of Credit as set
forth in, and to the extent required by, Section 2.06(l). 
 Each Borrowing and each issuance, amendment, renewal or extension of a Letter of Credit
shall be deemed to constitute a representation and warranty by the Borrowers on the date thereof as to the matters specified in paragraphs (a) and (b) of this Section. 

  
 60 

 ARTICLE V 

Affirmative Covenants 

Until the Commitments have expired or been terminated and the principal of and interest on each Loan and all fees payable hereunder shall have
been paid in full and all Letters of Credit shall have expired or terminated (or, in the case of any Letter of Credit extending past the Maturity Date, been cash collateralized in accordance with Section 2.06(j)) and all LC Disbursements shall
have been reimbursed, each of the Borrowers covenants and agrees with the Lenders that: 
 SECTION 5.01. Financial Statements; Ratings
Change and Other Information. The Borrowers will furnish to the Administrative Agent for distribution to each Lender: 
 (a) within 90
days after the end of each fiscal year of the Parent, audited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such year (including unaudited consolidated balance
sheet and income statement schedules, as customarily prepared by the Parent, for the Parent and its consolidated subsidiaries). The consolidated financial statements will set forth in each case in comparative form the figures for the previous fiscal
year as available, all reported on by Ernst & Young LLP or other independent public accountants of recognized national standing (without a “going concern” or like qualification or exception and without any qualification or
exception as to the scope of such audit) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of the Parent and its consolidated Subsidiaries on a
consolidated basis in accordance with GAAP consistently applied; 
 (b) with respect to Argonaut Insurance Company, Colony Insurance Company,
Rockwood Casualty Insurance Company, Argo Re, Ltd, Syndicate 1200 and other Significant Insurance Subsidiaries created subsequent to the Closing Date, as soon as available, and in any event (i) within 15 days after the date required to be
filed, a copy of each such entity’s statutory Annual Statement for such year ended December 31, as filed with the insurance department (or other equivalent insurance regulatory authority) of the state or other jurisdiction of domicile of
such entity, and (ii) within 15 days after the date required to be filed, a copy of each such entity’s audited or unaudited, as the case may be, financial statements for such year ended December 31, as filed with the insurance
department (or other equivalent insurance regulatory authority) of the state or other jurisdiction of domicile of such entity. The financial statements referred to in this Section 5.01(b)(ii) shall fairly present in all material respects the
statutory financial position of each such entity as of the dates therein specified and the statutory results of operations and cash flow of each such entity for the periods therein specified, and shall be prepared in conformity with SAP (or an
equivalent standard in the applicable jurisdiction). The financial statements referred to in sub-clause (ii) of this Section 5.01(b) shall, if required, be accompanied by an audit report thereon of Ernst & Young LLP or such other
firm of independent auditors of recognized national standing selected by the Parent that is reasonably satisfactory to the Administrative Agent to the effect that such financial statements present fairly, in all material respects, the financial
position of each such entity as of the end of the fiscal year being reported on in conformity with SAP and that the examination of such auditors in connection with such financial statements has been conducted in accordance with generally accepted
auditing standards and included such tests of the accounting records and such other auditing procedures as said auditors deemed necessary in the circumstances. 

  
 61 

 (c) within 60 days after the end of each of the first three fiscal quarters of each fiscal year
of the Parent, unaudited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such fiscal quarter and the then elapsed portion of the fiscal year (including unaudited
consolidated balance sheet and income statement schedules, as customarily prepared by the Parent, for the Parent and its consolidated subsidiaries). The consolidated financial statements will set forth in each case in comparative form the figures
for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous fiscal year as available, all certified by a Financial Officer of either the Parent or the Borrower Representative as presenting fairly
in all material respects the financial condition and results of operations of the Parent and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the
absence of footnotes; 
 (d) concurrently with any delivery of financial statements under clause (a) or (c) above, a certificate of
a Financial Officer of either the Parent or the Borrower Representative (i) certifying as to whether a Default has occurred and, if a Default has occurred, specifying the details thereof and any action taken or proposed to be taken with respect
thereto, (ii) setting forth reasonably detailed calculations demonstrating compliance with Sections 6.09 and 6.10, (iii) stating whether any change in GAAP or in the application thereof has occurred since the date of the audited financial
statements referred to in Section 3.04 and, if any such change has occurred, specifying the effect of such change on the financial statements accompanying such certificate and (iv) solely with respect to certificates delivered with
Section 5.01(a) deliveries, updated versions of Schedules 3.11 and 3.12 providing current lists of the information required thereby; 

(e) promptly after the same become publicly available, copies of all 10-K, 10-Q and 8-K reports (or successor forms thereof) and other material
reports, proxy statements and other materials filed by any Borrower or a Subsidiary with the SEC or with any national securities exchange, as the case may be, in any event other than routine reports which are required to be provided to any of the
above-listed entities concerning the management of employee benefit plans, including, without limitation, stock purchases or the exercise of stock options made under any such employee benefit plan; 

(f) promptly after S&P or any other nationally recognized rating agency shall have announced a change in Rating, written notice of such
rating change; 
 (g) promptly after A.M. Best, S&P or any other nationally recognized rating agency shall have announced a change in its
financial strength rating of an Insurance Subsidiary or any Affiliate thereof, or shall have first assigned a rating thereto, written notice of such changed or initial rating; 

(h) promptly after the creation of any Significant Subsidiary or of any Person becoming a Significant Subsidiary, notice of such creation or
occurrence; and 

  
 62 

 (i) promptly following any request therefor, such other information regarding the operations,
business affairs and financial condition of the Parent or any Subsidiary, or compliance with the terms of this Agreement, as the Administrative Agent or any Lender may reasonably request, including any actuarial reports prepared regarding any
Insurance Subsidiary, provided, that the delivery of any actuarial reports shall be subject to the consent of the applicable independent actuarial consulting firm (if then required). 

Information required to be delivered pursuant to the foregoing Section 5.01(a), (c) and (e) shall be deemed to have been delivered on the date
on which the Borrowers deliver copies of such information to the Administrative Agent on behalf of the Lenders or on the date on which the Borrowers provide notice (including notice by electronic transmission) to the Administrative Agent that such
information has been posted on the SEC website on the Internet at sec.gov/edgar/searches.htm or at another website identified in such notice and accessible by the Lenders without charge. 

SECTION 5.02. Notices of Material Events. The Borrowers will furnish to the Administrative Agent for distribution to each Lender as
soon as possible but in any event within five (5) Business Days after any officer of a Borrower becomes aware thereof, written notice of the following: 

(a) the occurrence of any Default; 

(b) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting any
Borrower or any Affiliate thereof that could reasonably be expected to result in a Material Adverse Effect; 
 (c) the occurrence of any
ERISA Event that, alone or together with any other ERISA Events that have occurred, could reasonably be expected to result in liability of the Parent and its Subsidiaries in an aggregate amount exceeding $10,000,000; 

(d) the receipt by the Parent or any Subsidiary of any notice from any Governmental Authority, trustee or actuary in relation to any
non-compliance with any laws, regulations and rules applicable to any Foreign Pension Plan, including funding requirements and the respective requirements of the governing documents for such Foreign Pension Plan, which could reasonably be expected
to result in liability of the Parent and its Subsidiaries in an aggregate amount which, either alone or with any other such events which have occurred, exceeds $10,000,000; 

(e) (i) the receipt by any Borrower or any Insurance Subsidiary of any notice from any Governmental Authority of the expiration without
renewal, revocation or suspension of, or the institution of any proceedings to revoke or suspend, any License now or hereafter held by any Insurance Subsidiary which is required to conduct insurance business in compliance with all applicable laws
and regulations, other than such expiration, revocation or suspension which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, (ii) the receipt of any notice from any Governmental Authority of
the institution of any disciplinary proceedings against or in respect of any Insurance Subsidiary, or the issuance of any order, the taking of any action or any request for an extraordinary audit for cause by any Governmental Authority which, if
adversely determined, could reasonably be expected to have a 

  
 63 

 
Material Adverse Effect or (iii) any judicial or administrative order limiting or controlling the insurance business of any Insurance Subsidiary (and not the insurance industry generally)
which has been issued or adopted and which could reasonably be expected to have a Material Adverse Effect; and 
 (f) any other development
that results in, or could reasonably be expected to result in, a Material Adverse Effect. 
 Each notice delivered under this Section shall be
accompanied by a statement of a Financial Officer or other executive officer of either the Parent or the Borrower Representative setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken
with respect thereto. 
 SECTION 5.03. Existence; Conduct of Business. The Borrowers will, and will cause each Subsidiary to, do or
cause to be done all things necessary to preserve, renew and keep in full force and effect (i) its legal existence and (ii) the rights, licenses, permits, privileges and franchises (including without limitation, certificates of authority
and other required insurance licenses) material to the conduct of the business of the Borrowers and their Subsidiaries, taken as a whole, except, in the case of clause (ii), where failure to do so, individually or in the aggregate, could not be
expected to result in a Material Adverse Effect; provided that the foregoing shall not prohibit any merger, consolidation, liquidation or dissolution permitted under Section 6.03. 

SECTION 5.04. Payment of Obligations. The Borrowers will, and will cause each Subsidiary to, pay its obligations, including Tax
liabilities, that, if not paid, could result in a Material Adverse Effect before the same shall become delinquent or in default, except where (a) the validity or amount thereof is being contested in good faith by appropriate proceedings,
(b) such Borrower or such Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP and (c) the failure to make payment pending such contest could not reasonably be expected to result in a
Material Adverse Effect. 
 SECTION 5.05. Maintenance of Properties; Insurance. The Borrowers will, and will cause each Subsidiary to,
(a) keep and maintain all property material to the conduct of the business of the Borrowers and their Subsidiaries taken as a whole in good working order and condition, ordinary wear and tear excepted, and (b) maintain, with financially
sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses operating in the same or similar locations. 

SECTION 5.06. Books and Records; Inspection Rights. The Borrowers will, and will cause each Subsidiary to, keep proper books of record
and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities. The Borrowers will, and will cause each Subsidiary to, permit any representatives designated by the
Administrative Agent or any Lender, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent
accountants, all at such reasonable times and as often as reasonably requested. 

  
 64 

 SECTION 5.07. Compliance with Laws. The Borrowers will, and will cause each Subsidiary to,
comply with all applicable laws, rules, regulations and orders of any Governmental Authority applicable to it or its property, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a
Material Adverse Effect. The Borrowers will maintain in effect and enforce policies and procedures reasonably designed to ensure compliance in all material respects by the Borrowers, their Subsidiaries and their respective directors, officers,
employees and agents under their control with Anti-Corruption Laws and applicable Sanctions. 
 SECTION 5.08. Use of Proceeds and Letters
of Credit. The proceeds of the Loans will be used only for general corporate purposes, including working capital and acquisitions permitted hereby. No part of the proceeds of any Loan will be used, whether directly or indirectly, for any purpose
that entails a violation of any of the Regulations of the Board, including Regulations T, U and X. Letters of Credit shall be used solely to support the ordinary course obligations of the Parent and its Subsidiaries. Notwithstanding anything herein
to the contrary, no Letter of Credit hereunder shall be issued to support the capital requirements at Lloyd’s of London, otherwise known as “Funds at Lloyd’s”. The Borrowers will not request any Borrowing or Letter of Credit, and
the Borrowers shall not use, and shall procure that their Subsidiaries and its or their respective directors, officers, employees and agents shall not use, the proceeds of any Borrowing or Letter of Credit (A) in furtherance of an offer,
payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business
or transaction of or with any Sanctioned Person, or in any Sanctioned Country, or (C) in any manner that would result in the violation of any Sanctions applicable to any party hereto. 

ARTICLE VI 
 Negative Covenants

 Until the Commitments have expired or terminated and the principal of and interest on each Loan and all fees payable hereunder have
been paid in full and all Letters of Credit have expired or terminated (or, in the case of any Letter of Credit extending past the Maturity Date, been cash collateralized in accordance with Section 2.06(j)) and all LC Disbursements shall have
been reimbursed, each of the Borrowers covenants and agrees with the Lenders that: 
 SECTION 6.01. Indebtedness. The Borrowers will
not, and will not permit any Subsidiary to, create, incur, assume or permit to exist any Indebtedness, except: 
 (a) Indebtedness created
hereunder; 
 (b) Indebtedness and commitments to provide Indebtedness existing on the date hereof and set forth on Schedule 6.01 (and any
guaranties by the Borrowers thereof) and extensions, renewals and replacements of any such Indebtedness that do not increase the outstanding principal amount thereof; 

  
 65 

 (c) Indebtedness of any Borrower to any Subsidiary and of any Subsidiary to any Borrower or any
other Subsidiary; 
 (d) Guarantees, including Net Worth Maintenance agreements or similar capital support or credit enhancement agreements,
by the Parent or any Subsidiary of the obligations of the Parent or any Wholly-Owned Subsidiary of the Parent; provided, however, that (i) this clause (d) shall not permit any Guarantee by a Subsidiary which is not a Borrower
of the obligations of a Borrower unless such Subsidiary has also guaranteed the Obligations pursuant to a guarantee in form and substance reasonably satisfactory to the Administrative Agent), (ii) no Subsidiary other than a Borrower shall
Guarantee the Indebtedness of any Special Purpose Entity and (iii) any Guarantee by a Borrower of the Indebtedness of a Special Purpose Entity shall rank pari passu with, or be subordinated to, the Obligations; 

(e) Indebtedness in respect of Trust Preferred Securities or other instruments of the same or a similar character issued by a trust or other
special purpose entity formed by a Borrower as to which no Subsidiary (other than a Borrower, such trust or other special purpose entity) has any obligation, together with all guaranty obligations owing by a Borrower in respect thereof and
constituting Subordinated Indebtedness; 
 (f) Indebtedness assumed in connection with any Acquisition, provided that such
Indebtedness is not incurred in contemplation of such Acquisition and no other Subsidiary (other than the Subsidiary being acquired, if applicable) has any liability or obligations in respect of such Indebtedness; 

(g) Indebtedness in respect of (i) collateralized letters of credit in the ordinary course of business of insurance or reinsurance
operations or (ii) fully collateralized letters of credit which are to support the capital requirements applicable to the Borrowers or any Subsidiary at Lloyd’s of London; 

(h) Indebtedness in respect of letters of credit in the ordinary course of business in an outstanding undrawn face amount and/or unreimbursed
drawn amount not to exceed $10,000,000 in the aggregate at any time; 
 (i) Indebtedness incurred by the Borrowers and Special Purpose
Entities in addition to the foregoing to the extent that after giving effect thereto the Borrowers are in compliance with Section 6.09; and 

Indebtedness incurred by the Subsidiaries of the Borrowers (which Subsidiaries are not themselves Borrowers), provided that the aggregate outstanding
principal amount of Indebtedness permitted by this clause shall not at any time exceed $25,000,000. 
 For purposes of determining compliance with this
Section 6.01, the Borrowers will be entitled to divide an item of Indebtedness that meets the criteria of one of the categories of Indebtedness described in clauses (a) through (j) above between such applicable clause and any other
clause of this Section 6.01 the criteria of which such item of Indebtedness also meets. 

  
 66 

 SECTION 6.02. Liens. The Borrowers will not, and will not permit any Subsidiary to,
create, incur, assume or permit to exist any Lien on any property or asset now owned or hereafter acquired by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect of any thereof, except: 

(a) Permitted Encumbrances; 
 (b)
Liens which (x) do not secure Indebtedness and (y) are incurred in the ordinary course of business, including Liens granted in connection with any Swap Agreement or investments, trades, facilities or other arrangements with any
counterparty, securities or other broker/dealer or clearing exchange; provided that the aggregate amount of all obligations secured pursuant to this clause (b) shall at no time exceed $100,000,000; and 

Liens on cash or debt securities and other investments pursuant to Section 6.04(a) securing (i) Indebtedness permitted pursuant to
Section 6.01(g) or (ii) obligations under or in respect of any Primary Policy, Reinsurance Agreement, Industry Loss Warranty and/or collateralized trusts, withheld balances or other collateral or security arrangements in the ordinary
course of reinsurance or insurance business. 
 For purposes of determining compliance with this Section 6.02, the Borrowers will be entitled to divide
an item of Liens that meets the criteria of one of the categories of Liens described in clauses (a) and (b) above between or among such applicable clause and any other clause of this Section 6.02 the criteria of which such item of
Liens also meets. 
 SECTION 6.03. Fundamental Changes. (a) The Borrowers will not, and will not permit any Subsidiary to, merge
into or consolidate with any other Person, or permit any other Person to merge into or consolidate with it, or liquidate or dissolve, except that, if at the time thereof and immediately after giving effect thereto no Default shall have occurred and
be continuing (i) any Subsidiary may merge into a Borrower in a transaction in which such Borrower is the surviving corporation, (ii) any Subsidiary (other than a Borrower) may merge into any Subsidiary in a transaction in which the
surviving entity is a Subsidiary, (iii) a Person may be merged into a Borrower or any Subsidiary pursuant to a Permitted Acquisition, and (iv) any Subsidiary (other than a Borrower) may liquidate or dissolve if the Borrowers determine in
good faith that such liquidation or dissolution is in the best interests of the Borrowers and is not materially disadvantageous to the Lenders; provided that any such merger involving a Person that is not a wholly owned Subsidiary immediately
prior to such merger shall not be permitted unless also permitted by Section 6.04. 
 The Borrowers will not, nor will they permit any
Subsidiary to, make any Asset Disposition except for (i) Asset Dispositions expressly permitted by Sections 6.04, 6.06 or 6.07 and (ii) other Asset Dispositions of property that, together with all other property of the Borrowers and the
Subsidiaries previously leased, sold or disposed of in Asset Dispositions made pursuant to Section 6.03(b) during the twelve-month period ending with the month in which any such lease, sale or other disposition occurs, do not constitute a
Substantial Portion of the property of the Parent and its Subsidiaries; provided that under no circumstances shall the Equity Interests in a Borrower be included in a permitted Asset Disposition. 

(b) The Borrowers will not, and will not permit any Subsidiary to, engage to any material extent in any business other than businesses of the
type conducted by the Parent and its Subsidiaries on the date of execution of this Agreement and businesses complementary, reasonably related or incidental thereto. 

  
 67 

 SECTION 6.04. Investments and Acquisitions. The Borrowers will not, and will not permit
any Subsidiary to, purchase, hold or acquire (including pursuant to any merger with any Person that was not a Wholly-Owned Subsidiary prior to such merger) any capital stock or other equity securities (including any option, warrant or other right to
acquire any of the foregoing) of any other Person, or purchase or otherwise acquire (in one transaction or a series of transactions) any assets of any other Person constituting a business unit, except: 

(a) investments complying with the terms of the Argo Investment Policy; 

(b) subject to the provisions of this Section 6.04 and, as applicable, the requirements contained in the definition of Permitted
Acquisition, the Parent and its Wholly-Owned Subsidiaries may from time to time (i) effect Permitted Acquisitions for aggregate consideration (including Equity Interests and the assumption of Indebtedness) such that the Borrowers remain in
compliance with the financial covenants set forth in Sections 6.09 and 6.10 and (ii) make investments in joint ventures; provided that (A) no Default is existing either at the time of the consummation of such proposed investment and
immediately after giving effect thereto; (B) with respect to any such proposed investment for aggregate consideration (including Equity Interests and the assumption of Indebtedness) exceeding $50,000,000, (1) the Rating shall be at least
BBB - both immediately before the consummation of such proposed investment and immediately after giving effect thereto (and after giving effect to any adjustment of the Rating associated with the consummation of such proposed investment) and
(2) the Administrative Agent shall have received written notice of any such proposed investment and information materials related thereto in form and substance reasonably satisfactory to it from the Borrower Representative not less than 7 days
prior to the consummation of such investment and (C) the aggregate amount invested in joint ventures pursuant to this Section 6.04(b) (valued at initial cost less capital distributions) shall not exceed $50,000,000; 

(c) investments of any Person in existence at the time such Person becomes a Subsidiary pursuant to a Permitted Acquisition; provided
that such investment was not made in connection with or in anticipation of such Person becoming a Subsidiary; and 
 (d) investments by the
Parent or any Subsidiary in the capital stock of a Subsidiary. 
 SECTION 6.05. Swap Agreements. The Borrowers will not, and will not
permit any Subsidiary to, enter into any Swap Agreement, except (a) non-speculative Swap Agreements entered into to hedge or mitigate risks to which a Borrower or any Subsidiary has (or reasonably expects to have) actual exposure (other than
those in respect of Equity Interests of a Borrower or any of its Subsidiaries), (b) non-speculative Swap Agreements entered into in order to effectively cap, collar or exchange interest rates (from fixed to floating rates, from one floating
rate to another floating rate or otherwise) with respect to any interest-bearing liability or investment of a Borrower or any Subsidiary and (c) Swap Agreements entered into in connection with any Restricted Payments permitted to be made under
Section 6.06(a)(ii). 

  
 68 

 SECTION 6.06. Restricted Payments. The Borrowers will not, and will not permit any
Subsidiary to, declare, pay or make, or agree to declare, pay or make, directly or indirectly, any Restricted Payment, except: 
 (a) (i) the
Parent may declare and pay publicly announced and regularly scheduled dividends on its issued and outstanding common stock that is traded publicly on a national securities exchange, and (ii) the Parent or any Subsidiary may make stock
repurchases and other Restricted Payments, in each case of or relating to the Equity Interests of the Parent, after the Effective Date; provided, however that no Restricted Payment shall be permitted to be declared, and no Restricted
Payment (other than dividends declared in compliance herewith) shall be permitted to be paid, under this clause (a) if any Default is existing either at the time of the proposed Restricted Payment or immediately after giving effect thereto;

 (b) the Parent may pay dividends payable solely in its common stock; 

(c) any Subsidiary may declare and pay or make Restricted Payments to any of the Borrowers or to a Wholly-Owned Subsidiary provided,
however, that Argo US shall not make any Restricted Payment pursuant to this clause (c) upon the occurrence and during the continuance of a Default or if a Default would result therefrom; and 

(d) the Parent or any Subsidiary may make Restricted Payments in respect of Trust Preferred Securities or other instruments described in
Section 6.01(e) so long as no Default is existing either at the time of the proposed Restricted Payment or immediately thereafter. 

SECTION 6.07. Transactions with Affiliates. The Borrowers will not, and will not permit any Subsidiary to, sell, lease or otherwise
transfer any property or assets to, or purchase, lease or otherwise acquire any property or assets from, or otherwise engage in any other transactions with, any of its Affiliates, except (a) in the ordinary course of business at prices and on
terms and conditions not less favorable to such Borrower or such Subsidiary than could be obtained on an arm’s-length basis from unrelated third parties, (b) transactions between or among the Parent and its Wholly Owned Subsidiaries not
involving any other Affiliate, (c) any Restricted Payment permitted by Section 6.06 and (d) as permitted by Section 6.01(d) or Section 6.04. 

SECTION 6.08. Restrictive Agreements. The Borrowers will not, and will not permit any Subsidiary to, directly or indirectly, enter into,
incur or permit to exist any agreement or other arrangement that prohibits, restricts or imposes any condition upon (a) the ability of the Borrowers or any Subsidiary to create, incur or permit to exist any Lien upon any of its property or
assets to secure the obligations of the Borrowers hereunder or under any guaranty thereof, or (b) the ability of any Subsidiary to pay dividends or other distributions with respect to its Equity Interests or to make or repay loans or advances
to the Borrowers or any other Subsidiary or to Guarantee Indebtedness of the Borrowers or any other Subsidiary; provided that (i) the foregoing shall not apply to restrictions and conditions imposed by law or by this Agreement,
(ii) the foregoing shall not apply to restrictions and conditions existing on the date hereof identified on Schedule 6.08 (but shall apply to any extension or renewal of, or any amendment or modification expanding the scope of, any such
restriction or condition) or to restrictions and conditions similar to those set forth in the Trust Preferred Securities upon the ability of special purpose trust 

  
 69 

 
Subsidiaries and other entities to pay dividends or make distributions related to Indebtedness of the same or similar character as the Trust Preferred Securities, (iii) the foregoing shall
not apply to customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary or assets pending such sale, provided that such restrictions and conditions apply only to the Subsidiary or assets to be sold and
such sale is permitted hereunder, (iv) clause (a) of the foregoing shall not apply to restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Agreement if such restrictions or conditions apply
only to the property or assets securing such Indebtedness and (v) clause (a) of the foregoing shall not apply to customary provisions in leases and other contracts restricting the assignment thereof. 

SECTION 6.09. Maximum Leverage Ratio. The Borrowers will not permit the Leverage Ratio to exceed .35 to 1.00 at any time. 

SECTION 6.10. Tangible Net Worth. The Parent will not permit at any time its Tangible Net Worth to be less than the sum of
(i) $838,300,000 plus (ii) 50% of the positive Net Income of the Parent and its subsidiaries for each fiscal quarter ending after September 30, 2013 plus (iii) 50% of the net proceeds received by the Parent and its Subsidiaries
from the issuance and sale of Equity Interests of the Parent or any Subsidiary (other than the issuance to the Parent or a Wholly-Owned Subsidiary), including any conversion of debt securities of the Parent or any Subsidiary into Equity Interests
after September 30, 2013. 
 SECTION 6.11. Sale and Leaseback Transactions. Except for Sale and Leaseback Transactions entered
into in the ordinary course of business with respect to real property owned by the Borrowers on the Effective Date or acquired thereafter pursuant to a Permitted Acquisition or with respect to any personal property, the Borrowers will not, and will
not permit any Subsidiary to, enter into or suffer to exist any Sale and Leaseback Transaction. 
 SECTION 6.12. Rating. All
Significant Insurance Subsidiaries of Argo US will at all times maintain an AM Best Financial Strength Rating of at least B++. 
 ARTICLE VII

 Events of Default 

If any of the following events (“Events of Default”) shall occur: 

(a) any of the Borrowers shall fail to pay any principal of any Loan or any reimbursement obligation in respect of any LC Disbursement or any
cash collateral amount due pursuant to Section 2.06(j) when and as the same shall become due and payable (including under Section 2.20 hereof), whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; 

(b) any of the Borrowers shall fail to pay any interest on any Loan or any fee or any other amount (other than an amount referred to in clause
(a) of this Article) payable under this Agreement, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three Business Days; 

  
 70 

 (c) any representation or warranty made or deemed made by or on behalf of the Borrowers or any
Subsidiary in or in connection with this Agreement or any amendment or modification hereof or waiver hereunder, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any
amendment or modification hereof or waiver hereunder, shall prove to have been incorrect when made or deemed made; 
 (d) the Borrowers shall
fail to observe or perform any covenant, condition or agreement contained in Sections 5.02, 5.03 (with respect to any Borrower’s existence), 5.08 or in Article VI; 

(e) the Borrowers shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified
in clause (a), (b) or (d) of this Article), and such failure shall continue unremedied for a period of 30 days after notice thereof from the Administrative Agent to the Borrower Representative (which notice will be given at the request of
any Lender); 
 (f) any of the Borrowers or any Subsidiary shall fail to make any payment (whether of principal or interest and regardless of
amount) in respect of any Material Indebtedness (other than the Obligations), when and as the same shall become due and payable (giving effect to any applicable cure period relating thereto); 

(g) any event or condition occurs that results in any Material Indebtedness or any Trust Preferred Security Indebtedness becoming due prior to
its scheduled maturity or that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of any Material Indebtedness or Trust Preferred Security Indebtedness or any trustee or agent on its or their
behalf to cause any Material Indebtedness or Trust Preferred Security Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this clause
(g) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness; 

(h) an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, winding-up,
administration, reorganization or other relief in respect of any of the Borrowers or any Significant Subsidiary or its debts, or of a substantial part of its assets, under any Federal, state or foreign bankruptcy, insolvency, administration,
receivership or similar law now or hereafter in effect or (ii) the appointment of a liquidator, receiver, trustee, custodian, sequestrator, conservator, administrator, administrative receiver or similar official for any of the Borrowers or any
Significant Subsidiary or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for 60 days or an order or decree approving or ordering any of the foregoing shall be entered; 

(i) any of the Borrowers or any Significant Subsidiary shall (i) voluntarily commence any proceeding or file any petition seeking
liquidation, winding-up, administration, reorganization or other relief under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, (ii) consent to the institution of, or fail to contest
in a timely and appropriate manner, any proceeding or petition described in clause (h) of 

  
 71 

 
this Article, (iii) apply for or consent to the appointment of a liquidator, receiver, trustee, custodian, sequestrator, conservator, administrator or similar official for any of the
Borrowers or any Significant Subsidiary or for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of
creditors or (vi) take any action for the purpose of effecting any of the foregoing; 
 (j) any Borrower or any Significant Subsidiary
shall become unable, admit in writing its inability or fail generally to pay its debts as they become due; 
 (k) one or more judgments for
the payment of money in an aggregate amount in excess of $20,000,000 shall be rendered against any Borrower, any Significant Subsidiary or any combination thereof and the same shall remain undischarged for a period of 45 consecutive days during
which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Borrower or any Significant Subsidiary to enforce any such judgment; 

(l) an ERISA Event or circumstance in respect of any Foreign Pension Plan shall have occurred that, in the opinion of the Required Lenders,
when taken together with all other ERISA Events and such circumstances that have occurred, could reasonably be expected to result in a Material Adverse Effect and continues unremedied for five (5) Business Days; 

(m) a Change in Control shall occur; 

(n) obligations owing in connection with the Trust Preferred Securities or any other Subordinated Indebtedness shall at any time and for any
reason cease to be fully subordinated to the Obligations outstanding in connection with the Credit Documents; 
 (o) any governmental
authority revokes or fails to renew any material license, permit or franchise of any Borrower or any Significant Insurance Subsidiary, or any Borrower or any Significant Insurance Subsidiary for any reason loses any material license, permit or
franchise, or any Borrower or any Significant Insurance Subsidiary suffers the imposition of any restraining order, escrow, suspension or impound of funds in connection with any proceeding (judicial or administrative) with respect to any material
license, permit or franchise, which could reasonably be expected to result in losses or liability of the Borrowers or any of the Significant Insurance Subsidiaries, individually or in the aggregate, in excess of $10,000,000 and such event shall
continue unremedied for a period of five (5) Business Days; 
 then, and in every such event (other than an event with respect to any of the Borrowers
described in clause (h) or (i) of this Article), and at any time thereafter during the continuance of such event, the Administrative Agent may, and at the request of the Required Lenders shall, by notice to the Borrower Representative,
take either or both of the following actions, at the same or different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in
whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest
thereon and all fees and other obligations of the 

  
 72 

 
Borrowers accrued hereunder, shall become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrowers; and in
case of any event with respect to any of the Borrowers described in clause (h) or (i) of this Article, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon
and all fees and other obligations of the Borrowers accrued hereunder, shall automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrowers. 

ARTICLE VIII 
 The
Administrative Agent 
 Each of the Lenders and the Issuing Bank hereby irrevocably appoints the Administrative Agent as its agent and
authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof, together with such actions and powers as are reasonably incidental thereto. 

The bank serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender
and may exercise the same as though it were not the Administrative Agent, and such bank and its Affiliates may accept deposits from, lend money to and generally engage in any kind of business with the Borrowers or any Subsidiary or other Affiliate
thereof as if it were not the Administrative Agent hereunder. 
 The Administrative Agent shall not have any duties or obligations except
those expressly set forth herein. Without limiting the generality of the foregoing, (a) the Administrative Agent shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing,
(b) the Administrative Agent shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby that the Administrative Agent is required to
exercise in writing as directed by the Required Lenders (or such other number or percentage of the Lenders as shall be necessary under the circumstances as provided in Section 9.02), and (c) except as expressly set forth herein, the
Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrowers or any of its Subsidiaries that is communicated to or obtained by the bank serving as
Administrative Agent or any of its Affiliates in any capacity. The Administrative Agent shall not be liable for any action taken or not taken by it with the consent or at the request of the Required Lenders (or such other number or percentage of the
Lenders as shall be necessary under the circumstances as provided in Section 9.02) or in the absence of its own gross negligence or willful misconduct. The Administrative Agent shall be deemed not to have knowledge of any Default unless and
until written notice thereof is given to the Administrative Agent by the Borrower Representative or a Lender, and the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or
representation made in or in connection with this Agreement, (ii) the contents of any certificate, report or other document delivered hereunder or in connection herewith, (iii) the performance or observance of any of the covenants,
agreements or other terms or conditions set forth herein, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth
in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. 

  
 73 

 The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for
relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing believed by it to be genuine and to have been signed or sent by the proper Person. The Administrative Agent also may rely upon any statement
made to it orally or by telephone and believed by it to be made by the proper Person, and shall not incur any liability for relying thereon. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrowers), independent
accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 

The Administrative Agent may perform any and all its duties and exercise its rights and powers by or through any one or more sub-agents
appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all its duties and exercise its rights and powers through their respective Related Parties. The exculpatory provisions of the preceding
paragraphs shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for
herein as well as activities as Administrative Agent. 
 Subject to the appointment and acceptance of a successor Administrative Agent as
provided in this paragraph, the Administrative Agent may resign at any time by notifying the Lenders, the Issuing Bank and the Borrowers. Upon any such resignation, the Required Lenders shall have the right, in consultation with the Borrowers, to
appoint a successor. If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation, then the retiring
Administrative Agent may, on behalf of the Lenders and the Issuing Bank, appoint a successor Administrative Agent which shall be a bank with an office in New York, New York, or an Affiliate of any such bank. Upon the acceptance of its appointment as
Administrative Agent hereunder by a successor, such successor shall succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall be discharged from
its duties and obligations hereunder. The fees payable by the Borrowers to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrowers and such successor. After the
Administrative Agent’s resignation hereunder, the provisions of this Article and Section 9.03 shall continue in effect for the benefit of such retiring Administrative Agent, its sub agents and their respective Related Parties in respect of
any actions taken or omitted to be taken by any of them while it was acting as Administrative Agent. 
 If the Person serving as
Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, the Required Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrower and such Person remove such Person as
Administrative Agent and, in consultation with the Borrowers, appoint a successor. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days (or such earlier day as shall be
agreed by the Required Lenders) (the “Removal Effective Date”), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date. 

  
 74 

 Each Lender acknowledges and agrees that the extensions of credit made hereunder are commercial
loans and letters of credit and not investments in a business enterprise or securities. Each Lender further represents that it is engaged in making, acquiring or holding commercial loans in the ordinary course of its business and has, independently
and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement as a Lender, and to make, acquire
or hold Loans hereunder. Each Lender shall, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information (which may contain material, non-public information within the meaning of
the United States securities laws concerning the Borrowers and their Affiliates) as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any related
agreement or any document furnished hereunder or thereunder and in deciding whether or to the extent to which it will continue as a lender or assign or otherwise transfer its rights, interests and obligations hereunder. 

The Administrative Agent shall be permitted from time to time to designate one of its Affiliates to perform the duties to be performed by the
Administrative Agent hereunder with respect to Loans and Borrowings denominated in Foreign Currencies. The provisions of this Article VIII shall apply to any such Affiliate mutatis mutandis. 

The Lenders identified on the front page of this Agreement as Syndication Agent or Co-Documentation Agents shall not have any right, power,
obligation, liability, responsibility or duty under this Agreement other than those applicable to all Lenders as such. Without limiting the foregoing, none of such Lenders shall have or be deemed to have a fiduciary relationship with any Lender.
Each Lender hereby makes the same acknowledgments with respect to such Lenders as it makes with respect to the Administrative Agent in this Article VIII. 

ARTICLE IX 
 Miscellaneous

 SECTION 9.01. Notices. (a) Except in the case of notices and other communications expressly permitted to be given by
telephone (and subject to paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by
telecopy, as follows: 
 (i) if to any Borrower, to it c/o Argo Group US, Inc., 10101 Reunion Place, Suite 500, San Antonio,
Texas 78216, Attention of Jay Bullock, (Telecopy No. (210) 377-2637); with a copy to Lynn Geurin, (email: lgeurin@argogroupus.com) and Craig Comeaux, (email: ccomeaux@argogroupus.com); 

  
 75 

 (ii) if to the Administrative Agent, to JPMorgan Chase Bank, N.A., 10 S.
Dearborn, 9th Floor, Suite IL1-0364, Chicago, IL 60603, Attention of Danielle Babine (Telecopy No. (312) 325-3190); 

(iii) if to the Administrative Agent for Eurocurrency Loans in Foreign Currencies, to J.P. Morgan Europe Limited, 125 London
Wall, London EC1W 2JD, Attention of Ching Loh/The Manager, Telecopy No. +44(0) 207 777 2360); 
 (iv) if to the Issuing
Bank, to it at JPMorgan Chase Bank, N.A., 10 S. Dearborn, 9th Floor, Suite IL1-0364, Chicago, IL 60603, Attention of Danielle Babine (Telecopy No. (312) 325-3190); and 

(v) if to any other Lender, to it at its address (or telecopy number) set forth in its Administrative Questionnaire. 

Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent
by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for the recipient). Notices
delivered through Electronic Systems, to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b). 

(b) Notices and other communications to the Lenders hereunder may be delivered or furnished by using Electronic Systems electronic
communications pursuant to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices pursuant to Article II unless otherwise agreed by the Administrative Agent and the applicable Lender. The
Administrative Agent or the Borrower Representative may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that approval of such
procedures may be limited to particular notices or communications. 
 Unless the Administrative Agent otherwise prescribes, (i) notices
and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail
or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient, at its e-mail address as described in the foregoing
clause (i), of notification that such notice or communication is available and identifying the website address therefor; provided that, for both clauses (i) and (ii) above, if such notice, email or other communication is not
sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient. 

(c) Any party hereto may change its address or telecopy number for notices and other communications hereunder by notice to the other parties
hereto. All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of receipt. 

  
 76 

 (d) Electronic Systems. 

(i) Each Borrower agrees that the Administrative Agent may, but shall not be obligated to, make Communications (as defined
below) available to the Issuing Banks and the other Lenders by posting the Communications on Debt Domain, Intralinks, Syndtrak, ClearPar or a substantially similar Electronic System. 

(ii) Any Electronic System used by the Administrative Agent is provided “as is” and “as available.” The
Agent Parties (as defined below) do not warrant the adequacy of such Electronic Systems and expressly disclaim liability for errors or omissions in the Communications. No warranty of any kind, express, implied or statutory, including, without
limitation, any warranty of merchantability, fitness for a particular purpose, non-infringement of third-party rights or freedom from viruses or other code defects, is made by any Agent Party in connection with the Communications or any Electronic
System. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrowers, any Lender, the Issuing Bank or any other Person or entity for damages of any kind,
including, without limitation, direct or indirect, special, incidental or consequential damages, losses or expenses (whether in tort, contract or otherwise) arising out of any Borrower’s or the Administrative Agent’s transmission of
Communications through an Electronic System. “Communications” means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of any Borrower pursuant to any Credit Document or the
transactions contemplated therein which is distributed by the Administrative Agent, any Lender or any Issuing Bank by means of electronic communications pursuant to this Section, including through an Electronic System. 

SECTION 9.02. Waivers; Amendments. (a) No failure or delay by the Administrative Agent, the Issuing Bank or any Lender in
exercising any right or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or
further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent, the Issuing Bank and the Lenders hereunder are cumulative and are not exclusive of any rights or remedies that they would
otherwise have. No waiver of any provision of this Agreement or consent to any departure by the Borrowers therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) of this Section, and then such waiver or
consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan or issuance of a Letter of Credit shall not be construed as a waiver of any Default,
regardless of whether the Administrative Agent, any Lender or the Issuing Bank may have had notice or knowledge of such Default at the time. 

(b) Neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing
entered into by the Borrowers and the Required Lenders or by the Borrowers and the Administrative Agent with the consent of the Required Lenders; provided that no such agreement shall (i) increase the Commitment of any Lender without the
written consent of such Lender, (ii) reduce the principal amount of any Loan or LC Disbursement or reduce the rate of interest thereon, or reduce any 

  
 77 

 
fees payable hereunder, without the written consent of each Lender affected thereby, (iii) postpone the scheduled date of payment of the principal amount of any Loan or LC Disbursement, or
any interest thereon, or any fees payable hereunder, or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date of expiration of any Commitment, without the written consent of each Lender affected thereby,
(iv) change any portion of this Agreement in a manner that would alter the pro rata nature of payments, loans and Commitment reductions under this Agreement, without the written consent of each Lender, (v) change any of the provisions of
this Section or the definitions of “Required Lenders” or any other provision hereof specifying the number or percentage of Lenders required to waive, amend or modify any rights hereunder or make any determination or grant any consent
hereunder, without the written consent of each Lender, (vi) release any Borrower from any of its joint and several liabilities in respect of the Obligations without the written consent of each Lender or (vii) change any provision of
Sections 2.06(c), 2.06(j), 2.10(g) or 2.10(h) without the consent of each Lender adversely affected thereby; provided further that no such agreement shall amend, modify or otherwise affect the rights or duties of the Administrative
Agent or the Issuing Bank hereunder without the prior written consent of the Administrative Agent or the Issuing Bank, as the case may be. 

(c) Notwithstanding the foregoing, Schedule 3.11 hereto shall be deemed amended without the consent of any other party solely to reflect
revisions or supplements of the type described in the parenthetical in the first sentence of Section 3.11 upon the delivery by the Borrower Representative to the Administrative Agent of a revised Schedule 3.11 reflecting such revisions and
supplements. 
 (d) Notwithstanding the foregoing, no amendment or amendment and restatement of this Agreement which is in all other respects
approved by the Lenders in accordance with this Section 9.02 shall require the consent or approval of any Lender (i) which immediately after giving effect to such amendment or amendment and restatement, shall have no Commitment or
other obligation to maintain or extend credit under this Agreement (as so amended or amended and restated), including, without limitation, any obligation in respect of any drawing under or participation in any Letter of Credit and (ii) which,
substantially contemporaneously with the effectiveness of such amendment or amendment and restatement, is paid in full all amounts owing to it hereunder (including, without limitation principal, interest and fees, but excluding unmatured contingent
obligations). From and after the effectiveness of any such amendment or amendment and restatement, any such Lender shall be deemed to no longer be a “Lender” hereunder or a party hereto; provided, that any such Lender shall retain
the benefit of indemnification and other provisions hereof which, by the terms hereof would survive a termination of this Agreement. 
 (e)
Notwithstanding the foregoing, upon the execution and delivery of all documentation required by Section 2.09(e) to be delivered in connection with an increase to the aggregate Commitments, the Administrative Agent, the Borrowers and the new or
existing Lenders whose Commitments have been affected may and shall enter into an amendment hereof (which shall be binding on all parties hereto and the new Lenders) solely for the purpose of reflecting any new Lenders and their new Commitments and
any increase in the Commitment of any existing Lender. 

  
 78 

 (f) Notwithstanding the foregoing, the Administrative Agent and the Borrowers may amend any
Credit Document to correct administrative or technical errors or omissions, or to effect administrative changes that are not adverse to any Lender and any such amendment shall become effective without any further consent of any other party to such
Credit Document. 
 SECTION 9.03. Expenses; Indemnity; Damage Waiver. (a) The Borrowers shall pay (i) all reasonable,
documented out of pocket expenses incurred by the Administrative Agent and its Affiliates, including the reasonable fees, charges and disbursements of one firm of legal counsel for the Administrative Agent plus any required local counsel, in
connection with the syndication of the credit facilities provided for herein, the preparation and administration of this Agreement or any amendments, modifications or waivers of the provisions hereof (whether or not the transactions contemplated
hereby or thereby shall be consummated), (ii) without duplication of amounts otherwise payable hereunder, all reasonable, documented out-of-pocket expenses incurred by the Issuing Bank in connection with the issuance, amendment, renewal or
extension of any Letter of Credit or any demand for payment thereunder and (iii) all reasonable, documented out-of-pocket expenses incurred by the Administrative Agent, the Issuing Bank or any Lender, including the fees, charges and
disbursements of (A) (1) one primary counsel and, as deemed appropriate by the Administrative Agent, one additional local counsel and/or regulatory counsel in each applicable jurisdiction for the Administrative Agent and (2) one
primary counsel and, as deemed appropriate by the Lenders, one additional local and/or regulatory counsel for all the Lenders in each applicable jurisdiction (as well as additional counsel for the Lenders in light of actual or potential conflicts of
interest), and (B) a financial advisor for the Administrative Agent, the Issuing Bank and the Lenders, in connection with the enforcement or protection of its rights in connection with this Agreement, including its rights under this Section, or
in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit. 

(b) The Borrowers shall indemnify the Administrative Agent, the Issuing Bank and each Lender, and each Related Party of any of the foregoing
Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, penalties, liabilities and related expenses, including the fees, charges and disbursements
of any counsel for any Indemnitee, incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement or any agreement or instrument contemplated hereby, the
performance by the parties hereto of their respective obligations hereunder or the consummation of the Transactions or any other transactions contemplated hereby, (ii) any Loan or Letter of Credit or the use of the proceeds therefrom (including
any refusal by the Issuing Bank to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged
presence or release of Hazardous Materials on or from any property owned or operated by the Borrowers or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrowers or any of its Subsidiaries, or (iv) any actual
or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by any Borrower or any of the Borrowers’ directors,
shareholders or creditors, and regardless of whether any Indemnitee is a party thereto; provided  

  
 79 

 
that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses resulting from the gross negligence or willful
misconduct of such Indemnitee. This Section 9.03(b) shall not apply with respect to Taxes other than any Taxes that represent losses, claims or damages arising from any non-Tax claim. 

(c) To the extent that the Borrowers fail to pay any amount required to be paid by them to the Administrative Agent or the Issuing Bank under
paragraph (a) or (b) of this Section, each Lender severally agrees to pay to the Administrative Agent or the Issuing Bank, as the case may be, such Lender’s Revolving Commitment Exposure Percentage (determined as of the time that the
applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted
against the Administrative Agent or the Issuing Bank in its capacity as such. 
 (d) To the extent permitted by applicable law, the Borrowers
shall not assert, and hereby waive, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result
of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Loan or Letter of Credit or the use of the proceeds thereof; provided that, nothing in this clause (d) shall relieve any Borrower of any
obligation it may have to indemnify an Indemnitee against special, indirect, consequential or punitive damages asserted against such Indemnitee by a third party. 

(e) All amounts due under this Section shall be payable not later than ten days after written demand therefor. 

SECTION 9.04. Successors and Assigns. (a) The provisions of this Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and assigns permitted hereby (including any Affiliate of the Issuing Bank that issues any Letter of Credit), except that (i) the Borrowers may not assign or otherwise transfer any of their
respective rights or obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by the Borrowers without such consent shall be null and void) and (ii) no Lender may assign or otherwise
transfer its rights or obligations hereunder except in accordance with this Section. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and
assigns permitted hereby (including any Affiliate of the Issuing Bank that issues any Letter of Credit), Participants (to the extent provided in paragraph (c) of this Section) and, to the extent expressly contemplated hereby, the Related
Parties of each of the Administrative Agent, the Issuing Bank and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. 

(b) (i) Subject to the conditions set forth in paragraph (b)(ii) below, any Lender may assign to one or more assignees (other than an
Ineligible Institution) all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it) with the prior written consent (such consent not to be unreasonably
withheld) of: 

  
 80 

 (ii) the Parent; provided that after the passage of ten (10) Business
Days from receipt of written notice to the Parent from the Administrative Agent of a proposed assignment without the Parent giving the Administrative Agent written notice of the Parent’s objection to such assignment, the Parent shall be deemed
to have consented to such assignment; provided further that no consent of the Parent shall be required for an assignment to a Lender, an Affiliate of a Lender, an Approved Fund or, if an Event of Default has occurred and is continuing, any
other assignee; 
 (iii) the Administrative Agent, provided that no consent of the Administrative Agent shall be
required for an assignment of any Commitment to an assignee that is a Lender with a Commitment immediately prior to giving effect to such assignment; and 

(iv) the Issuing Bank. 

(v) Assignments shall be subject to the following additional conditions: 

(vi) except in the case of an assignment to a Lender or an Affiliate of a Lender or an assignment of the entire remaining
amount of the assigning Lender’s Commitment or Loans, the amount of the Commitment or Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is
delivered to the Administrative Agent) shall not be less than $5,000,000 unless the Parent and the Administrative Agent otherwise consent, provided that no such consent of the Parent shall be required if an Event of Default has occurred and
is continuing; 
 (vii) each partial assignment shall be made as an assignment of a proportionate part of all the assigning
Lender’s rights and obligations under this Agreement; 
 (viii) the parties to each assignment shall execute and deliver
to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee of $3,500; and 

(ix) the assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire in
which the assignee designates one or more credit contacts to whom all syndicate-level information (which may contain material non-public information about the Borrowers and their affiliates and their Related Parties or their respective securities)
will be made available and who may receive such information in accordance with the assignee’s compliance procedures and applicable laws, including Federal and state securities laws. 

For the purposes of this Section 9.04(b), the term “Approved Fund” and “Ineligible Institution” have
the following meanings: 
 “Approved Fund” means any Person (other than a natural person) that is engaged in making,
purchasing, holding or investing in bank loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate
of an entity that administers or manages a Lender. 

  
 81 

 “Ineligible Institution” means (a) a natural person, (b) a Defaulting
Lender, (c) any Borrower or any of their Affiliates, or (d) a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural person or relative(s) thereof. 

(x) Subject to acceptance and recording thereof pursuant to paragraph (b)(iv) of this Section, from and after the effective
date specified in each Assignment and Assumption the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the
assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning
Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Sections 2.15, 2.16, 2.17 and 9.03). Any assignment or transfer by a Lender of rights or
obligations under this Agreement that does not comply with this Section 9.04 shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (c) of
this Section. 
 (xi) The Administrative Agent, acting for this purpose as an agent of the Borrowers, shall maintain at one
of its offices a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount of the Loans and LC Disbursements owing to, each Lender
pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive, and the Borrowers, the Administrative Agent, the Issuing Bank and the Lenders shall treat each Person whose name is
recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrowers, the Issuing Bank and any Lender,
at any reasonable time and from time to time upon reasonable prior notice. 
 (xii) Upon its receipt of a duly completed
Assignment and Assumption executed by an assigning Lender and an assignee, the assignee’s completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in
paragraph (b) of this Section and any written consent to such assignment required by paragraph (b) of this Section, the Administrative Agent shall accept such Assignment and Assumption and record the information contained therein in
the Register; provided that if either the assigning Lender or the assignee shall have failed to make any payment required to be made by it pursuant to Section 2.06(d) or (e), 2.07(b), 2.18(d) or 9.03(c), the Administrative Agent shall
have no obligation to accept such Assignment and Assumption and record the information therein in the Register unless and until such payment shall have been made in full, together with all accrued interest thereon. No assignment shall be effective
for purposes of this Agreement unless it has been recorded in the Register as provided in this paragraph. 

  
 82 

 (c) Any Lender may, without the consent of the Borrowers, the Administrative Agent or the Issuing
Bank, sell participations to one or more banks or other entities (a “Participant”) other than an Ineligible Institution in all or a portion of such Lender’s rights and obligations under this Agreement (including all or a
portion of its Commitment and the Loans owing to it); provided that (A) such Lender’s obligations under this Agreement shall remain unchanged, (B) such Lender shall remain solely responsible to the other parties hereto for the
performance of such obligations and (C) the Borrowers, the Administrative Agent, the Issuing Bank and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations
under this Agreement. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any
provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in the first proviso to
Section 9.02(b) that affects such Participant. The Borrowers agrees that each Participant shall be entitled to the benefits of Sections 2.15, 2.16 and 2.17 (subject to the requirements and limitations therein, including the requirements
under 2.17(f) and (g) (it being understood that the documentation required under Section 2.17(f) shall be delivered to the participating Lender and the information and documentation required under 2.17(g) will be delivered to the Borrowers
and the Administrative Agent)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the
provisions of Section 2.19 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Section 2.15 or 2.17, with respect to any participation, than its
participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation. Each Lender that sells
a participation agrees, at any Borrower’s request and expense, to use reasonable efforts to cooperate with such Borrower to effectuate the provisions of Section 2.19(b) with respect to any Participant. To the extent permitted by law, each
Participant also shall be entitled to the benefits of Section 9.08 as though it were a Lender; provided that such Participant agrees to be subject to Section 2.18(c) as though it were a Lender. Each Lender that sells a participation
shall, acting solely for this purpose as a non-fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in
the Loans or other obligations under the Credit Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of
any Participant or any information relating to a Participant’s interest in any Commitments or its other obligations under any Credit Document) to any Person except to the extent that such disclosure is necessary to establish that such
Commitment or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person
whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as
Administrative Agent) shall have no responsibility for maintaining a Participant Register. 

  
 83 

 (d) Any Lender may at any time pledge or assign a security interest in all or any portion of its
rights under this Agreement to secure obligations of such Lender, including without limitation any pledge or assignment to secure obligations to a Federal Reserve Bank, and this Section shall not apply to any such pledge or assignment of a
security interest; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 

SECTION 9.05. Survival. All covenants, agreements, representations and warranties made by the Borrowers herein and in the certificates
or other instruments delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of this Agreement and the making of any Loans and
issuance of any Letters of Credit, regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent, the Issuing Bank or any Lender may have had notice or knowledge of any Default or
incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount payable under this
Agreement is outstanding and unpaid or any Letter of Credit is outstanding and so long as the Commitments have not expired or terminated. The provisions of Sections 2.15, 2.16, 2.17 and 9.03 and Article VIII shall survive and remain in full force
and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Letters of Credit and the Commitments or the termination of this Agreement or any provision hereof.

 SECTION 9.06. Counterparts; Integration; Effectiveness. (a) This Agreement may be executed in counterparts (and by different
parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement and any separate letter agreements with respect to fees payable to the
Administrative Agent constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided
in Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof which, when taken together, bear the signatures of
each of the other parties hereto, and thereafter shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Delivery of an executed counterpart of a signature page of this Agreement by telecopy
shall be effective as delivery of a manually executed counterpart of this Agreement. 
 (b) Delivery of an executed counterpart of a
signature page of this Agreement by telecopy, emailed pdf. or any other electronic means that reproduces an image of the actual executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement. The words
“execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed
to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a
paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act
or any other similar state laws based on the Uniform Electronic Transactions Act. 

  
 84 

 SECTION 9.07. Severability. Any provision of this Agreement held to be invalid, illegal or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions hereof; and the
invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction. 
 SECTION
9.08. Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of its Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply
any and all deposits (general or special, time or demand, provisional or final) at any time held and other obligations at any time owing by such Lender or Affiliate to or for the credit or the account of any of the Borrowers against any of and all
the obligations of such Person now or hereafter existing under this Agreement held by such Lender, irrespective of whether or not such Lender shall have made any demand under this Agreement and although such obligations may be unmatured. The rights
of each Lender under this Section are in addition to other rights and remedies (including other rights of setoff) which such Lender may have. 

SECTION 9.09. Governing Law; Jurisdiction; Consent to Service of Process. (a) This Agreement shall be construed in accordance with
and governed by the law of the State of New York. 
 (b) Each of the Borrowers hereby irrevocably and unconditionally submits, for itself and
its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County, Borough of Manhattan, and of the United States District Court of the Southern District of New York, and any appellate court from
any thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any
such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and
may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that the Administrative Agent, the Issuing Bank or any Lender may otherwise have to bring any
action or proceeding relating to this Agreement against the Borrowers or their respective properties in the courts of any jurisdiction. 

(c) Each of the Borrowers hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any
objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Credit Document in any court referred to in paragraph (b) of this Section. Each of
the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

(d) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 9.01. Nothing in
this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law. 

  
 85 

 SECTION 9.10. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER
THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND
(B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

SECTION 9.11. Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only,
are not part of this Agreement and shall not affect the construction of, or be taken into consideration in interpreting, this Agreement. 

SECTION 9.12. Confidentiality. Each of the Administrative Agent, the Issuing Bank and the Lenders agrees to maintain the
confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its and its Affiliates’ directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being
understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority,
(c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party to this Agreement, (e) in connection with the exercise of any remedies hereunder or any suit, action or
proceeding relating to this Agreement or the enforcement of rights hereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective
assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to any Borrower and its obligations,
(g) with the consent of the Borrowers or (h) to the extent such Information (i) becomes publicly available other than as a result of a breach of this Section or (ii) becomes available to the Administrative Agent, the Issuing
Bank or any Lender on a non-confidential basis from a source other than the Borrowers. For the purposes of this Section, “Information” means all information received from the Borrowers relating to any Borrower or its business, other
than any such information that is available to the Administrative Agent, the Issuing Bank or any Lender on a non-confidential basis prior to disclosure by the Borrowers. Any Person required to maintain the confidentiality of Information as provided
in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential
information. 
 EACH LENDER ACKNOWLEDGES THAT INFORMATION AS DEFINED IN THE PRECEDING PARAGRAPH FURNISHED TO IT PURSUANT TO THIS
AGREEMENT MAY INCLUDE MATERIAL NON-PUBLIC INFORMATION CONCERNING THE PARENT AND ITS RELATED PARTIES OR THEIR 

  
 86 

 
RESPECTIVE SECURITIES, AND CONFIRMS THAT IT HAS DEVELOPED COMPLIANCE PROCEDURES REGARDING THE USE OF MATERIAL NON-PUBLIC INFORMATION AND THAT IT WILL HANDLE SUCH MATERIAL NON-PUBLIC
INFORMATION IN ACCORDANCE WITH THOSE PROCEDURES AND APPLICABLE LAW, INCLUDING FEDERAL AND STATE SECURITIES LAWS. 
 ALL INFORMATION,
INCLUDING REQUESTS FOR WAIVERS AND AMENDMENTS, FURNISHED BY THE BORROWERS OR THE ADMINISTRATIVE AGENT PURSUANT TO, OR IN THE COURSE OF ADMINISTERING, THIS AGREEMENT WILL BE SYNDICATE-LEVEL INFORMATION, WHICH MAY CONTAIN MATERIAL NON-PUBLIC
INFORMATION ABOUT THE BORROWERS AND THEIR AFFILIATES AND THEIR RELATED PARTIES OR THEIR RESPECTIVE SECURITIES) AND ITS SECURITIES. ACCORDINGLY, EACH LENDER REPRESENTS TO THE BORROWERS AND THE ADMINISTRATIVE AGENT THAT IT HAS IDENTIFIED IN ITS
ADMINISTRATIVE QUESTIONNAIRE A CREDIT CONTACT WHO MAY RECEIVE INFORMATION THAT MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION IN ACCORDANCE WITH ITS COMPLIANCE PROCEDURES AND APPLICABLE LAW. 

SECTION 9.13. Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to
any Loan, together with all fees, charges and other amounts which are treated as interest on such Loan under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”)
which may be contracted for, charged, taken, received or reserved by the Lender holding such Loan in accordance with applicable law, the rate of interest payable in respect of such Loan hereunder, together with all Charges payable in respect
thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable as a result of the operation of this Section shall be cumulated and the
interest and Charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate to the date
of repayment, shall have been received by such Lender. 
 SECTION 9.14. USA PATRIOT Act. Each Lender that is subject to the
requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”) hereby notifies the Borrowers that pursuant to the requirements of the Act, it is required to obtain, verify and
record information that identifies such Person, which information includes the names and addresses of the Borrowers and other information that will allow such Lender to identify the Borrowers in accordance with the Act. 

SECTION 9.15. Conversion of Currencies. (a) If, for the purpose of obtaining judgment in any court, it is necessary to convert a
sum owing hereunder in one currency into another currency, each party hereto agrees, to the fullest extent that it may effectively do so, that the rate of exchange used shall be that at which in accordance with normal banking procedures in the
relevant jurisdiction the first currency could be purchased with such other currency on the Business Day immediately preceding the day on which final judgment is given. 

  
 87 

 (b) The obligations of each Borrower in respect of any sum due to any party hereto or any holder
of the obligations owing hereunder (the “Applicable Creditor”) shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than the currency in which such sum is stated to be due hereunder (the
“Agreement Currency”), be discharged only to the extent that, on the Business Day following receipt by the Applicable Creditor of any sum adjudged to be so due in the Judgment Currency, the Applicable Creditor may in accordance with
normal banking procedures in the relevant jurisdiction purchase the Agreement Currency with the Judgment Currency; if the amount of the Agreement Currency so purchased is less than the sum originally due to the Applicable Creditor in the Agreement
Currency, the Borrowers agree, as a separate obligation and notwithstanding any such judgment, to indemnify the Applicable Creditor against such loss. The obligations of the Borrowers contained in this Section 9.15 shall survive the termination
of this Agreement and the payment of all other amounts owing hereunder. 
 SECTION 9.16. Appointment and Authorization of Borrower
Representative. 
 (a) Each Borrower hereby designates, appoints, authorizes and empowers Argo US as its agent to act as specified in the
capacity of Borrower Representative under this Agreement and each of the other Credit Documents and Argo US hereby acknowledges such designation, authorization and empowerment, and accepts such appointment. Each Borrower hereby irrevocably
authorizes and directs the Borrower Representative to take such action on its behalf under the respective provisions of this Agreement and the other Credit Documents, and any other instruments, documents and agreements referred to herein or therein,
and to exercise such powers and to perform such duties hereunder and thereunder as are specifically delegated to or required of the Borrower Representative by the respective terms and provisions hereof and thereof, and such other powers as are
reasonably incidental thereto, including, without limitation, to take the following actions for and on such Borrower’s behalf: 

(i) to submit on behalf of each Borrower Borrowing Requests, and notices of conversion or continuation of Loans to the
Administrative Agent in accordance with the provisions of this Agreement, each such notice to be submitted by the Borrower Representative to the Administrative Agent as soon as practicable after its receipt of a request to do so from a Borrower; and

 (ii) to submit on behalf of each Borrower requests for the issuance of Letters of Credit in accordance with the provisions
of this Agreement, each such request for the issuance of a Letter of Credit to be submitted by the Borrower Representative as soon as practicable after its receipt of a request to do so from any Borrower. 

(b) The Borrower Representative is further authorized and directed by each of the Borrowers to take all such actions on behalf of such Borrower
necessary to exercise the specific powers granted in clauses (i) and (ii) above and to perform such other duties hereunder and under the other Credit Documents, and deliver such documents as delegated to or required of the Borrower
Representative by the terms hereof or thereof. The Administrative Agent and each Lender may regard any notice or other communication pursuant to any Credit Documents from the Borrower Representative as a notice or communication from all Borrowers,
and may give any notice or communication required or permitted to be given to any Borrower or Borrowers 

  
 88 

 
hereunder to the Borrower Representative on behalf of such Borrower or Borrowers. Each Borrower agrees that each notice, election, representation and warranty, covenant, agreement and undertaking
made on its behalf by the Borrower Representative shall be deemed for all purposes to have been made by such Borrower and shall be binding upon and enforceable against such Borrower to the same extent as if the same had been made directly by such
Borrower. 
 (c) The Borrower Representative may perform any of its duties hereunder or under any of the other Credit Documents by or through
its agents or employees. 
 (d) Each Borrower (other than Argo US) hereby irrevocably appoints Argo US as its agent to receive on behalf of
itself and its property service of copies of the summons and complaint and any other process which may be served in any such action or proceeding. Such service may be made by mailing or delivering a copy of such process to such Borrower in care of
Argo US at its address set forth in Section 9.01(a) hereto. Each Borrower hereby irrevocably authorizes and directs Argo US to accept such service on its behalf. 

SECTION 9.17. No Fiduciary Duty. The Administrative Agent, each Lender and their Affiliates (collectively, solely for purposes of this
paragraph, the “Lenders”) may have economic interests that conflict with those of the Parent, its stockholders and/or its Affiliates. The Borrowers agrees that nothing in the Credit Documents or otherwise will be deemed to create an
advisory, fiduciary or agency relationship or fiduciary or other implied duty between any Lender, on the one hand, and any Borrower, its stockholders or its Affiliates, on the other. The Borrowers acknowledge and agree that (i) the transactions
contemplated by the Credit Documents (including the exercise of rights and remedies hereunder and thereunder) are arm’s-length commercial transactions between the Lenders, on the one hand, and the Borrowers, on the other, and (ii) in
connection therewith and with the process leading thereto, (x) no Lender has assumed an advisory or fiduciary responsibility in favor of the Borrowers, its stockholders or its Affiliates with respect to the transactions contemplated hereby (or
the exercise of rights or remedies with respect thereto) or the process leading thereto (irrespective of whether any Lender has advised, is currently advising or will advise the Borrowers, their respective stockholders or Affiliates on other
matters) or any other obligation to the Borrowers except the obligations expressly set forth in the Credit Documents and (y) each Lender is acting solely as principal and not as the agent or fiduciary of the Borrowers, their management,
stockholders, creditors or any other Person. The Borrowers acknowledge and agree that it has consulted its own legal and financial advisors to the extent it deemed appropriate and that it is responsible for making its own independent judgment with
respect to such transactions and the process leading thereto. The Borrowers agree that it will not claim that any Lender has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty, to the Borrowers in connection
with such transactions or the process leading thereto. 
 SECTION 9.18. Termination of Existing Agreement. The Lenders party to this
Agreement, in their capacities as “Lenders” under the Credit Agreement dated as of April 30, 2010 among the Borrowers, the lenders party thereto and the Administrative Agent (as amended, the “Existing Agreement”),
constituting the Required Lenders (as such term is defined in the Existing Agreement) thereunder, hereby waive (a) the notice required pursuant to Section 2.11(b) thereof of the prepayment of obligations thereunder contemplated by
Section 4.01(f) hereof and (b) the notice required pursuant to Section 2.09(d) thereof to terminate the Commitments (as 

  
 89 

 
such term is defined in the Existing Agreement) thereunder and agree with Borrower that upon effectiveness of this Agreement, the Existing Agreement, the other Loan Documents (as such term is
defined in the Existing Agreement), the Commitments (as such term is defined in the Existing Agreement) and the Obligations (as such term is defined in the Existing Agreement) (other than those that expressly survive termination) will be terminated
without any further act of any Person. 
 [Signature pages follows] 

  
 90 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written. 
  

			
	ARGO GROUP INTERNATIONAL HOLDINGS, LTD.
		
	By:	 	 /s/ George Luecke

	Name:	 	George Luecke
	Title:	 	Senior Vice President and Treasurer
	
	ARGO GROUP US, INC.
		
	By:	 	 /s/ Lynn K. Geurin

	Name:	 	Lynn K. Geurin
	Title:	 	Vice President and Treasurer
	
	ARGO INTERNATIONAL HOLDINGS LIMITED
		
	By:	 	 /s/ Darren Argyle

	Name:	 	Darren Argyle
	Title:	 	Director
	
	ARGO UNDERWRITING AGENCY LIMITED
		
	By:	 	 /s/ Darren Argyle

	Name:	 	Darren Argyle
	Title:	 	Director

 [Signature Page to Argo Credit Agreement] 

 
			
	 JPMORGAN CHASE BANK, N.A., individually

and as Administrative Agent

		
	By:	 	 /s/ Thomas A. Kiepura

	Name:	 	Thomas A. Kiepura
	Title:	 	Sr. Credit Executive

 [Signature Page to Argo Credit Agreement] 

 
			
	WELLS FARGO BANK, N.A.
		
	By:	 	 /s/ William R. Goley

	Name:	 	William Goley
	Title:	 	Director

 [Signature Page to Argo Credit Agreement] 

 
			
	U.S. BANK NATIONAL ASSOCIATION
		
	 By:
	 	 /s/ Bonnie S. Wiskowski

	Name:	 	Bonnie S. Wiskowski
	Title:	 	Vice President

 [Signature Page to Argo Credit Agreement] 

 
			
	 BARCLAYS BANK PLC

		
	 By:
	 	 /s/ Samuel Coward

	Name:	 	Samuel Coward
	Title:	 	VP, Debt Finance

 [Signature Page to Argo Credit Agreement] 

 
			
	 BANK OF AMERICA, N.A.

		
	 By:
	 	 /s/ Jason Cassity

	Name:	 	Jason Cassity
	Title:	 	Director

 [Signature Page to Argo Credit Agreement] 

 
			
	 THE FROST NATIONAL BANK

		
	 By:
	 	 /s/ Julie Glass

	Name:	 	Julie Glass
	Title:	 	Senior Vice President

 [Signature Page to Argo Credit Agreement] 

 
			
	HSBC BANK BERMUDA LTD.
		
	 By:
	 	 /s/ Louise Twiss West

	Name:	 	Louise Twiss West
	Title:	 	 Associate Director,
 Financial Institutions
Group

  

			
	 By:
	 	 /s/ Neville Grant

	Name:	 	Neville Grant
	Title:	 	Head of Corporate Banking

 [Signature Page to Argo Credit Agreement] 

 Schedule 1.02 

PRICING SCHEDULE 
  

																					
	 APPLICABLE MARGIN
	  	LEVEL I
STATUS	 	 	LEVEL II
STATUS	 	 	LEVEL III
STATUS	 	 	LEVEL IV
STATUS	 	 	LEVEL V
STATUS	 
	 Eurocurrency Spread
	  	 	1.375	% 	 	 	1.50	% 	 	 	1.625	% 	 	 	1.875	% 	 	 	2.25	% 
	 Alternative Base Rate Spread
	  	 	.375	% 	 	 	.50	% 	 	 	.625	% 	 	 	.875	% 	 	 	1.25	% 

  

																					
	 APPLICABLE FEE RATE
	  	LEVEL I
STATUS	 	 	LEVEL II
STATUS	 	 	LEVEL III
STATUS	 	 	LEVEL IV
STATUS	 	 	LEVEL V
STATUS	 
	 Commitment Fee
	  	 	.175	% 	 	 	.225	% 	 	 	.25	% 	 	 	.30	% 	 	 	.40	% 
	 Letter of Credit Fee
	  	 	1.375	% 	 	 	1.50	% 	 	 	1.625	% 	 	 	1.875	% 	 	 	2.25	% 

 “Level I Status” exists at any date if, on such date, the S&P Rating is BBB+ or
better or the Moody’s Rating is Baa1 or better. 
 “Level II Status” exists at any date if, on such date,
(i) the Borrowers have not qualified for Level I Status and (ii) the S&P Rating is BBB or better or the Moody’s Rating is Baa2 or better. 

“Level III Status” exists at any date if, on such date, (i) the Borrowers have not qualified for Level I Status
or Level II Status and (ii) the S&P Rating is BBB- or better or the Moody’s Rating is Baa3 or better. 

“Level IV Status” exists at any date if, on such date, (i) the Borrowers have not qualified for Level I Status,
Level II Status or Level III Status and (ii) the S&P Rating is BB+ or better or the Moody’s Rating is Ba1 or better. 

“Level V Status” exists at any date if, on such date, the Borrowers have not qualified for Level I Status, Level II
Status, Level III Status or Level IV Status. 
 “Moody’s Rating” means, at any time, the issuer credit rating
(or comparable rating) issued by Moody’s Investors Service, Inc. and then in effect with respect to Argo US or AGII. 

“Rating” means a Moody’s Rating or an S&P Rating. 

 “S&P Rating” means, at any time, the issuer credit rating issued by
Standard and Poor’s Financial Services LLC and then in effect with respect to Argo US or AGII. 
 The Applicable Rate shall be
determined in accordance with the foregoing table based on the Borrowers’ Status as determined from the then-current Moody’s and S&P Ratings. The Rating in effect on any date for the purposes of this Schedule is that in effect at the
close of business on such date. If at any time one Rating exists but the other does not, then Status shall be determined on the basis of the existing Rating. If at any time a Borrower has no Moody’s Rating and no S&P Rating, Level V Status
shall exist. If at any time a different credit rating is issued by either Moody’s or S&P, then the higher of such credit ratings shall apply (with the credit rating for Level I being the highest and the credit rating for Level V being the
lowest), unless there is a split in credit ratings of more than one Level, in which case the Level that is one Level higher than the Level of the lower credit rating shall apply. 

If on any date of determination of the Moody’s Rating or S&P Rating, as applicable, there exists both an Argo US rating by such
rating agency and a Parent rating by such rating agency and there is a split between such ratings, then the higher of such ratings shall apply for purposes of determining the Moody’s Rating or S&P Rating, as applicable, (unless there is a
split in the ratings of such ratings agency by more than one level, in which case the level that is one level higher than the lower rating shall apply). 

  
 2 

 Schedule 2.01 

Commitments 
  

					
	 JPMorgan Chase Bank, N.A.
	  	$	35,000,000	  
	 Wells Fargo Bank, N.A.
	  	$	35,000,000	  
	 U.S. Bank National Association
	  	$	27,500,000	  
	 Barclays Bank PLC
	  	$	20,000,000	  
	 Bank of America, N.A.
	  	$	15,000,000	  
	 Frost Bank
	  	$	22,500,000	  
	 HSBC Bank Bermuda Ltd.
	  	$	20,000,000	  
	 TOTAL
	  	$	175,000,000	  

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]